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ABSTRACT 
 
Chemotherapy is an effective treatment for cancer and other serious diseases such as 
cardiovascular restenosis and AIDS. It is a complicated procedure in which many factors 
are involved in determining its success or failure. Furthermore it carries a high risk due to 
drug toxicity, with the more effective drugs tending to be more toxic. Patients have to 
tolerate severe side effects and sacrifice their quality of life. The inefficiency and side 
effects of chemotherapy are caused mainly by the formulation, pharmacokinetics and 
toxicity of chemotherapeutic agents and the drug resistance. Hence, the development of 
effective carriers for both existing and newly developed drugs may be as important as the 
discovery of new anticancer drugs. All these concerns lead to the concept of sustained, 
controlled and targeted release of drugs. 
The ideal goal of a drug delivery system is to deliver high efficacy drug(s) at the right 
time to the desired location, at high concentration but safe enough, over a sufficiently 
long period.  
Effective drug delivery has also important implications from a market viewpoint. More 
effective drug delivery can provide drug companies with a means of expanding market 
share or of revitalizing therapeutics with previously unrealized potential because of poor 
pharmacokinetic profiles. Nanomedicine is not only important from the social and welfare 
aspects, but also for its economic potential. 
In the framework of a long–standing research activity ongoing in the Bioactive Polymeric 
Materials Group at the Department of Chemistry and Industrial Chemistry of the 
University of Pisa, the present work was aimed at the development of polymeric 
nanoparticles for the site specific and controlled delivery of drugs for cancer treatment 
and tissue engineering application. The primary objective of the present PhD was the 
advancement of knowledge and the theoretical understanding of the relations among 
variables that play important roles in the development and optimization of procedures for 
the preparation of polymeric nanoparticle suspensions. The work was conducted keeping 
in mind the practical aspects of preparing nanodelivery structures for bioactive agents 
administration in cancer therapy and tissue engineering applications. 
A variety of polymers including PLGA, PHB, VAM41, multi block copolymers of PCL-
PLU, and Chitosan, were investigated. Retinoic Acid and Chondroitin Sulphate, were 
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loaded into nanoparticles as hydrophobic and hydrophilic model drugs respectively. 
Proteins have been also co-encapsulated as stabilizing agent or as model proteic drugs. 
For the preparation of RA loaded nanoparticles several methods were investigated and set 
up: dialysis, nanoprecipitation, co-precipitation and colloidal-coating. Colloidal-coating 
is an original solvent-free method developed in the framework of the research activity 
carried out in the present PhD thesis. The first two methods were employed for the 
preparation of formulations based on PLGA, PHB and the multi block copolymer PCL-
co-PLU, while the last two for formulations based on VAM41. The resulting nanoparticle 
suspensions were analyzed macroscopically in terms of homogeneity and formation of 
precipitates, and characterized from a dimensional and morphological point of view by 
means of light scattering (LS) and scanning electron microscopy (SEM). Particles were 
purified and storage modalities were set up.  
Drug release studies were carried out by an original method that might better reflect 
bioavailability data. Since HSA is one of the most abundant plasma protein it was added 
to the releasing medium overcoming problems related to the poor solubility of RA in 
water. Solubility problems often hamper the evaluation of drugs release kinetics of 
hydrophobic drugs in phosphate buffer solution (PBS) at 37°C, which is commonly used 
in in vitro environment and that should match the in vivo condition. The obtained results 
showed that HSA affected the stability and life of nanoparticle formulations.  
The activity of RA encapsulated by colloidal-coating method was evaluated on SK-N-SH 
human neuroblastoma cell line that is known to undergo inhibition of proliferation and 
neuronal differentiation upon treatment with RA. The data obtained suggested that the 
anticancer activity of RA was not impaired by incorporation and purification processes. 
A careful in vitro investigation of PHB and the relative nanoparticles cytotoxicity 
was carried out using two type of assays aimed at the evaluation of the interactions of the 
materials with cell metabolism (WST-1 tetrazolium salts) and cell endocytosis functions 
(Neutral Red Uptake). In vitro cytotoxicity of PHB resulted fairly low as highlighted by 
the high IC50 values obtained both with Tetrazolium Salts and Neutral Red assays. PHB 
based nanoparticles prepared by dialysis method exhibited as well a very good 
cytocompatibility and can be considered fully biocompatible 
It was also investigated the preparation of suitable vehicles for intra-articular injection in 
regenerated cartilages tissue, in form of nanoparticles, to allow Chondroitin Sulphate 
sustained release. Synthetic bioerodible (VAM41), biodegradable (PLGA), natural 
(Chitosan) polymers and nanoprecipitation or co-precipitation methods were used to 
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develop the nanostructured formulations. The limit of nanoprecipitation method mainly 
concerns the possibility to achieve an efficiently loading of hydrophilic drug substances 
inside the nanoparticles. Drug is easily lost in water during the preparation and 
incompatibilities between the polymer and the drug could worse the situation. Due to the 
wide differences among the utilized polymers the nanoprecipitation and co-precipitation 
methods were adjusted and modified in relation to the physical-chemical characteristics of 
the utilized material. 
PLGA, VAM 41 and Chitosan nanoparticles were prepared. No detectable amounts of CS 
were loaded onto the PLGA nanoparticles indicating the not suitability of the method for 
the encapsulation of this drug or a strong incompatibility between the hydrophobic 
polymer and hydrophilic drug. CS was detected into VAM41 and Chitosan NPs. A 
quantitative determination of the drug encapsulation was not possible due to several 
occurrences.  Spectrophotometric UV assays have been based on changes in the 
absorption spectrum of the dye 1,9-dimethylmethylene blue (DMMB) when bound to 
Glycosaminoglycans (GAGs). CS interacted somehow with VAM41 and the 
characteristic UV band of absorbance of DMMB was shifted to higher wavelengths. 
Another attempt to evaluate encapsulation was done by IR spectrophotometry. The ratio 
between the intensity of the peak characteristic for CS and the intensity of the peak 
characteristic for VAM41 was evaluated and related to the percentage of CS in the 
samples. Although the developed method was effective for evaluating the encapsulation 
of CS it was not possible to verify whether the observed interaction affected these results 
or not.  
Chitosan nanoparticles were insoluble in all the tested solvents. Hence, an approximate 
evaluation of CS content was carried out by XPS analysis. The presence of sulphur in the 
sample qualitatively confirmed the encapsulation of CS into the NPs.  
The reported results and relevant discussions, which give exhaustive theoretical 
understanding of the phenomena occurring during colloidal formations, contribute to both 
basic and applied research in biomedical science and pharmaceutical technology.  
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1 INTRODUCTION 
 
 
1.1 BIOMATERIALS 
 
In the last decades the development of biomaterials science has been of enormous impact 
in the scientific world, especially in the field of regenerative medicine. The peculiarity of 
biomaterials science is its multidisciplinary nature, which involves connections between 
scientific, medical, and engineering disciplines. The continuous flow of knowledge in 
materials science, molecular and cell biology, human physiology and pathology and the 
constant demand for new technological solutions have driven the biomaterials science to 
be one of the most promising areas of scientific and social interest. 
 
1.1.1. Definitions and Classifications 
 
The first generation of materials to be used inside the human body was developed during 
the 1960s and 1970s. The objective of these early biomaterials was to “achieve a suitable 
combination of physical properties to match those of the replaced tissue with a minimal 
toxic response in the host” [Hench 1980]. The general required feature of these 
biomaterials stood in their biological “inertness”, as the reduction to a minimum of the 
immune response to the foreign body. The advanced approaches concerned the 
production of bioactive materials that could either elicit a controlled action and reaction in 
the physiological environment or the development of bioresorbable biomaterials that 
exhibited controlled chemical breakdown and elimination [Hench 1980, Wilson 1984]. 
Finally, the third generation of biomaterials involves the unification of the former 
concepts. These materials are thus designed to stimulate specific cellular responses at the 
molecular level (bioactivity) and simultaneously possess bioresorbable features [Hence 
2002]. At present, the two most widely accepted definitions of biomaterials are: 
 
o “A biomaterial is a nonviable material used in a medical device, intended to interact 
with biological systems” [Williams 1987]. 
o “A biomaterial is a material intended to interface with biological systems to evaluate, 
treat, augment or replace any tissue, organ or function of the body” [European 
Society of Biomaterials, Consensus Conference, Chester, UK, 1991]. 
CESARE ERRICO – PHD THESIS 
 2 
Indeed, the design and manufacture of biomaterials address several scientific aspects and 
need to assure specific requirements. In particular, a deep investigation of the chemical, 
physical and biological characteristics of the environment in which the material is 
expected to perform its action is of outmost importance. The acquired knowledge may 
lead to a better understanding of the factors that determine the final performances of the 
materials, and therefore allowing for the optimization of their design. The biofunctionality 
of the device under investigation should hence be associated to proper mechanical and 
chemical characteristics. Nevertheless, these products must retain their functionality and 
safety over the desired time, as ensured by their biocompatibility. 
A general classification based on the chemical nature of biomaterials comprises [Barbucci 
1994]: 
 
o Biologically derived materials include natural proteins (collagen, elastin, gelatin), 
polysaccharides (hyaluronic acid, chitosan, dextran, cellulose), and proteins produced 
with biotechnological techniques (genetic engineering), as well as entire cells and 
natural tissues. They are often used in combination with other synthetic biomaterials, 
especially in dermatology. 
o Synthetic polymers can be employed in a wide range of applications, of either 
intracorporeal or extracorporeal type. The most common uses include short–term 
devices (sutures, adhesives, artificial tendons, contact lenses), long–term cardiac 
valves, complex systems aimed at substituting the function of body organs (such as 
artificial kidney, heart, pancreas), catheters, filters for hemodialysis, orthopaedic 
material, and drug delivery devices. 
o Metals are mainly used in orthopaedic and dental implants, as well as in the 
production of pacemakers and heart valves. The most commonly used metals are 
stainless steel, cobalt–based alloys, titanium and its alloys. 
o Composites can be manufactured by the combination of polymers, ceramics, and 
metals. Composites currently used in biomaterial applications include bone particle– 
or carbon fiber–reinforced methyl methacrylate bone cement and ultra–high–
molecular–weight polyethylene, porous surface orthopaedic implants, and dental 
filling composites.   
o Ceramics are widely employed in orthopaedic implants, as bone fillers, and in dental 
and ear–nose–throat implants. The most common bioceramics are aluminum oxides, 
calcium phosphates, titanium oxides, zirconium oxides, and glass–ceramics. 
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1.1.2. Polymeric Biomaterials 
 
The interest for polymeric biomaterials and their application for medical purposes are 
growing very fast. Polymeric materials have found applications in diverse biomedical 
fields, such as ophthalmology, dentistry, orthopaedics, implantation of medical devices, 
bioartificial organs, drug delivery and many more [Jagur-Grodzinski 1999].  
Compared with other types of biomaterials, such as metals and ceramics, polymers offer 
the advantage of being engineered and processed in different ways to meet specific end–
use requirements. Besides the broad variety of commercially available polymers, the 
synergy between advanced organic chemistry and polymer synthesis has led to the 
development of precious tools for the design of polymer architecture and the grafting of 
bioactive molecules [Drotleff 2004, Hawker 2005]. Therefore, according to key “device” 
characteristics such as mechanical resistance, degradability, permeability, solubility, and 
transparency, polymers can be selected and specifically tailored for appropriate surface or 
bulk properties.  
Whereas the original uses of polymers in clinical medicine focused primarily on the 
replacements of connective tissues, new applications are emerging. Nowadays, two 
important application fields of polymeric biomaterials are tissue engineering and 
controlled drug delivery. 
Tissue engineering is aimed at restoring, maintaining, or enhancing tissues and organs 
functions by assuring synergistic interactions of living cells and synthetic materials. 
Although transplantation and reconstructive surgery are the most used therapies to 
address the loss and failure of organs and tissues, they remain imperfect solutions. Tissue 
engineering could actually afford a valid alternative [Griffith 2002].  
Drug delivery main issues are the control of the pharmacokinetics and biodistribution of 
drugs in order to restrict their action to the treated tissue and keep their concentration at 
therapeutically relevant levels for the desired time.  
Polymers are currently used as physical carriers for drugs, components of prodrugs, 
conjugates or in complexes with proteins or nucleic acids, as well as direct therapeutics in 
their own right [Twaites 2005]. The role of polymers in drug delivery covers multiple 
aspects, from the enhancement of the physical-chemical stability of the drug to the 
regulation of drug release and targeting. The goal of drug delivery and the involvement of 
polymeric biomaterials is hence to increase drug efficacy and reduce the toxicity of 
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traditional drug administration, create easier dosage regimes and achieve a better patient 
compliance. [Vasir 2005].  
As a further step towards the development of third–generation “smart” materials for 
biomedical use, the possibilities of synergistically combine the approaches of both 
conventional tissue engineering and controlled drug delivery has been recently envisaged. 
The aim of such association is to afford systems that not only constitute a supportive 
scaffold for cell proliferation, but also guide cell development and organization by 
progressive and controlled release of cell growth and differentiating factors [Saltzmann 
2002]. This concept, which could promote the formation of highly organized and complex 
tissues, is actually under investigation by the most eminent research groups involved in 
biomaterial science. 
Generally, polymeric biomaterials are classified as synthetic polymers and polymers of 
natural origin. The field of applications of synthetic and natural polymeric biomaterials is 
indeed very wide, including surgical devices, implants and supporting materials (e.g. 
artificial organs, prostheses and sutures), drug delivery systems with different routes of 
administration and design, carriers of immobilized enzymes and cells, biosensors 
components of diagnostic assays, bioadhesives, ocular devices, and materials for 
orthopaedic applications [Angelova 1999]. Biopolymers and their applications are 
summarised in Table 1.1-1.2 [Park 1992, Jagur-Grodzinski 1999, Saltzmann 2002, 
Kashyap 2004, Twaites 2005]. 
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Table 1 - Natural polymers and their application. 
Polymer Main applications and comments 
Proteins and protein-base polymers Resorbable. Biocompatible and not toxic. Elastic materials 
 applied in implantology and tissue engineering. 
 Collagen Sutures, drug release. 
 Albumin Drug stabiliser and drug release. 
 Gelatin Used in the preparation of gels and in drug release 
Polyaminoacids Not toxic, not antigenic and biocompatible. Used as carriers 
 for oligomeric drugs. 
Polysaccharides and vegetal derived polymers 
 Carboxymethylcellulose Drug release, dialysis membranes, cell immobilisation  
  (ionotropic gelation and formation of polyelectrolyte 
  complexes) 
 Starch Drug delivery 
 Cellulose sulphate In polyelectrolytic complexes for imunoisolation 
 Agarose Used in clinical analysis and as matrix 
 Alginate Biocompatible. Applied in gel preparation and to immobilise 
  cell matrix and enzymes. For the release of bioactive 
  molecules, injectable microcapsules for neurodegenerative  
  diseases and hormones deficiency. 
Polysaccharides and human/animal derivatives 
 Hyaluronic acid Moisturizing agent, wound dressing, artificial tears in 
  ophthalmology, various orthopaedic applications 
 Eparin and Eparin-like Trombolytic anticoagulant properties. Used in surgery for 
 glycosaminoglycans ionotropic gelation and in capsules preparation. 
Microbial Polysaccharides 
 Dextran and derivatives Excellent reological properties, plasma expander. Used in  
  drug delivery. 
 Chitosan and derivatives Natural polycation. Biocompatible, not toxic. Used in gel  
  and film preparation. Applied in drug delivery. 
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Table 2 - Synthetic polymers used for biomedical applications 
Polymer Main applications and comments 
Aliphatic polyesters 
Poly(lactic acid), poly(glycolic acid) Used in sutures, drug delivery systems and tissue engineering. 
and their copolymers Biodegradable. Copolymerized to regulate degradation time. 
Poly(hydroxybutirate)s Biodegradable, used as matrix for drug 
Poly(γ–caprolactone) and copolymers Delivery systems, cell microencapsulation. 
Poly(alkylene succinate), etc. Properties can be tuned by chemical modification, 
  copolymerization and blending. 
Polyanhydrides Biodegradable, useful in tissue engineering  and for the release 
 of bioactive molecules. 
Polyorthoesters Surface–eroding polymers. Application in  sustained drug  
 delivery, ophtalmology. 
Polycyanoacrylates Biodegradable, depending on the length of  the alkyl chain. 
 Used as surgical adhesives, glues, and in drug delivery. 
Polyacrylonitrile Dialysis membranes  
Polyphosphazenes Can be tailored with versatile side–chain  functionality.  
 Applications in drug delivery. 
Polyamides Used for sutures, hemofiltration membranes. Inhibitors of DNA 
transcription 
Polyurethanes  Used for prostheses, vascular grafts, catheters tissue adhesives, 
artificial cardiac structures, coatings 
Polyethylene Used for orthopaedic materials and catheters. 
Polypropylene Plasmapheresis membranes, sutures, external medical devices. 
Poly(methyl methacrylate) This and its copolymers are used as dental implants, in bone  
  replacement and as intraocular lenses. 
Poly(hydroxyethyl methacrylate) Used for contact lenses, ocular prostheses, skin coatings,  
 catheters. 
Polytetrafluoroethylene (Teflon®) Used for vascular grafts, clips and sutures facial prosthes,  
 coatings. 
Polydimethylsiloxanes Used for implants in plastic surgery,   
 orthopaedics, blood bags, 
 pacemakers, drug delivery devices, membrane ossigenators. 
Poly(N-vinylpyrrolidone) in hydrogels for controlled release of drugs  from metal stents, 
 or in blood substitutes. 
Polysulfone Heart valves, penile prostheses 
Poly(vinyl chloride) Used for tubing, blood bags. 
Polystyrene Used as substrates for cell cultures. 
Poly(ethylene oxide) Different polymer derivatives and  copolymers used in a 
variety of biomedical  applications. 
Poly(ethylene glycol) Several applications as spacer, in  bioconjugations, coatings,  
 etc. Covalently bound in Pegvisomant for agromegaly; 
and in Pegfilgrastim to increase neutrophilis production in bone 
marrow for neutropenia. 
Polylisine Applied in gene delivery, formation of conjugate vectors  
Polyethylenimine Applied in gene delivery, formation of conjugate vectors 
Polyamidoimine Vectors of oligonucleotide transfer and gene delivery 
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1.1.2.1. Poly-3-Hydroxybutirate (PHB) 
 
A majority of drug delivery systems using natural polymers have been based on proteins 
and polysaccharides [Park 2005]. Poly (3-hydroxyalkanoates), synthesized by a wide 
variety of micro-organisms, have recently attracted a great deal of industrial attention. In 
particular, much interest focused on the use of poly (3-hydroxybutyrate) (PHB) and 
related copolymers as carriers or implants for drug delivery. When compared with 
chemically produced polymers such as polyglycolate, polylactate, and poly (lactide-co-
glycolide)  (PLGA), which are mostly well known as biologically degradable drug 
carriers with good retarding characteristics, PHB advantages are that it is easily 
processed, fully biologically degradable and compatible with animal tissue. 
In addition, the controllable retarding properties of PHB can be manipulated by variations 
in processing and molecular weight of the polymer. Thus, it could be anticipated to be an 
ideal basic material for matrix composition [Kim 2000]. PHB is produced 
biosynthetically by bacteria from natural raw materials, and indeed can be readily broken 
down by micro-organisms under different conditions, such as those present in sewage. 
The novel method of manufacture has several implications which may be advantageous 
for biomedical applications. Biosynthesis avoids the use of chemical catalysts or initiators 
that could cause toxicological problems if they remain in a pharmaceutical product. The 
involvement of microbial enzymes results in polymers which are regular from a 
stereochemical point of view, which is likely to result in highly reproducible physical 
properties. Hydrolytic degradation of PHB in vitro proceeds to the monomer, D-(-)-3-
hydroxy butyric acid. This acid is a normal constituent of blood and, in common with 
acetoacetate and acetone, is one of the three ketone bodies that are produced 
endogenously by the process known as ketogenesis. It is therefore thought that PHB can 
be well tolerated in vivo [Pouton 1996]. 
  
1.1.2.2.  Copolymers of maleic anhydride (MAn) and alkyl vinyl ethers (RVE) (VAM) 
 
In order to have suitable matrices for the preparation of colloidal drug delivery systems, 
amphiphilic polymeric materials were developed by hemiesterification of alternating 
copolymers of maleic anhydride (MAn) and alkyl vinyl ethers (RVE) by the research 
group involved in the present work. These synthetic polymers possess favourable 
physical–chemical properties for the formulation of bioerodible controlled release 
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systems of high and low molecular weight active agents. Each repeating unit carries has a 
hydrophilic ionisable acid group, a hydrophobic but potentially degradable ester residue, 
and an alkyl ether moiety of variable structure. By accurate choice of these groups, the 
polymeric material may result insoluble under physiological conditions. However, 
because of the progressive ester hydrolysis, the number of ionisable groups along the 
chain increases (Figure 1.1), affording a partially degraded structure, which becomes 
water soluble, thus allowing to classify the system as bioerodible. 
 
 
OO O
OH O R'
Physiological
  conditions
Degradation
(Hydrolysis)
OO O
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Water insoluble Water soluble
R
 
 
Figure 1.1 - Bioerosion of poly(maleic anhydride–alt–alkyl vinyl ether) hemiesters. 
 
The fraction of ionized carboxyl groups necessary for matrix solubilization and the pH at 
which ionization occurs depend on the hydrophilic/hydrophobic balance of both ether and 
ester residues [Chiellini 1992a, Heller 1978, Woodruff 1972]. Moreover, the presence of 
hydrophobic chains in either position tends to slow down the swelling and the hydrolysis 
process. Therefore, the release pattern from systems based on these polymers can be 
tuned easily by an appropriate choice of the ester and the ether chains. 
Quite a large number of examples are reported in the literature in which hemiesters of 
copolymers of maleic anhydride and alkyl vinyl ethers have been utilized for the 
formulation of release systems. For instance, the n–butyl hemiester of maleic anhydride–
methyl vinyl ether alternating copolymer was used in ophthalmology for the preparation 
of monolithic systems or as pH sensitive covers of microcapsules [Chiellini 1992a]. 
Similarly, alkyl hemiesters of maleic anhydride–oligo(oxyethylene) vinyl ether 
copolymers were formulated as monolithic inserts for the controlled release of pilocarpine 
[Chiellini 1988, Saettone 1988] and α–interferon [Chiellini 1992a, 1992b]. 
These polymers attracted particular interest as controlled delivery systems of protein 
drugs. Indeed, the presence of carboxyl groups should favour the incorporation of 
proteins and peptides, which usually are hardly entrapped in non–functional hydrophobic 
INTRODUCTION 
 9 
matrices, such as PLA and PLGA copolymers. Moreover, the presence of poly(ethylene 
glycol) segments in the side chains can promote the establishment of non–covalent 
interactions among the polymeric matrix and hydrophilic multifunctional drugs, such as 
peptides and proteins [Chiellini 2001, 1992b]. Materials belonging to this class were 
successfully formulated as bioerodible nanoparticles loaded with α–interferon [Chiellini 
2001, Cowdall 1999a, 1999b]. Additionally, it is well known that the presence of PEG 
segments on the surface of release systems may develop antiopsonizing effects, resulting 
in lower toxicity and longer circulation time [Kim 1998, Gref 1995]. 
 
1.1.3. Biodegradation and Bioerosion 
Biopolymers used for medical application must often be biodegradable and polymers 
degradation may occur under active or passive processes. Generally, the human body is 
described as an aqueous environment with a pH of 7.4 and a temperature of 37°C. It is 
important to observe that actually, the physiological environment of particular organs or 
tissues may be different and it is also subjected to drastic changes in case of disease. The 
saline solution of the human body is an excellent electrolyte, which induces hydrolysis 
and corrosion processes on the implanted foreign body or to the polymeric drug carrier. 
Catalysts produced by cells and tissues may accelerate these processes as well as isolate, 
attack and destroy the implanted device. The majority of the polymers employed for the 
production of medical devices are subjected to water diffusion and consequently to 
hydrolysis reactions. The hydrophilicity of the polymer is a fundamental parameter to be 
considered in the selection of the material and it is strictly related to the final application 
of the device; i.e. it is preferable to choose bioresorbable materials for the production of 
sutures. The degradation of polymers in vivo (biodegradation) is not only related to water 
absorption but also to a complexity of factors that highly accelerate the degradation 
process. Numerous cells, e.g. the cells involved in inflammation, produce enzymes which 
catalyses some of the reactions responsible for significant alteration of the molecular 
structure of the implanted devices. In particular, phagocytes migrate to the areas of 
inflammation where the implant is located. Through specific recognition mechanisms 
(mediated by antibodies) or non-specific absorption of proteins, phagocytes adsorb on the 
surface of the foreign body. The consequence of the described behaviours is the 
enhancement of the metabolic activity and of the immune response of the body, which 
lead to the activation of the degradation processes on the implanted system. 
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Biomaterial degradation is affected by both material physical-chemical properties and 
general conditions of the host (age, health, therapeutic treatments) as well as by the 
specific location of the implant and the type of the surrounding tissues. Scaffolds made of 
biostable polymers require the removal of the device once the therapeutic activity is 
exhausted and may induce a chronic inflammation. Nonetheless, when biodegradable 
polymers are employed, they should not generate harmful or immunogenic products as a 
result of their degradation. 
Generally, hydrophobic biomaterials displaying a bioerodible surface are used for devices 
that require a long half-life in vivo. Typically polyanhydrides and polyorthoesters are 
mostly applied [Angelova, 1999].  
A polymer is considered “bioerodible” if its solubility in water changes from not soluble 
to soluble, under physiological conditions. As formerly explained, the solubilization of 
the polymer may not necessarily involve the chemical breakdown of polymer backbone 
but can simply be associated to pH changes and ionic transfers. Therefore, bioerosion 
includes both physical processes (dissolution) and chemical processes (hydrolytic 
cleavage of chemical bonds, also mediated by enzymes). The suffix “bio” imply an 
erosion process that takes place under physiological conditions and distinguishes 
bioerosion from other degradative processes due to temperature, radiations or to the 
presence of either strong acids or bases. Biodegradation includes also the concept of 
bioresorption. Bioresorption (also called bioassorption) concerns the removal of the 
polymer and of its degradation products from the biological environment, mostly 
performed by cells by means of phagocytosis [Kohn, 1996]. The removal of solubilised 
polymer chains and degradation products may also ensue from renal excretion [Griffith, 
2002b]  
The bioerosion of a solid polymeric implant correspond to macroscopic changes of the 
device aspect, alterations of the physical-chemical properties, swelling, weight loss, shape 
changes and loss of functionality. Two different bioerosion modalities have been 
described in literature, namely bulk and surface erosions. In bulk erosion, water diffusion 
inside the polymer matrix is faster than the rate at which the polymer is converted into a 
water-soluble material. Therefore, water uptake is followed by an erosion process that 
occur inside the entire volume of the solid device. Typically, bulk erosion of polymeric 
materials induces the formation of pores that drive the physical decomposition of the 
device.  
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Conversely, in surface erosion, water penetration inside the polymeric device is slower 
than the dissolution process on the surface. Differently from bulk erosion, the gradual 
dissolution of polymer surface has a minor but progressive influence on the shape and 
mechanical characteristics of the device.   
 
1.2 BIOLOGICAL EVALUATION OF BIOMATERIALS 
 
1.2.1. Biocompatibility and Hemocompatibility 
 
The fundamental characteristic of biomaterials is their capability of interacting with 
organic tissues and biological fluids without inducing secondary alterations or damaging 
processes in the host living organism. Summarising, when biomaterials are in contact 
with body tissues, they should not cause toxic, inflammatory, or carcinogenic responses 
(biocompatibility) and their interactions with blood should not elicit coagulative or cell–
disruptive activities (hemocompatibility). Until the 1970s, the term “biocompatibility” 
was related to the biological inertness of the material. At present, the concept of inertia is 
questionable because there is no material that does not elicit a response when in contact 
with body compartments. Moreover, with the improvements in material technology and 
instrumentation, new materials have appeared on the scientific scenario. The 
characteristic of such materials is to degrade in the biological tissues and release 
degradation products that can interact “positively” with the living cells and their 
metabolism, thus bringing about favourable biological reactions for the implant life and 
functionality [Gatti 2002]. Because of this insight and development, biocompatibility was 
defined as “the ability of a material to perform with an appropriate host response in a 
specific application” [Williams 1987]. 
In general, any foreign material in contact with body tissues or fluids generates a specific 
reaction. The type and level of this reaction will depend on the particular body organ 
where this reaction originates and will consist of a complex and integrated defensive 
system. In particular, a reaction of inflammatory type can occur, involving the progressive 
intervention of macrophages and leukocytes and subsequent secretion of 
mucopolysaccharides and procollagen, which will finally give rise to a fibrous tissue 
coating the foreign body. A further reaction can be of immune type, due to the antigenic 
activity exerted by the material or by its release products. Other adverse reactions can be 
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represented by thrombogenesis, hemolysis, carcinogenesis or mutagenesis phenomena 
[Marconi 2002]. 
More in detail, a biocompatible material must satisfy the following requirements: 
o the material must not release soluble components, unless such release is intentional 
(e.g. controlled drug delivery systems); 
o the host organism must not degrade the implant, unless this degradation is 
programmed and desired (e.g. resorbable sutures); 
o the mechanical, physical, and chemical properties of the material must be modeled 
upon the required function and must be constant over the desired period of time; 
o the material must not be toxic, carcinogenic or theratogenic and must not negatively 
interact with the host immune system; 
o the implant must be able to undergo sterilization processes and preserve its properties. 
 
Polymeric biomaterials may be considered as constituted of mixtures of chemicals. Some 
of these chemicals are bound to the polymer backbone or held in the material matrix, 
while others are able to migrate and disperse in the biological environment, where they 
perform their functional role. Polymer matrix can also be contaminated by residuals of the 
solvents employed in both synthesis and processing of the material, as well as being 
constituted of polymers with a high polydispersity index and present chains with different 
molecular weights. The type and amount of these chemicals may determine the 
biocompatibility of the material.  
The evaluation of the biocompatibility is hence necessary to ensure the safety of the 
product and, in order to be declared suitable for clinical application a new material must 
undergo a series of in vitro and in vivo biocompatibility tests.  
Evaluation under in vitro conditions can provide rapid and inexpensive data on biological 
interactions, minimizing the use of animals in research. However, this must be tempered 
with an appreciation that the obtained results may not be relevant to the implant situation. 
Up to now, no in vitro protocol exists that is universally considered as substitute of in vivo 
tests.  
After the in vitro assessment of tissue compatibility, materials must undergo the in vivo 
evaluation by means of animal models. Several standard procedures for the biological 
identification and quantification of the risks associated with the biomedical materials have 
been defined by the International Organisation of Standardisation [ISO 10993, ISO 1992] 
in Europe, by Food and Drug Administration (FDA) [G95-1] and the American Society 
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for Testing and Materials (ASTM) in the United States. The most important assays 
(sometimes performed both in vitro and in vivo) include those aimed at the evaluation of 
hemocompatibility, in terms of hemolysis and thrombogenicity, irritation and 
sensitization effects, local effect after implantation, systemic toxicity, genotoxicity, 
carcinogenicity, and reproductive toxicity [Gatti 2002]. 
 
1.2.2. Cytotoxicity 
 
The term “cytotoxicity” is referred to toxic effects (death, alterations in cellular 
membrane permeability, enzymatic inhibition, etc.) at the cellular level [Ratner 1996].  
Nowadays, in vitro systems range from simple subcellular fraction, primary cultures and 
cell line, to three-dimensional organotypic cultures.  
In vitro cell culture represents certainly a powerful tool for the preliminary screening of 
biomaterials cytotoxicity. A wide variety of cell types ranging from stem cells, 
undifferentiated fibroblast like or epithelial like cells as well as highly differentiated and 
tissue specific cells can be isolated from many tissues and species, cultured over extended 
periods of time and/or cryopreserved for future use. Moreover, since most of the 
chemicals in charge for the development of diseases and death in animal and human are 
ultimately excreted at the cellular level, cultures of mammalian cells are particularly 
indicated for cytotoxicity evaluation. Cell-based assays can provide essential information 
on potential effects of chemicals on specific cell properties and provide relevant basis for 
further molecular studies [Chiellini F. 2006a].   
The main cell culture assays for testing cytotoxicity are: 
o Direct contact with the biomaterial surface 
o Exposure of the cells to solutions of the biomaterial or to extracts of solutions in 
which the biomaterial is placed (elution), depending on the solubility of the 
material in the culture medium 
o Indirect contact via, for example a diffusion layer such as agar. 
 
The choice of the method varies with the characteristics of the investigated material, the 
rational for doing the test, and the application of the data for evaluating biocompatibility. 
Commonly, the interpretation of the assays is based on morphologic effects on cell 
cultures, which are classified as light, moderate or strong grade. 
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When the cell culture is exposed to specific amounts of material, it is possible to evaluate 
the concentration of material that induces the 50% of cell death in respect to the control 
cell culture (IC50 value). The calculated values are useful for the establishment of the 
initial concentration of material to be employed in in vivo experiments. 
In the selection of the experimental method is important to weight the benefits and 
drawbacks of each assay, which are strictly related to the modality of the diffusion of 
toxic compounds from the tested material to the cells. 
In the direct contact and agar-diffusion methods, the diffusion of toxic products generates 
a concentration gradient that is expected arranged in concentric areas. The major 
difference between the two is that in direct contact method, the physical movement of the 
device may determine a trauma on the surrounding cells. Their morphology and vitality 
will result altered by the physical presence of the material and by the elevated 
concentration of toxic agents, if released. Despite the presence of cells in direct contact 
with the device, if the released toxic agents have good solubility in water they can diffuse 
in the culture medium and hence influence the entire cell population.  
In the agar-diffusion method the diffusion of the toxic compounds is still occurring but 
the physical trauma is prevented. 
In the elution tests, the interpretation of the assay considers the entire cell population. In 
this case, the toxic compounds are uniformly distributed in the plate and capable of 
affecting the entire cell population. Generally, a deeper experience in morphology 
evaluation is required when the elution tests are performed.  
The assay that involves the direct contact of the cells with the surface of the material 
mimics the clinical application of a device in a biological fluid, e.g. placed in the blood 
compartment. Aimed to a better reproduction of the physiological conditions, the material 
is directly located in a serum containing cell medium and kept at 37°C. In vivo, the 
proteins of the serum are responsible for the transport of insoluble compound in the 
blood. Similarly, when involved in the in vitro assays they are thought to enhance the 
solubilization of the substances extracted or released from the material. The direct contact 
assay is useful for the evaluation of specific surface geometries of a manufactured device 
as well as for the study of the raw material.   
In all the methods described, the quantitative evaluation of cytotoxicity can be performed 
by means of chromogenic assays. Cell response to the presence of the exgoneous material 
is usually measured in terms of cell vitality, proliferation and metabolic activity 
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(Tetrazolium salts), cell membrane damage (LDH release) and endocytosis capability 
(Neutral Red).  
A significant role is also played by cell adhesion on the biomaterial surface. Depending 
on the final application of the device, cell adhesion may be desirable or not. Chemical and 
physical factors, such as material surface charge, wettability, topography exposure of 
specific moieties, can affect cellular adhesion. Recently, new techniques for the 
evaluation of cytocompatibility in terms of cell adhesion have been reviewed. 
Immunochemistry, spectrophotometric analysis and image analysis have been applied 
[Manso 2002, Owen 2005].  
The arising of positive or negative false results in cytotoxicity assays can be obviated by 
an accurate morphological investigation, performed by means of different techniques, 
such as optical microscopy, confocal laser microscopy, epifluorescence, scanning electron 
microscopy and transmission electron microscopy. 
When the cytotoxicity profile of a material has been determined, application–specific 
tests are then performed to assess the biocompatibility. Current experience indicates that a 
material that is judged non-toxic in vitro will be non-toxic by in vivo assays. This does not 
necessarily mean that materials that are toxic in vitro could not be used in a given clinical 
application. The clinical acceptability of a material depends on many different factors, of 
which target cell toxicity is but one. 
 
1.2.3. Genotoxicity 
 
A material is defined mutagenic when it determines an increase of the number of 
mutations in specific genes and/or in entire chromosomes. Presently, in vitro methods for 
the quantitative evaluation of genotoxicity are not well developed. The most applied test 
aimed at the evaluation of genotoxicity is Ames test. This test verifies the mutagenic 
potential of a material on cell culture by comparison to a well know genotoxic material, 
applied as positive control, and a negative control [Gatti 2002]. 
The advances in genomic and proteomic will lead to deeper investigation of gene 
expression profiles at either the transcriptional or translational level, with expression 
profiles specifically related to the tested material or extracts [Butte 2004,Carpenter 2004]. 
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1.2.4. Carcinogenicity and Teratogenicity 
 
At present, the carcinogenicity of the materials is assayed in vivo. Polyethylene is 
commonly used as reference material, because it has been assessed that it does not induce 
neoplastic tissue formation. The main drawbacks of the assay are the long experimental 
time and the lack of absolute certainty that, once implanted, the material would not induce 
a carcinogenic response.  
Recently, in vitro tests have been set for the evaluation of the teratogenicy of a material 
during the cellular reproduction cycle. Future development of these assays concern the 
exploitation in vitro of cells containing manipulated DNA, similar to human DNA [Gatti 
2002]. 
 
1.2.5. Hemocompatibility 
 
Blood is a complex tissue with particular chemical, biological and biomechanical 
features. Blood is composed of a multitude of cell types that participate in a vast array of 
functions, including tissue repair and immune responses as well as oxygen transport. 
Moreover, blood also contains several soluble multicomponent protein systems that 
systematically interact in various ways to perform key functions. Because of the range 
and criticality of these functions, any source of cytotoxicity to blood cells or significant 
interaction with serum proteins can cause considerable harm.  
The sensitiveness of blood to the presence of a foreign body is appreciable also when it is 
withdrawn. Its properties and functionality may change with the extraction modality and 
affected by the chemical surface of the container. The reliability and reproducibility of in 
vitro hemocompatibility tests is therefore inadequate and do not predict the real 
hemocompatibility of the material [Gatti 2002].  
 
1.3 DRUG DELIVERY TECHNOLOGY 
 
The efforts in the identification of new lead compounds are often followed by failings in 
the late clinical trials or in the postmarket follow-up (phase IV). The main reason of this 
failure is that the 95% of all new potential therapeutics have poor pharmacokinetics and 
pharmaceutical properties [Orive 2004, Willis 2004]. Therefore, the development of 
appropriate drug delivery system for the transport to the target tissue and the release at 
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required time and concentration is essential. The aim of drug delivery technology is hence 
the maximization of the therapeutic efficacy and the minimization of the adverse effects 
of the drugs of interest. Indeed, drug delivery technology offers the possibility of 
mitigating the costs associated with drug failure, makes feasible the administration of 
labile drugs with good therapeutic potential but unsuitable physical-chemical properties, 
as well as provide solutions to many problems related to classical therapeutics currently 
available on the market.  
Controlled drug delivery technology is a multidisciplinary field that embraces chemistry, 
pharmaceutical technology and medicine, all contributing to human health care. 
Furthermore, the controlled release of active agents finds interesting applications also in 
tissue engineering and, more in general, in regenerative medicine. In tissue engineering, a 
new approach for driving cell orientation, proliferation and differentiation consist in the 
loading of required active molecules in the scaffold and design their release in agreement 
with tissue demand. Indeed, the synergic application of drug delivery concepts and the 
availability of advanced technology for the processing of the materials will lead to the 
production of multifunctional devices for regenerative medicine applications.   
Conventional drug administration usually leads to a “pulsed pattern” of the drug 
concentration in the blood, characterised by a typical peak and valley trend. During the 
therapy, the plasmatic concentration of the bioactive agent may fall outside the 
therapeutic range and the administration of the drug must be repeated after precisely time 
intervals in order to maintain the therapeutic action. Moreover, the active agent can be 
sensitive to changes in tissue pHs as well as been attacked by enzymatic degradation, 
loose some activity and have a reduced half-life. To avoid the rapid breakdown or 
clearance in vivo, the drug is commonly administered in high concentration, resulting 
sometimes in strong toxic effects or induced inflammatory processes. On the other side, 
when the plasmatic concentration drops below the therapeutic level there is a significant 
decrease of the therapeutic benefits (Figure 1.2). The possibility of optimizing the 
pharmaceutical form of bioactive agents by means of drug delivery technology gives a 
great chance to the new biotechnological drugs such as peptides, proteins, and 
oligonucleotides that usually are very active and often have very narrow therapeutic 
window. 
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Figure 1.2. - Variation of drug plasmatic concentration within time following 
conventional administration and by using controlled release devices. 
 
The drug delivery systems offer several advantages as compared to conventional dosage 
forms. The system is usually a reservoir of the therapeutic agent, with a specific time 
release of the drug, thus leading to a partial control of the pharmacokinetic that become 
complete if the system is also designed for the targeted release of the drug and influences 
its biodistribution. In addiction, the delivery system safeguards the drug from the attack of 
enzymatic degradation, it can enhance the penetration of the active agent in the diseased 
tissues improving its efficiency and reducing the toxicity. A better compliance and 
convenience of the patient are also achieved [Veronese 2002]. 
Compared to tradition drug formulation and administration, the advantages of a controlled 
delivery system can be summarised as follows: 
− continuous maintenance of drug levels within the desired therapeutic range; 
− reduction of harmful side effects; 
− potentially decreased amount of drug; 
− lower number of administrations and possibly less invasive, leading to improved 
patient compliance; 
− administration of pharmaceuticals with short in vivo half–life (for example 
peptides and proteins). 
 
In the development of drug delivery systems, the rational should be modified according to 
the specific biological substance and/or the particular therapeutic situation. Although 
clinical introduction of the first controlled release systems occurred 30 years ago, 
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nowadays these systems have an incredible impact on nearly every branch of modern 
medicine, including cardiology, ophthalmology, endocrinology, oncology, pneumology, 
immunology, and pain management. In the United States alone, the market size for drug 
delivery systems in 1997 was over 13 billions US$, in 2002 it raised to about $47 billions 
and is projected to grow to about $67 billion in 2006. As matter of fact, every year a 
considerable number of improved devices are presented and adopted for health care. In 
addition, many of highly profitable blockbuster drugs will reach patent expiry by 2006 
and lose about $37 billion in market value to generic competition. Optimizing products 
through drug delivery might be a successful strategy to re-launch competitive 
pharmaceutics [Langer 1998, Fuji-Keizai 2003]. 
 
Common types of controlled drug release systems are reported by following: 
o Oral systems 
o Formulates for parenteral administration 
o Therapeutic transdermal delivery systems 
o Ocular systems 
o Intrauterin and intravaginal systems 
 
Recently, the interest of pharmaceutical scientists is mainly focus on the formulation of 
nanosized drug delivery devices for the administration of protein drugs [Pawar 2004, 
Bilati 2005] oligonucleotides, DNA and RNA for gene regulation [Lambert 2001, Ravi 
Kumar 2004, Zhu 2004]. Next generation of drug delivery systems will be influenced by 
the “intelligent material design” in terms of developing systems sensitive to drug 
concentration itself and to certain physiological stimuli. Recognitive molecular systems 
with biosensing properties will be integrated in the delivery device so that the release of 
the therapeutic will occur only under specific conditions [Kayser 2005].  
Among the general characteristics that drug delivery systems should present, it is possible 
to mention the ability to incorporate the drug without damaging it, tuneable release 
kinetics, long in vivo stability, biocompatibility, in terms of lack of toxicity and 
immunogenicity, potential of targeting specific organs and tissues. All of these features 
are related to the nature of the materials that constitute the delivery system. In particular, 
the pursuit of an adequate compromise of both bulk and surface property represents an 
important issue to be addressed. Organic macromolecules have highly tuneable physical–
chemical characteristics and in some cases, polymeric materials can be further processed 
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or functionalized. Accordingly, they very likely represent the best–suited class of 
materials for drug delivery technology [Kashyap 2004]. 
 
1.3.1. Polymer–Based Drug Delivery Systems 
 
Polymeric systems have had an enormous impact on pharmacological therapy. In the past, 
many efforts were focused on using polymers that have a history of medical use and then 
adapting their microstructures to provide the desired delivery rate. Intentional design of 
materials is a more modern approach to solve specific issues of drug delivery [Kashyap 
2004]. First generation drug delivery devices were based on drug encapsulation in non–
degradable macromolecular matrices from which the drug could diffuse. Therefore, the 
release kinetics was completely dependent on the diffusive behaviour of the drug through 
the polymer matrix [Langer 1998]. Today, a second generation of drug delivery devices 
are under investigation. The polymer matrix is engineered in order to play an active role 
and permit the selective release of the incorporated drug to a specific site or against a 
selected tissue (drug targeting). Moreover, due to the in vivo degradability, the release 
kinetic profile can be precisely modulated [Uhrich 1999]. The first category of release 
systems consisted of simpler devices that could not be easily applied to particular cases, 
for example to protein delivery. On the other hand, the second–generation systems are 
characterized by high selectivity and efficiency, although they need careful control of the 
macromolecular structure of the polymer matrix. The particular requirements for 
controlled release applications dictate on each occasion the choice of polymer. Normally, 
the demand is less severe if the device is designed for external use or for oral 
administration; it is much more stringent if the system must be given intravenously, 
subcutaneously or for application into internal body compartments. For the external use, 
the polymer may be non–biodegradable, such as those having carbon–carbon or silicon–
oxygen backbones, whereas biodegradable materials are in great demand for internal 
applications.  
Typical examples of biodegradable and non–biodegradable polymers used in controlled 
release technology are listed in Table 1.3. 
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Table 3 - Non–biodegradable and biodegradable polymers commonly used in controlled 
release applications. 
 Non–degradable polymers Degradable polymers 
 Polysiloxanes Polylactides Polyglycolides 
 Polyacrylates Polycyanoacrylates  Polysaccharides 
 Polyurethanes Polyorthoesters  Polycarbonates 
 Polyethylene Polyphosphazenes  Poly(ε–caprolactone) 
 Polymethacrylates Polyanhydrides 
 
Drug delivery systems can be roughly classified in two main categories, namely systems 
in which the biological substance release is controlled respectively by the drug diffusion 
and by the degradation of the device. A historical excursus of the most applied delivery 
systems is reported briefly by following. 
 
1.3.1.1 Diffusion controlled delivery systems 
 
Diffusion controlled release systems are generally based on non–degradable polymeric 
materials [Uhrich 1999, Langer 1998], such as: 
o Ethylene–vinyl acetate copolymers (EVAc) 
o Ethylene vinyl alcohol copolymers (EVA) 
o Polymers and copolymers of 2–hydroxyethyl methacrylate (HEMA) and more in 
general poly(methacrylate)s 
o Polysiloxanes (silicones) 
In these systems, the drug diffuses through the polymer matrix or membrane because of 
the thermodynamic driving force arising from the different concentration of the drug 
inside and outside the device. Two different classes of release devices can be identified, 
namely membrane (reservoir) devices and matrix (monolithic) systems. 
 
1.3.1.1.1 Membrane systems 
 
In membrane systems, the drug is surrounded by a polymeric film (Figure 1.2) whose 
porosity is not homogeneous, and which determines the drug release rate [Theeuwess 
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1991]. These devices are more complex than matrix systems, but they offer a higher 
control of release profiles. 
             Drug
time = 0
Polymer
membrane
Released 
drug
Polymer
membrane                    
time = t
 
 
Figure 1.2 - Schematic representation of membrane release systems. 
 
The drug can be a dry powder dispersed in a liquid or entrapped in a solid polymer 
matrix. The membrane can be a microporous or macroporous polymer film. Its 
composition changes from one component to a mixture of polymers, or to a 
heterogeneous matrix in which hydrophilic polymer particles are dispersed in a 
hydrophobic polymer matrix. The membrane and the active core can be assembled using 
different technologies: drug and solid membrane lamination into films; drug coating with 
a volatile solution of the polymer; drug microencapsulation; tubular membrane loading 
with dissolved or dispersed drug; drug loading in membrane capsules. 
This latter approach led to the development of Norplant, small silicone capsules 
containing contraceptives that are slowly released by diffusion through the polymer for 5 
years. The main limit of these systems is that the sustained delivery of ionic species and 
of molecules with molecular mass over about 400 cannot be accomplished. 
 
1.3.1.1.2 Matrix systems 
 
To address the issues of matrix systems, drugs can be physically embedded in polymers at 
large enough concentrations to create a series of interconnecting pores through which the 
drug can slowly diffuse. 
In these systems, the matrix may consist of hydrophobic or viscous hydrophilic polymers 
in which the solid drug is dispersed (Figure 1.3). Generally, the drug is sparingly soluble 
in the polymer matrix. These release systems are cheap and readily available, since they 
are prepared simply by mixing the polymer matrix and the drug. The desired device shape 
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is obtained later by extrusion. The release mechanism is based on the diffusion of the 
drug molecules to the device surface where they are delivered. This process takes place as 
long as the higher concentration of the drug in the system core affords a constant flow of 
drug molecules through the matrix. 
In this dissolution–diffusion process, the interface between the drug reservoir and the 
release moiety progressively moves towards the core of the device. 
 
Drug
dispersed
in the
matrix
Drug
released from
the matrix
time = 0 time = t  
 
Figure 13 - Schematic representation of matrix release systems. 
 
1.3.1.2 Degradable delivery systems 
 
In degradable delivery systems, the drug is loaded in a bioerodible and/or biodegradable 
polymer matrix. The release takes place because of a combination of processes, such as 
matrix degradation and drug diffusion. The use of these materials was considered in order 
to avoid the problems related to the physiological excretion or mechanical removal of the 
not degradable drug delivery devices after their function is completed. Of course, these 
devices are the preferred ones for internal application. It is worth noting that the 
combination of diffusion through pores and polymer degradation process provides a 
further control of the drug release rate. 
In ideal systems, the degradation occurs only at the surface of the device, affording a 
progressive delivery of the drug (Figure 1.4). 
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             Drugdispersedin the polymermatrixtime = 0      Releaseddrugtime = t  
Figure 1. 4 - Schematic representation of degradable matrix systems. 
 
However, swelling phenomena and/or internal polymer degradation usually take place, 
thus making the overall kinetics more complex. Especially bulk erosion makes constant 
release rates difficult to be achieved and creates the possibility of dose dumping as the 
system eventually hydrolyzes. To address these issues, it would be desirable to design 
polymers that display only surface erosion. One strategy to achieve this goal is based on 
the use of polymers constituted by hydrophobic units connected by water–labile bonds. 
This approach has the advantage of keeping water away from the polymer bulk while 
allowing for controlled erosion when water reacts with the matrix surface [Langer 1998]. 
In general, an almost constant release profile over long periods can be achieved by fine 
modulation of geometric, chemical, degradation, and porosity characteristics of the 
device. In this respect, degradable drug delivery systems can be formulated in different 
shapes, i.e. cylinders, sticks, microcapsules, microspheres, nanoparticles, films, and 
fibers. 
It is convenient to classify biodegradable release systems according to the mechanism 
responsible of matrix degradation and hence of drug delivery. Three main types of 
polymer matrix can be identified [Heller 1980]. 
 
o Bioerodible crosslinked matrix. This kind of matrix is constituted of water–soluble 
polymers that are crosslinked to give non–soluble networks. By hydrolytic or 
enzymatic cleavage, water–soluble macromolecules are formed, and the release of the 
incorporated drug is achieved (Figure 1.5). 
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Figure.1.5 - Schematic representation of bioerodible crosslinked matrix. 
 
o Water insoluble/soluble matrix. In this case, water insoluble polymers may become 
soluble because of ionization, hydrolysis, or protonation of the side chains, allowing 
the drug to be released (Figure 1.6). 
 
 
Figure 1.6 -  Schematic representation of water insoluble/soluble matrix. 
o Bioerodible/biodegradable matrix. Hydrolytic cleavage of main chain bonds of water 
insoluble polymers may afford medium–low molecular weight fragments that are 
soluble in water (Figure 1.7). 
 
 
Figure 1.7 -  Schematic representation of bioerodible/biodegradable matrix. 
 
 
In recent years, the awareness of the concept of circadian rhythms and the deeper 
understanding of pathophysiology of several diseases have given rise to the concept of 
novel pulsatile drug delivery systems. In these systems, the release of the drug is 
modulated in order to match the effective need of drug action. This ad hoc release profiles 
would increase drug effectiveness, reduce the toxicity as well as avoid the development of 
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tolerance and receptors downregulation. Polymers able to receive and respond to specific 
stimuli have been prepared and applied for the development of such drug delivery 
systems [Bi-Botti 2004, Orive 2005]. The mentioned stimuli can be physiological (pH, 
temperature, presence of specific agents and chemicals, e.g. enzymes, antigens, sugars 
etc.) or external (ultrasonic radiations, magnetic fields, light, mechanical, electrical, etc.) 
[Kataoka 1998, Ferreira 2000, Lee 2000]. 
 
1.3.2. Colloidal Drug Delivery Systems 
 
Colloidal drug delivery systems represent one of the most studied and developed systems 
during the last decades, due to the possibility to achieve a controlled release of active 
principles. Because of their small particle size, once suitably modified, colloidal drug 
carriers are the most promising systems to attain the goal of targeted release. 
The fate of a drug after administration in vivo is determined by the combination of drug 
absorption, distribution, metabolism, and elimination. Regardless the administration path, 
the bioavailability of the drug depends mainly on its physicochemical properties and 
therefore on its chemical structure. In particular for intravenous injection, the limit of 
drug solubility can be solved in different ways. General approaches consist in specific or 
non-specific complexation (e.g. with PEG or cyclodextrins), the use of solvent mixtures, 
micronization, micro-precipitation or disintegration techniques (pearl milling, high 
pressure homogenization) [Müller 2001]. Release control from these products is hardly 
tuneable, whereas the loading of the therapeutic agent into drug carriers allows for a 
better control of drug biodistribution, bioavailability and pharmacokinetics [Barratt 2003]. 
Colloidal drug delivery systems include liposomes, niosomes, dendrimers, micelles, 
nanoparticles, and microemulsions. Ointments, which also can be conceived as colloidal 
drug delivery systems, are mainly used topically and therefore are very different in their 
way of action from the above mentioned systems. Colloidal carriers are very similar in 
their size, shape, and mode of administration, and for this reason they may be used 
alternatively. Nevertheless, they present a number of different advantages and 
disadvantages, so that the most suitable system will have to be chosen depending on the 
drug and the therapeutic goal to be reached [Kreuter 1994, Moghimi 2005]. 
Examples of different colloidals and their application is summarised in Table 4 [Orive 
2004] 
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Table 4 - Colloidal drug delivery systems and examples of their applications 
 Nanoparticle  Description Recent applications 
 Dendrimers  Macromolecular compound that Rapid and complete release of paclitaxel 
  comprises a series of branches  (used in the treatment of cancer) from  
  around an inner core  dendrimers; dendrimer degradation products 
   are not cytotoxic [De Groot2003] 
 Liposomes  Artificial spherical vesicles  Liposomal doxorubicin has been employed 
  produced from natural  successfully in the treatment of recurrent  
  phospholipids and cholesterol uterine adenosarcoma in mice [Vaage 1995] 
 Ceramic nanoparticles  Nanoparticles made using  Ultra-fine silica-based nanoparticles that 
  inorganic compounds such release water-insoluble anticancer drugs 
  as silica and titania [Roy 2003] 
 Nanocapsules  Vesicular systems in which the  Artificial red blood cell nanocapsules with 
   drug is surrounded by a  PEG–PLA membrane; circulation half-life 
  polymeric membrane  of blood cells is doubled [Chang 1998] 
 Micelles  Amphiphilic block copolymers  PCL–PEO block copolymer micelles that 
   that can self-associate in  could selectively deliver drugs to specified 
  aqueous solution  subcellular targets [Savic 2003] 
 Hybrid nanodevices  Hybrid nanoparticles  DNA TiO2 nanoparticles with the ability to 
  covalently bond to oligonucleotide target, bind and clave DNA 
   [Paunesku 2003]] 
 Nanospheres  Matrix systems in which the  Uptake of PLGA nanospheres by human 
  drug is physically and uniformly  dendritic cells in vitro; has implications for 
  dispersed  the selective activation of the T-cell- 
   mediated immune response [Lutsiak 2002] 
 
 
1.3.2.1.  Liposomes and niosomes 
 
Liposomes were first suggested as carriers for bioactive agents in 1971 [Gregoriadis 
1971] and nowadays they are the most developed and available carrier system 
[Gregoriadis 1988]. Liposomes are small artificial spherical vesicles constituted of one or 
more concentric lipid (usually phospholipids and cholesterol) layers delimiting an inner 
water phase. When mixed in water under low shear conditions, the phospholipids arrange 
themselves in sheets, the molecules aligning side by side in “heads” up and “tails” down 
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orientation. Once the critical concentration of lipids is overcome, these sheets join tails–
to–tails to form a bilayer membrane, which encloses some of the water in a phospholipid 
sphere. Typically, several of these vesicles will form one inside the other in diminishing 
size, creating a multilamellar structure of concentric phospholipid spheres separated by 
layers of water. The diameter of these vesicles ranges from 200 nm to 1 µm. By 
sonication or ultra high–shear processing, unilamellar vesicles and bilayer spheres having 
30–200 nm diameter can be obtained (Figure 1.8).  
Based on their size and structure, liposomes are generally classified in three cathegories: 
small unilamellar vescicles (SUV), large unilamellar vescicles (LUV) and multilamellar 
vescicles (MLV).  
The introduction of positively or negatively charged lipids provides liposome surface 
charge, whereas liposome bilayer can be chemically grafted to functional moieties or 
polymers, e.g. PEG-grafting [Lasic 1999].  
Liposomes are used as biocompatible carriers of conventional and unconventional drugs, 
for pharmaceutical, cosmetic, and biochemical purposes. 
 
 
Figure 8 - Schematic representation of unilamellar liposome. 
 
 
The enormous versatility in particle size and in the physical characteristics of the lipids 
afford an attractive potential for constructing tailor–made vehicles for a wide range of 
applications. Liposomes can be custom designed for almost any need by varying the lipid 
content, size, surface charge, and method of preparation. A special quality of liposomes is 
that they enable water–soluble and water–insoluble materials to be used together in a 
formulation without the use of surfactants or other emulsifiers. Water–soluble materials 
are dissolved in the water in which the phospholipids are hydrated, and when the 
liposomes form, these materials are trapped in the aqueous centre. Conversely, the 
liposome wall holds hydrophobic features. Even thought liposomes are characterized by 
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positive aspects, such as high drug payloads and good bio–acceptability, they present 
some drawbacks related to their in vitro and in vivo instability (sensitivity of the 
phospholipid membranes to environmental degradation, rapid drug leakage across the 
phospholipid bilayer), unreliable reproducibility and difficult surface functionalization. 
Niosomes are vesicles made of non–ionic surfactants [Uchegbe 1998] characterized by an 
increased chemical stability that gives them a significant advantage over liposomes. 
Examples of substances entrapped in this kind of carrier include anti–cancer [Naresh 
1996] and anti–leishmanial drugs. Moreover, niosomes are intended as vaccine 
adjuvants, since the formulation of antigens as niosomes in water–in–oil emulsion further 
increases the activity of antigens [Sarker 2005]. 
 
1.3.2.2.  Nanoparticles 
 
Polymeric nanoparticles have been developed since 1976 by using non–biodegradable 
polymers [Birrenbach 1976] and since 1979 by using biodegradable polymeric systems 
[Couvreur 1979]. Over the past few decades, pharmaceutical principles and 
nanotechnology have been applied for the preparation of nanoparticles for either 
therapeutical or diagnosis purposes [Brigger 2002, Sahoo 2003, Sinha 2004, Bala 2004, 
Hoet 2004, Salata 2004]. Nanoparticles are solid colloidal particles made of synthetic or 
natural polymers with diameter ranging from about 10 nm to 1 µm.  
The biologically active molecules can be adsorbed or attached onto nanoparticle surface, 
or entrapped, dissolved, or encapsulated inside the carrier. Nanoparticles is a collective 
name for nanospheres and nanocapsules. The first ones have a matrix type structure in 
which the drug is dispersed physically and uniformly, whereas the second ones have a 
polymeric outer shell and an inner liquid core [Allemann 1993a] (Figure 1.9). 
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Figure 1.9 -  Comparison of the structure of nanospheres (matrix systems) and 
nanocapsules (reservoir systems) 
 
 
The design of a polymer matrix for NP formulation does improve material performance in 
terms of physical chemical characteristics, surface properties and allows for tailoring 
targeting systems, as surface engineered nanoparticles. In particular, the size and surface 
characteristics of the nanoparticles, in terms of charge, hydrophilic–hydrophobic balance, 
and presence of reactive groups will dramatically affect their body distribution and their 
targeting attitude [Kreuter 1994]. 
The advantages of using nanoparticles as drug carrier mainly result from their two basic 
properties. First, because of their size, they can penetrate through small capillaries and be 
uptaken by cells, thus inducing efficient drug accumulation at the target sites [Panyam 
2003]. Second, the availability of a wide set polymeric materials and further possibility of 
biofunctionalize particles surface with targeting and stealth moieties [Hawker 2005].  
Nanoparticles can be administered in fluidized form with a liquid carrier. This permits 
their use in the preparation of intravascular infusions and of injectable suspensions for 
both parenteral and enteric administration. Nanoparticles for sustained release can be 
formulated based upon the composition and material characteristics of the specific 
polymers, drugs, and excipients used [Song 1997]. Nanoparticles can be designed for 
different kind of administration routes: intravenous, intramuscular, subcutaneous, oral, 
nasal, ocular, transdermal. Depending on the desired mode of administration, the size of 
the carriers should be optimized. By taking into account that the diameter of the smallest 
Nanocapsule
Nanosphere
Polymer matrix
Polymeric membrane
Oily or aqueous core
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blood capillaries is about 4 µm, a reduction of the particle size enables intravenous 
injection; this is desirable also for intramuscular and subcutaneous administration, 
because it minimizes possible irritant reactions [Kreuter 1994, Hoet 2005]. 
Among the most used synthetic nanoparticle matrices, poly(alkyl cyanoacrylate)s, 
poly(ethylene glycol) (PEG), and polyesters, such as poly(lactic acid) (PLA), poly(lactic–
co–glycolic acid) (PLGA), poly(ε–caprolactone) (PCL), and copolymers thereof can be 
mentioned. With regard to available toxicological and clinical data, the aliphatic 
polyesters based on lactic and glycolic acids are unquestionably the most widely 
investigated polymers. Their high biodegradability and biocompatibility are well 
assessed. In fact, it is known that lactide/glycolide polymer chains are cleaved by 
hydrolysis to form natural metabolites (lactic and glycolic acids), which are eliminated 
from the body through the Krebs cycle. The use of biodegradable materials avoids the 
problems related to the physiological excretion or mechanical removal of the delivery 
device after drug depletion. Moreover, the presence of a biodegradable matrix can 
provide a further control of the release rate, by joining the typical diffusive mechanism 
with tunable polymer degradation [Bala 2004]. 
As mentioned above, a fundamental characteristic of nanoparticles is their ability to 
deliver drugs across several biological barriers. Recently, it has been demonstrated that 
poly-(butylcyanoacrylate) nanoparticles coated  with polysorbate 80, are effective in 
crossing blood–brain barrier and transporting the hexapeptide dalargin and other agents 
into the brain [Kreuter 2003]. Nanoparticles have been produced also for the sustained 
intracellular drug delivery. As an example, nanoparticles were effective in sustaining 
intracellular dexamethasone levels in the treatment of vascular smooth muscle cells 
[Panyam 2003, 2004]. The delivery of antigens for vaccination has also been considered 
as a novel application of nanoparticles [Lutsiak 2002]. 
 
1.4. NANOPARTICLES IN CANCER THERAPY 
 
A death every 4–5 seconds worldwide is attributed to cancer, accounting for some 10 
million diagnosed sufferers per year of which 6 million are estimated to lose their life to 
the disease every year [Parkin 2005]. The number of incidences is expected to increase by 
an additional 50% by 2020 [WHO]. Typically nearly 1million people in Europe die of this 
disease annually, accounting for 1 every 4 deaths [Commission Report IP/03/657]. The 
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potential benefits to be gained by successful treatment, when considering the basis of 
quality of life alteration by a therapy as being defined as the extent of change in quality of 
life over the length of change of that quality of life, are considerable. For a disease that is 
often fatal and affects such a vast proportion of the population, intervention is an 
extremely worthy goal as it has the potential for those successfully treated to lead a 
relatively normal and healthy life.  
The advantage of using polymer based nanosystems for the administration of 
commercially available or newly investigated anti-cancer drugs is the improvement of 
their physico-chemical features in order to tune their the pharmacokinetics accordingly to 
the specific tumour treatment, minimize inherent toxicity to other non-targeted tissues and 
gain cost-effective utilization of the active species (particularly in the case of expensive 
peptide-based materials). Furthermore, the failure of present treatments is sometimes 
associated with tumour resistance to cytotoxic drugs. The co-formulation of currently 
used antimetabolite or peptidic chemotherapeutics and adjuvant agents into polymeric 
nanostructured delivery systems is a promising approach to achieve anticancer drug 
retention in tumour sites and maximize the effectiveness of tumour treatment. 
 
1.4.1. Routes of Administration  
 
1.4.1.1.  Systemic administration 
 
The association of a cytostatic drug to conventional carriers leads to modifications of the 
drug biodistribution profile [Brigger 2002]. For drugs associated to ‘conventional’ 
colloidal carriers, the usual fate is opsonization by plasma proteins followed by 
phagocytic cells uptake: either polymorphonuclear leukocytes in the blood or fixed 
macrophages, particularly the Kupffer cells in the liver [Barratt 2003], that is, to the 
mononuclear phagocytes system (MPS) (liver, spleen, lungs and bone marrow) [Brigger 
2002]. 
Hence, when conventional nanoparticles are used as carriers in chemotherapy, some 
cytotoxicity against the Kupffer cells or other targeted macrophages can be expected, as 
the class of drugs being used is able to induce apoptosis in these cells. Treatments 
featuring frequent administrations (with intervals shorter than 2 weeks, period of 
restoration of Kupffer cells) could result in a deficiency of Kupffer cells, which in turn 
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could lead to a decreased liver uptake, and a subsequent decreased therapeutic efficacy 
for hepatic tumours. A risk for bacteriemia can also not to be excluded. 
Moreover, conventional carriers also target the bone marrow (MPS organ), which is 
already an important but unfavourable site of action for most anticancer drugs. Hence, 
chemotherapy with such carriers may increase myelosuppressive effects. Acute renal 
toxicity was another reported doxorubicin toxicity [Brigger 2002], an anthracycline 
antibiotic and one of the most popular anticancer drugs [Mizutani 2005], which is 
amplified by the association of the drug to conventional nanospheres. This toxicity 
(proteinuria) on the kidneys was probably the result of a modified biodistribution of the 
associated drug, leading to a strong uptake by mesangial cells, which resulted in 
glomerular damage. 
However, despite the amplification of these side-effects, it is likely that conventional 
nanoparticles have a better safety profile than free anticancer agents, when acting on 
normal tissues. For example, a very important aspect is the significant reduction in 
distribution of doxorubicin to heart indicating their potential in reducing the 
cardiotoxicity associated with doxorubicin therapy [Reddy 2004]. 
Consequently, the contribution of conventional nanoparticles to enhance 
anticancer drugs efficacy is limited to targeting tumours at the level of MPS organs. 
Addressing anticancer drug-loaded nanoparticles to other tumoural tissues is not feasible, 
due to their very short circulation time (the mean half-life of conventional nanoparticles is 
3–5 min after intravenous administration). Besides, penetration of such a carrier system 
across the leaky tumoural endothelium would be derisory, leading to subtherapeutic 
concentrations of the drug near the neoplastic cells [Brigger 2002]. 
Since the usefulness of conventional nanoparticles is limited by their massive capture by 
the macrophages of the MPS after intravenous administration, other nanoparticulate 
devices must be considered to target tumours, which are not localized in the MPS area. A 
great deal of work has been devoted to developing so called ‘Stealth™’ particles, which 
are ‘invisible’ to macrophages [Brigger 2002]. Stealth particles circulate for prolonged 
hours; reported half-lives vary from 2 to 24 h in mice and rats and can be as high as 45 h 
in humans depending on the particle size and the characteristics of the coating polymer. 
Numerous interesting approaches for design and engineering of long circulating vehicles 
have been described. Among them, surface stabilization of nanoparticles and liposomes 
with a range of non-ionic surfactants or polymeric macromolecules has proved to be one 
of the most successful approaches for keeping the particles in the blood for prolonged 
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periods of time. Surface enrichment of nanocarriers with non-ionic surfactants can be 
performed by physical adsorption, incorporation during the production of the carriers, or 
by covalent attachment to any reactive surface groups. The presence of such surfactants 
on the particle surface strongly reduces interparticulate attractive Van der Waals forces 
while increasing the repulsive barrier between two approaching particles [Moghimi 
2003]. 
Recently the body distribution in mice of 14C-labeled poly methoxyethyleneglycol 
cyanoacrylate-co-n-hexadecyl cyanoacrylate (PEGPHDCA) nanoparticles and in situ 
evading of phagocytic uptake by mouse peritoneal macrophages has been investigated. 
Phagocytic uptake by macrophages was efficiently evaded by fluorescent PEG-PHDCA 
nanoparticles. The distribution of stealth PEG-PHDCA nanoparticles and non-stealth 
PHDCA nanoparticles in mice was poor in lung, kidney, and brain, and a little higher in 
hearts. Lymphatic accumulation was unusually high for both stealth and non-stealth 
nanoparticles, typical of lymphatic capture. The accumulation of stealth PEG-PHDCA 
nanoparticles in the spleen was 1.7 times as much as that of non-stealth PHDCA (P<0.01) 
but the accumulation of stealth PEG-PHDCA nanoparticles in the liver was 0.8 times as 
much as that of non-stealth PHDCA (P<0.05). PEGylation led to long-circulation of 
nanoparticles in the bloodstream and splenotropic accumulation [Huang 2005]. 
The influence of polysorbate 80 on the distribution of poly(butyl cyanoacrylate) (PBCA) 
doxorubicin-loaded nanoparticles in rats was investigated. The biodistribution profile and 
brain concentration of 14C-radiolabeled PBCA nanoparticles, polysorbate 80 coated 14C-
PBCA nanoparticles, and doxorubicin-loaded 14C-PBCA nanoparticles were determined 
by radioactivity counting after i.v. administration in rats. The 14C-PBCA nanoparticles 
showed a significant accumulation in the organs of the reticuloendothelial system (RES). 
Polysorbate 80 coating of the 14C-PBCA nanoparticles decreased this accumulation to 
about 40% after 1 h post injection. The brain concentration was increased about 2-fold 
after polysorbate 80-coating at this time point. The presence of doxorubicin in this 
preparation, however, decreased the brain concentration to levels similar to uncoated 
particles, probably caused by the positive charge of this compound. After longer time 
periods upon injection the differences between the three preparations decreased 
[Ambruosi 2005]. 
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1.4.1.2.  Local administration 
 
Unlike water-soluble molecules, which are rapidly absorbed through the blood capillary 
wall and pass into circulation, small particles injected locally infiltrate into the interstitial 
space around the injection site [Brigger 2002]. The introduction of local delivery devices 
for sustained administration of antineoplastic agents represents a new opportunity to 
effectively treat cancer [Raza 2005]. Subcutaneously or locally (in the peri-tumoural 
region) injected nanoparticles, gradually absorbed by the lymphatic capillaries into the 
lymphatic system, can be used for lymphatic targeting, i.e. as a tool for chemotherapy 
against lymphatic tumours or metastases [Brigger 2002]. Intracranial administration of 
targeted local delivery of therapeutic agents, which combine various antineoplastic 
strategies that include cytotoxic, anti-angiogenic and immunomodulatory mechanisms in 
the treatment of malignant brain tumours could improve the treatment and prognosis of 
patients affected by these tumours [Raza 2005] 
 
1.4.1.3.  Oral administration 
 
The oral route is attractive for drug administration because it is associated with patient 
convenience and compliance and lower costs. One of the major challenges of 
pharmaceutical technology remains the design of oral delivery systems able to minimise 
or circumvent the metabolism of a given drug in the intestinal tract and/or in the intestinal 
wall [Arbos 2004]. 
Bioadhesive drug delivery systems enhance drug bioavailability by prolonged residence 
at the site of absorption owing to increased epithelial contact. Most bioadhesives known 
to date are synthetic macromolecules, in the form of micro/nanoparticles that interact with 
the mucosal surface and are hence referred to as mucoadhesives [Sharma 2004]. 
Coating the particles by appropriate bioadhesive materials such as polyvinyl alcohol 
(PVA), poly(ethylene glycol) (PEG), Vitamin E succinated polyethylene glycol 1000 
(Vitamin E TPGS), etc. can greatly improve their adhesion to and absorption into the 
intestinal cells as well as the ability to escape from the multi-drug resistance pump 
proteins. 
Vitamin E TPGS is a water-soluble derivative of vitamin E, which has been found to be 
an excellent emulsifier/solubilizer/absorption enhancer of high emulsification efficiency 
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and cellular adhesion. Vitamin E TPGS acts as a reversal agent for P-glycoprotein 
mediated multi-drug resistance and inhibits P-gp mediated drug transport.  
Vitamine E TPGS-coated PLGA nanoparticles have significantly higher level of cellular 
uptake compared with PVA-coated PLGA nanoparticles and an observed plateau effect of 
the cellular uptake efficiency against nanoparticle concentration or cell incubation time 
suggested that the cellular uptake of polymeric nanoparticle is saturable. Once 
internalized, nanoparticles were mostly seen throughout the cytoplasm surrounding the 
nucleus and minority of them were found in the nucleus, especially in the case of vitamin 
E TPGS-coated PLGA nanoparticles. Nanoparticles of biodegradable polymers of small 
enough size and with appropriate surface coating may have great potential to be applied 
for oral delivery of anticancer drugs as well as other therapeutic agents [Khin 2005].  
Amifostine (Ethyol, WR-2721) is a cytoprotective drug approved by the US FDA 
[Pamujula 2004]. It is a selective broad-spectrum cytoprotector of normal tissues that 
provides cytoprotection against ionizing radiation and chemotherapeutic agents, thus 
preserving the efficacy of radiotherapy and chemotherapy [Koukourakis 2002]. Pamujula 
and co-workers (2004) [Pamujuka 2004] developed an orally active amifostine loaded 
nanoparticles formulation. Since amifostine is metabolized to its active form, WR-1065, 
by intracellular alkaline phosphatase, the tissue levels of WR-1065 were measured, 
instead of WR-2721. WR-1065 was detected in significant amounts in all tissues, 
including bone marrow, jejunum and the kidneys, and there was some degree of 
selectivity in its distribution in various tissues.  
 
1.4.1.4.  Gene therapy and gene silencing therapy  
 
Alternative therapies for cancer treatments include targeted gene therapy. The ideal gene 
therapy agent would be targeted for specific transduction of tumour cells and have 
specificity in its cytotoxic action. Several strategies have been investigated, including 
enzyme–pro-drug activating systems, correction of genetic mutations contributing to the 
malignant phenotype and stimulation of a T-cell-mediated anti-tumour immune response. 
A general overview of the most promising anti-tumour gene therapy strategies with 
particular reference to the clinical trials is reported in a recent review from Palmer et al. 
2006 [Palmer 2006]. In general, the development of effective olygonucleotides delivery 
system to be employed in gene therapies requires the achievement regarding both the 
tolerability under physiological conditions and an enhanced cellular uptake. The ideal 
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vector would be easy to produce, have an unlimited capacity for transgene inserts, be non-
immunogenic and mediate transgene expression efficiently and specifically in target cells. 
Presently, inefficient gene transfer and the inability to use systemic administration remain 
major limitations to cancer gene-therapy using the available vectors. Generally, polymeric 
nanoparticles are considered safer than other carriers, such as inactivated viruses; they can 
effectively be endocytosed by the cells and lead to higher cellular uptake compared to 
naked DNA administration [Varga 2005]. The endocytosis process can be ligand 
mediated, usually exploited in targeted drug release startegies, or nonspecific, due to ionic 
interaction with cells [Molas 2003]. Basically, the olygonucleotides can be adsorbed on 
particulate carriers surface or integrated in their matrix, either physically or through 
electrostatic interaction with positively charged materials [Lambert 2001].  
In the development of nano-sized synthetic vectors for gene therapy, poly cationic 
polymers and dendrimers have been extensively investigated for the formation of 
polymer/DNA complexes generally referred to as "polyplexes" [De Wolf 2005, 
Santhakuman 2004]. The most applied polymers are polyethylenimine (PEI) and 
polypropylenimine (PPI), which also have an intrinsic anti-tumour effect [Ambrose 1958, 
Dufes 2005]. Polyethylenglycol (PEG) has also been widely applied in the preparation of 
olygonucleotides-carriers due to its antiopsonising properties, exploited in a wide variety 
of nanoparticles studies. In fact, it is well known that PEG forms a brush corona on 
particle surface (branches pointing outwards) that, besides avoiding the recognition by 
RES, can enhance particle tolerance under physiological conditions, nuclease resistance, 
and gene-expression in serum-containing medium [Itaka 2004, Otsuka 2003].  
The use of PH-sensitive polymers appears also advantageous because they can help by 
effectively target the acidic extracellular matrix of tumours. Sethuraman et al. 2006 
[Sethuraman 2006] investigated the use of DNA/PEI/ poly(methacryloyl 
sulfadimethoxine) (PSD)-block-PEG (PSD-β-PEG) and evidenced high cytotoxicity and 
transfection on human ovarian carcinoma cell line.  
As alternative to synthetic and natural polymer, recombinant DNA technology has been 
applied for the biological synthesis of engineered protein polymers with precise 
aminoacids sequence [Haider 2004, Haider 2005]. Although limitations in cloning and 
expression of cationic polymers as well as the high costs of such methodology, the 
recombinant synthesis of protein-based polymers offers the opportunity to control over 
the detailed physicochemical properties of the polymers in order to specifically interact 
with DNA sequences and promote cell uptake. Silk-elastin-like protein polymers (SELP) 
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are the most investigated genetically engineered protein-based polymers applied in cancer 
gene therapy [Megeed 2004, Haider 2005b].  
SELPs are composed of amino acid motifs from two naturally occurring proteins: Bombyx 
mori (silkworm) silk (GAGAGS) and mammalian elastin (GVGVP). The combination of 
the two blocks in various ratios and sequences generates an assortment of biomaterials 
with diverse material properties, such as gelation, crosslinking density, biodegradation, 
biorecognition, and stimuli-sensitivity [Megeed 2002].  
The dimensions of the gene carrier have been correlated to the efficacy of cellular uptake 
and it has been shown that particles with a mean diameter of 70-130 nm lead to a more 
effective cellular uptake [Prabha 2002]. Conversely, the Zeta potential value (ζ) of 
nanoparticles (particle surface charge) has rarely been correlated to the cellular uptake, 
especially for negatively charged particles. It has been shown that Pegylated polyplexes 
displaying positive ζ potential values in the range of +20 mV lead to higher levels of 
cellular uptake, compared to similar polyplexes systems with lower positive surface 
charges [Schifferers 2004]. 
A powerful tool for cancer treatment is represented by the new RNA interference gene 
silencing approach. The discovery of RNA interference (RNAi) in 1990 [Napoli 1990, 
Koes 1990] and a vast new world of tiny regulatory RNAs has profoundly changed the 
way of thinking about gene regulation in plants, many fungi, and animals. RNAi is based 
on a gene-censoring mechanism originally developed by cells for silencing genes in 
viruses and mobile DNA sequences and then used in the regulation of gene expression. 
Cells may naturally produce long double-stranded RNA specifically to silence normal 
genes, but small RNA fragments are more common [Lau 2003]. These small RNAs are 
termed “short interfering RNAs” (siRNAs) 15-25 nulceotides, when the siRNA comes 
from the same type of gene or genomic region that ultimately become silenced, 
“microRNAs” (miRNAs) whereas they come from genes whose sole mission is to 
produce these tiny regulatory RNAs. siRNAs and miRNAs down-regulate gene 
expression by binding to complementary messenger RNA (mRNA) and either triggering 
mRNA elimination (siRNA) or arresting mRNA translation into protein (miRNA) 
[Matzke 2003]). To invoke RNAi-mediated gene silencing in human cells, duplex siRNA 
(or miRNA) is inserted into cells. Once inside cells, siRNA duplexes undergo 5-
phosphorylation, unwound and one strand of the duplex is loaded into an assembly of 
proteins to form the RNA-induced silencing complex (RISC), which includes an 
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undefined nuclease called “slicer”. The activated RISC (RISC*) and the unwound 
antisense strand will adhere well only to a messenger RNA that closely complements its 
own nucleotide sequence. A single site-specific cleavage of the mRNA target then occurs, 
in the middle of the complimentarity. Once cleavage has occurred, target mRNA is 
degraded and RISC is recycled for another cleavage reaction. Cells have also developed 
an amplification step of the RNAi mechanism. Single-stranded RNAs, not associated with 
RISC, can bind mRNA in a sequence specific manner and serves as primers for RNA-
dependent RNA polymerase to polymerise the antisense RNAs. The resulting dsRNAs are 
the substrates for a dsRNA-specific endonuclease belonging to the RNAse III family 
(called “dicer”) that cut the long dsRNAs in siRNAs [Agrawal 2003].  
The evolving understanding of the molecular pathways important for carcinogenesis, 
tumour-host interaction and tumour resistance to conventional therapies has created a 
wide library of targets for RNAi intervention. Several strategies have been recently 
reviewed by Lage  [Lage 2005] and Pai et al. [Pai 2006]. Similarly to dsDNA, “naked” 
double stranded siRNAs give minor in vitro transfection and poor stability. 
Nanoparticulate carrier systems lend themselves to an application in siRNA delivery. PEI 
has been the most investigated polymer for the preparation of RNAi delivery systems 
[Urban-klein 2005]. As example, ligand-targeted, sterically stabilized nanoplexes can be 
prepared by selfassembly and investigated to specifically target tumour neovasculature 
expressing integrins and deliver siRNA inhibiting vascular endothelial growth factor 
receptor-(VEGF R2) expression in order to inhibit tumour angiogenesis [Shiffelers 2004]. 
 
1.4.2. Tumour targeting 
 
1.4.2.1.   Epitope-Paratope interaction 
 
The use of specific ‘vector’ molecules that show affinity toward ligands characteristic for 
target tissues can further enhance tumour targeting of peptide and protein carriers or make 
them EPR-effect independent. The use of specific vector molecules is especially 
important for tumours with immature vasculature, such as those in the early stages of their 
development, and for delocalized tumours. Vector molecules capable of recognizing 
tumours include antibodies, peptides, lectins, saccharides, hormones and some low 
molecular weight compounds, such as folate and some vitamins. From this list, antibodies 
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and their fragments have the highest potential specificity and thus provide the most 
promising opportunity for targeting [Pwar 2004]. 
Monoclonal antibodies have been widely investigated as cancer-targeting agents because 
tumour cells are known to express surface antigens that are specific to the cancer cells. If 
an overexpressed molecule on a cancer cell is directly involved in growth promotion, an 
antibody by itself may be useful in inhibiting cell growth in a tumour. Antibodies can also 
be utilized to target a drug into the cell, either by direct conjugation of the drug to the 
antibody as an “immunoconjugate” or conjugated to a carrier molecule [Thomas 2004]. 
Core-shell polymeric nanoparticles (PNPs), amphiphilic block copolymers containing 
small-molecule drug segments and tosylated hexaethylene glycol segments, that allowed 
for the surface conjugation of single-stranded DNA sequences and/or tumour-targeting 
antibodies were recently prepared. To endow PNPs with biomolecules relevant to breast 
cancer, PNPs were modified with Bcl-2 antisense oligodeoxynucleotides (asODNs) and 
antibodies that target the transmembrane human epidermal growth factor receptor-2 
(HER-2). These multifunctional PNPs were readily internalized in breast cancer cells that 
overexpressed the corresponding antigens. Control experiments revealed minimal 
nonspecific binding [Bertin 2006].  
Two approaches to target biodegradable poly(lactic acid) (PLA) nanoparticles (NPs) to 
tumour cells were explored. Anti-HER2 monoclonal antibodies (mAbs) (trastuzumab, 
Herceptin) and anti-CD20 mAbs (rituximab, Mabthera) were used as targeting ligands. 
Experiments have shown that nanoparticles covalently coupled with antibodies can 
specifically and efficiently bind to cancer cells in both a pretargeting and a direct 
approach, suggesting that functionalized nanoparticles may be a useful drug carrier for 
tumour targeting [Nobs 2006]. 
Lipid nanoparticle encapsulating paclitaxel-7-carbonyl-cholesterol (Tax-Chol), a prodrug 
of paclitaxel with increased lipophilicity, were prepared in the presence of folate-
polyethylene glycolcholesterol (f-PEG-Chol) in order to target the tumour marker folate 
receptor (FR). FR-targeted lipid nanoparticles showed greater uptake and cytotoxicity in 
FR(+) KB, a human oral carcinoma cell line, and M109 a murine lung carcinoma cell line 
than non-targeted lipo nanoparticles [Stevens 2006]. 
Peptides such as vascular endothelial growth factor (VEGF), vasoactive intestinal peptide 
(VIP), luteinizing hormone releasing hormone (LHRH), somatostatin etc. are used for 
targeting drugs to their specific receptors which are expressed abundantly in different 
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disease states. Non-toxic binding fragment of tetanus toxin has been used to improve 
central nervous system delivery of proteins by systemic administration [Vasir 2005]. 
Lectins are proteins or glycoproteins of nonimmunological origin, which specifically 
recognize sugar molecules, and therefore are capable of binding glycosylated membrane 
components. They are widely used to characterize carbohydrates on cell surfaces. In the 
past 10 years, increasing attention has been focused on the lectins conjugated colloidal 
carrier systems, such as liposome or nanoparticles to improve oral drug absorption [Gao 
2006]. 
 
1.4.2.2.  Targeted Delivery Through Enhanced Permeability and Retention (EPR) 
 
A critical advantage in treating cancer with advanced, colloidal based therapies is the 
inherent leaky vasculature serving cancerous tissues. The defective vascular architecture, 
created due to the rapid vascularization necessary to serve fast-growing cancers, coupled 
with poor lymphatic drainage allows an enhanced permeation and retention effect (EPR 
effect) [Brannon-Peppas 2004] (Figure 1.8 ). 
Recently, studies were carried out to determine the biodistribution profiles and tumour 
localization potential of poly(ethylene oxide) (PEO)-modified poly(amino ester) (PbAE) 
as a novel, pH-sensitive biodegradable polymeric nanoparticulate system for tumour-
targeted drug delivery. PbAE nanoparticles effectively delivered the encapsulated payload 
into the tumour mass. PEO-modified PbAE nanoparticles showed considerable passive 
tumour targeting potential in early stages of biodistribution via the enhanced permeation 
and retention (EPR) mechanism. This prompts a detailed biodistribution profiling of the 
nanocarrier for prolonged periods to provide conclusive evidence for superiority of the 
delivery system [Shenoy 2005]. 
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Figure 1.8 - A schematic diagram depicting the passive or ligand-targeted accumulation 
of liposomal DDS in breast cancer tumours through the EPR effect. (A) Liposomes 
containing an anticancer drug extravasate from the blood through gaps in vascular 
endothelial cells and accumulate in tumour tissue (dark green), but not in  normal tissue 
(light green). (B) Drug is released from the liposomes in the vicinity of the tumour cells 
and taken up into the cells. (C) Ligand-targeted liposomes containing anticancer drugs, 
or nucleic acid– based  herapeutics such as plasmid DNA or antisense oligonucleotides, 
bind to cell surface receptors (dark green triangles), which triggers internalization of the 
DDS into endosomes when a ligand against an internalizing receptor is chosen. Some 
proportion of the encapsulated material escapes the endosomes and traffics to its 
intracellular site of action [Allen 2004] 
 
1.4.2.3.  Targeting Through Angiogenesis 
 
Tumour vascularization is a vital process for the progression of all solid tumours from a 
small, localized focus to a large tumour with the capability to metastasize [Huang 2004]. 
This process has been the subject of intense research due to its role in cancer development 
and has proven to be the result of numerous interactions between regulators, mediators 
and stimulatory molecules. These molecules regulate the proliferative and invasive 
activity of the endothelial cells that line blood vessels. Some of the most prominent 
angiogenesis stimulatory molecules include vascular endothelial growth factor (VEGF), 
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basic fibroblast growth factor (FGF), platelet-derived growth factor (PGF) and certain 
matrix metalloproteinases. Some endogenous angiogenesis inhibitors are the interferon 
family thrombospondin-1 and -2, certain tissue inhibitors of matrix metalloproteinases 
and protein fragments such as angiostatin and endostatin. 
Because a vascularized tumour is capable of increased growth and is more readily able to 
metastasize, increasing amounts of research are focused on developing treatments to slow 
angiogenesis and limit tumour growth and dissemination. So many different molecules 
are involved in angiogenesis hence giving many potential targets for therapy. Some 
examples of therapeutic strategies include limiting endothelial proliferation and motility, 
increased expression of angiogenesis inhibitors and use of molecules such as soluble 
VEGF receptor to try to decrease the amount of angiogenesis stimulatory factors at the 
tumour site [Torchilin 2003]. 
Integrin αvβ3 and vascular endothelial growth factor receptor 2 (Flk-1) have been shown 
to be involved in tumour-induced angiogenesis. Selective targeting of upregulated αvβ3 
and Flk-1 on the neovasculature of tumours is an antiangiogenesis strategy for treating a 
wide variety of solid tumours [Lingyun 2004]. 
 
1.4.2.4.  Targeting Through Magnetic Devices  
 
Magnetic Nanoparticles (MNPs) offer exciting new opportunities towards developing an 
effective drug targeting delivery system. It is possible to produce, characterize and 
specifically tailor the functional properties of magnetic nanoparticles for their clinical 
applications [Vasir 2005]. 
The sub-cellular accumulation of Superparamagnetic Iron Oxide Nanoparticles (SPIONs) 
in breast tumours and peripheral organs was investigated. Magnetic nanoparticles were 
conjugated with luteinizing hormone releasing hormone (LHRH), whose receptors are 
expressed by most types of breast cancer cells. After the nanoparticles were injected into 
female nude mice LHRH conjugated SPIONs (LHRH- SPIONs) were found to 
accumulate in cancer cells, mainly in the primary tumours and the metastatic lungs, where 
they aggregated to form clusters. In contrast, most of the unconjugated SPIONs were 
collected in the liver cells suggesting that LHRH-SPIONs can be used to target cancer 
cells in the primary breast tumours and the lung metastases. [Zhou 2006].  
CESARE ERRICO – PHD THESIS 
 44 
Copenhagen rats in which cancer cells had been implanted were treated with Magnetic 
Fluid Hyperthermia (MFH), a new technique for interstitial hyperthermia or 
thermoablation based on AC magnetic field-induced excitation of biocompatible 
superparamagnetic nanoparticles. Treatment animals received two MFH treatments 
following a single intratumoural injection of a magnetic fluid. MFH led to a significant 
growth inhibition in this orthotopic model of the aggressive MatLyLu tumour variant. 
Intratumoural deposition of magnetic fluids was found to be stable, allowing for serial 
MFH treatments without repeated injection [Johannsen 2005]. 
Other systems regarded as promising in the fight against cancer are ultrasmall 
superparamagnetic iron oxides particles (USPIO) with an anticancer drug entrapped in 
their ferrous core [Brigger 2002]. 
 
1.5. DRUG DELIVERY IN TISSUE ENGINEERING 
 
Recently, Tissue Engineering (TE) has become a well recognized technique, and many 
researchers with different areas of expertise are entering this medical field, thereby 
increasing its scientific implications. The objective of tissue engineering is to regenerate 
natural tissues from living cells to replace defective or lost tissues and organs [Tabata 
2001]. 
It is undoubtedly necessary for cell-based tissue regeneration to make use of key cells 
constituting the tissue. To this end, the research of basic medicine and biology regarding 
cells should be developed. However, only by providing the cells to a site to be 
regenerated, the induction of tissue regeneration cannot always be expected. It has been 
well recognized that cells generally interact with the extracellular matrix (ECM) to live 
and biologically function in the body. Considering this in vivo system, it will be easy to 
scientifically understand necessity to create an appropriate environment which enables 
cells to efficiently proliferate and differentiate, inducing tissue regeneration. It is tissue 
engineering that is a biomedical engineering or technology to create this regeneration 
environment. Without efficient creation of the regeneration environment, it will be 
impossible to realize the cell-induced regeneration therapy only by the basic results of cell 
medicine and biology [Tabata 2005 (1)]. 
In other words, it is necessary to increase the number of cells that constitute the tissue as 
well as reconstruct the structure to support the cells. In addition, growth factors are 
required to promote cell differentiation and proliferation and then achieve tissue 
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regeneration. The controlled release concepts can be inherent and be a potential assistant 
in these three main factors. The ‘traditional’ drug delivery approach can be applied to 
encapsulate living cells for incorporation within the scaffolds. In turn, scaffolds can be 
designed as ‘traditional’ drug delivery carriers to control a site and time-specific release 
profile and also to protect the growth factor [Malafaya 2002]. However, few researchers 
have applied this Drug Delivery System (DDS) to the field of Regenerative Medicine 
(RM) [Tabata 2005 (2)]. 
Drugs for RM include proteins and genes that are effective in promoting the proliferation 
and differentiation of cells for the induction of tissue and organ regeneration [Tabata 2005 
(2)].  
Although autologous cells are an excellent source for use in tissue engineering, they are 
fully differentiated and as thus have a decreased ability to proliferate. On the contrary the 
high proliferative potential of stem cells enables them to be directionally differentiated, 
according to their location, and the endocrine stimuli they receive. These cells, 
incorporated in an appropriate matrix (a drug delivery system–DDS vector) could be 
protected from aggressive environments, be targeted to precise locations and remain in 
place as long as they are needed. Their incorporation on a drug delivery system would not 
only protect them from the host immune response, as well as keep them viable, by 
providing protection and nutrients that could be encapsulated along with the cells in the 
carrier, and also release them at the desired rate that could be achieved through a 
controlled release system. In the future, these cells may prove extremely important in 
tissue engineering [Malafaya 2002].  
The use of PLGA microspheres as biodegradable microcarriers of pluripotent cells and as 
delivery systems of bioactive factors, which influence cell differentiation was 
investigated. The pluripotent P19 embryonal carcinoma cell line was used as a model to 
study cell attachment, growth and differentiation of pluripotent stem cells encapsulated 
into PLGA microspheres. Retinoic acid (RA) was encapsulated in the PLGA 
microcarriers to influence cell differentiation, more specifically, to induce P19 cell 
differentiation into neurons. The results of these ex-vivo studies clearly demonstrate the 
capacity of PLGA microspheres to serve a dual role as both delivery systems of bioactive 
factors and as scaffolds for pluripotent cells [Newman 2004]. 
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1.5.1. Growth Factors role and Delivery 
 
Drugs for RM include proteins and genes that are effective in promoting the proliferation 
and differentiation of cells for the induction of tissue and organ regeneration [Tabata 2005 
(2)]. Growth factors are proteins [Vasita 2006] secreted by a wide range of cell types to 
transmit signals that activate specific developmental programs controlling cell migration, 
differentiation, and proliferation [Chen 2003]. The term growth factor is perhaps not best 
suited to describe the functions that these polypeptides perform, since promoting growth 
is not the only activity they are involved in. Infact, quite often they are involved in just 
the opposite, that is stopping growth [Vasita 2006]. Cell signaling occurs through growth 
factor binding to its receptor on the cell surface. The signal is transferred through the 
membrane receptor and amplified, often through phosphorylation of secondary 
messengers within the target cell, to ultimately modify gene expression. Growth factors 
act in a concentration- and time-dependent manner, often requiring minute quantities to 
elicit biological activity, and their action can depend on a variety of factors, including cell 
location within a tissue structure and cell cycle state. Elucidation of differentiation and 
proliferation pathways for various tissues has revealed that they are complex events 
involving a cascade or a network of multiple growth factors [Chen 2003] 
The direct injection of growth factor in solution into the site to be regenerated is generally 
not effective because the growth factor rapidly diffuses from the injected site and is 
enzymatically digested or deactivated [Tabata 2005]. Therefore, it demands for either 
extremely higher doses and/or frequent injections. For clinical beneficial outcome, these 
growth factors require a delivery system to guide tissue regeneration and prevent the rapid 
dispersal of the factors from the site [Malafaya 2002]. Over time, DDS has been 
improved as a technology to enhance the in vivo efficacy of therapeutic drugs [Tabata 
2005 (2)]. 
There are several important considerations in the design of a delivery system for 
growth factors used to regenerate or engineer tissues. First, given the quantity and 
complex actions of growth factors, it is essential to identify the key growth factor or 
factors to deliver for a particular tissue application based on an understanding of 
biological developmental processes. Second, the mode of factor delivery must target the 
desired cell population and minimize signal propagation to nontarget tissues and cells. 
Third, the controlled delivery of factors requires a relatively long-term maintenance of 
biologic activity within the system. These systems function in many ways as an artificial 
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ECM to stabilize embedded or encapsulated growth factors. This is often challenging 
because processes used to formulate protein delivery constructs may denature or 
deactivate the protein. Therefore, methods of fabrication that do not require harsh 
solvents or high temperatures are often desirable if the protein itself is used as the 
regenerative agent. Finally, the release profile of the growth factor from the system 
should be controlled temporally and spatially to be appropriate for a specific tissue injury 
or disease [Chen 2003]. 
The two currently methods to administer growth factors on injured tissues are direct 
growth factors delivery and gene delivery.  
Direct growth factor delivery can be performed using one of the following two 
approaches: localized or systemic delivery. When the effect of the protein is desired for 
the entire body it is administered via the circulatory system. However for many 
applications, it is required to deliver the growth factor to a specific site of tissue 
regeneration, or localized delivery is sought. In such cases, delivery via the circulatory 
system could be inefficient or prove to be harmful and lead to toxic effects. In this case, 
the growth vehicle is directly implanted at the specific defect site [Vasita 2006].  
The development of tissues and organs is typically driven by the action of a number of 
growth factors. However, efforts to regenerate tissues (e.g., bone, blood vessels) typically 
rely on the delivery of single factors, and this may partially explain the limited clinical 
utility of many current approaches. 
Growth factors may be incorporated into scaffolds by two approaches The first approach 
involves simply mixing lyophilized VEGF with polymer particles before processing the 
polymer into a porous scaffold and results in a rapid release (e.g., days to weeks in 
duration) of VEGF. The second approach involves pre-encapsulating a factor in PLGA 
microspheres, and then fabricating scaffolds from these particles. The two approaches 
may be combined by mixing particulate polymer and one factor with microspheres 
containing a pre-encapsulated second factor to provide multiple growth factor delivery 
with a distinct release rate for each factor. Dual delivery of VEGF and Platelet-Derived 
Growth Factor (PDGF)-BB, each with distinct kinetics, from a single, structural polymer 
scaffold was demonstrated to lead to a rapid formation of a mature vascular network 
[Richardson 2001]. 
The list of growth factors having a putative effect on osteogenesis is considerable [Meinel 
2001]. A large body of data derived from in vitro and in vivo studies has substantiated the 
importance of Insulinlike Growth Factor-I (IGF-I) in promoting bone growth after 
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fracture. IGF-I is a polypeptide, which is secreted by the following two mechanisms: (1) 
Production in the liver for endocrine action; and local production, e.g., by osteoblasts or 
chondrocytes, for paracrine action. 
IGF-I was microencapsulated into an end-group uncapped poly(D,L-lactide-co-glycolide) 
by solvent extraction from a w/o/w dispersion. Released IGF-I causes cell proliferation 
and increases matrix apposition rates in bones. 
The developed microspheres proved to be suitable to release biologically intact IGF-I 
over up to 13 days, a time-period considered to be relevant to promote bone fracture 
healing. Indeed, one of the formulations presented here promoted very strongly new bone 
formation in an artificial bone defect in sheep [Meinel 2001]. 
Direct growth factor delivery is more suitable for fulfilling short-term, temporary 
requirements, wherein the growth is required to be present at the defect site for a limited 
duration (ideally until regeneration has occurred), after which its action is not desired. 
However, gene delivery, due to the possibility of both a lasting gene expression or a 
transient gene expression, is suitable for overcoming the deficiency of a growth factor 
permanently or temporarily as the need may be [Vasita 2006]. 
 
1.5.2. Cell-Based Gene Delivery 
 
Application of genes encoding for growth factors, for therapeutic use and tissue 
regeneration in particular, is the idea behind gene delivery. There are two methods 
through which gene therapy can be facilitated: cell-based gene delivery and direct gene 
delivery using a delivery vehicle. 
The first strategy includes the delivery cells such as stem cells, lymphocytes, fibroblasts 
or the cells of interest are removed from the body and injected via a therapeutic transgene. 
After their genetic modification, the cells are allowed to grow in vitro and increase in 
number. Once sufficient number of cells are obtained, they are readministered at the 
defect site in the patient. 
 
1.5.3. Direct Gene Delivery 
 
Tissue repair and regeneration can also be promoted by direct delivery of genes (encoding 
growth factors) from polymeric scaffolds used in tissue engineering. Direct gene delivery 
can be systemic or localized. In the case of systemic delivery, the vector (having the gene 
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of interest) is injected through a vein or artery, whereas in localized delivery, the vector is 
injected directly into the local site [Vasita 2006]. 
A number of non-viral approaches to gene delivery have been described in TE, mostly 
based on polycations such as polylysine, polyhistidine, or polyethylene imine. These 
polycations, with the exception of those based on histidine, induce high levels of 
transfection, but are also associated with relatively high levels of cytotoxicity, which can 
limit their usefulness for in vivo transfection. To avoid this toxic polycationic effect, 
oligomeric cationic peptides were developed. The potential of HIF-1 gene therapy in 
stimulating wound healing was explored. A gene encoding a stabilized form of HIF-1 was 
delivered in fibrin as a surgical matrix by using a peptide-based gene delivery vector. 
HIF-1 functions as a sensor of hypoxia and induces expression of vascular endothelial 
growth factor (VEGF).  When the peptide-DNA nanoparticles entrapped in fibrin 
matrices were applied to full thickness dermal wounds in the mouse, angiogenesis was 
increased comparably strongly to that induced by VEGF-A165 protein [Trentin 2006]. 
Gene delivery, due to the possibility of both a lasting gene expression and a transient gene 
expression, is suitable for overcoming the deficiency of a growth factor permanently or 
temporarily depending on the need. However direct growth factor delivery is more 
suitable for fulfilling short-term, temporary requirements, wherein the growth is required 
to be present at the defect site for a limited duration (ideally until regeneration has 
occurred), after which its action is not desired [Vasita 2006].  
 
1.6. TECHNIQUES OF NANO- AND MICROPARTICLE PREPARATION 
 
The setting up of polymeric nanoparticles preparation process requires an accurate 
investigation on polymer and drug physical chemical characteristics. The optimized 
preparation process should guarantee for the chemical stability and biological activity of 
the incorporated drug. Particularly, when the active loaded agent is a protein, its 
denaturation upon contact with hydrophobic organic solvents or acidic/basic aqueous 
solutions should be avoided by using appropriate preparation conditions. The 
encapsulation efficiency and the yield of the process should be high enough for mass 
production and the produced nanoparticles should display a homogeneous diameter 
distribution, in agreement with their end-use requirements. Nonetheless, the preparation 
and purification processes must lead to high reproducible results and the release profile of 
the drug should meet the specific final application requisites. Finally, in case of final 
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pharmaceutical dosage forms that involve the recovery of a suspension of nanoparticles in 
appropriate mediums, free-flowing nanoparticles should be prepared and appropriate 
storage conditions should be investigated.  
There are a number of techniques available for the preparation of drug loaded 
nanoparticulate systems such as the emulsion solvent evaporation/extraction method, 
spray drying, phase separation-coacervation, interfacial deposition, and in situ 
polymerization. Each method has its own advantages and disadvantages. The choice of a 
particular technique depends on polymer and drug features, site of action and therapy 
regimes [Sinha 2004]. An extensive description of several preparation methods has 
recently been reviewed [Reis 2006], additional techniques concerning the preparation of 
nanoparticles from preformed polymers are reported by following. 
 
1.6.1. Emulsion-Solvent Evaporation/Extraction Methods 
 
1.6.1.1.  Single Emulsion Method 
 
This method has been primarily used to encapsulate hydrophobic drugs through oil-in-
water (o/w) emulsification process [Tark 2005]. The hydrophobic drug is dissolved or 
dispersed in an organic solvent into the polymer solution, and the resulting mixture, after 
emulsification by high-speed homogenisation or sonication, is added into an aqueous 
solution to make an oil-in-water emulsion with the aid of amphiphilic macromolecules, 
which are termed emulsifier/stabilizer/additive [Si-Feng 2004]. The solvent in the 
emulsion is removed by either evaporation at elevated temperatures or extraction in a 
large amount of water, resulting in formation of compact particles. 
The solvent evaporation method has been used extensively to prepare PLA and PLGA 
micro- and nano-particles containing many different drugs [Kim 2006]. Several variables 
have been identified which can influence the properties of the nanoparticles, including 
drug solubility, internal morphology, solvent type, diffusion rate, temperature, polymer 
composition, viscosity, and drug loading [Panyam 2004]. This method, however, is only 
available for the hydrophobic drugs because the hydrophilic drugs may diffuse out or 
partitioning from the dispersed oil phase into the aqueous phase, leading to poor 
encapsulation efficiencies [Park 2005]. Many types of drugs with different physical and 
chemical properties have been formulated into polymeric systems, including anti-cancer 
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drugs, narcotic agents, local anesthetics, steroids, and fertility control agents [O’Donnel 
1997]. 
 
1.6.1.2.  Double Emulsion Method 
 
Several water-soluble drugs have been encapsulated by water-in-oil-in-water (w/o/w) 
methods. The aqueous solution of the water-soluble drug is emulsified with polymer-
dissolved organic solution to form the water-in-oil (w/o) emulsion. The emulsification is 
carried out using either high speed homogenizers or sonicators. This primary emulsion is 
then transferred into an excess amount of water containing an emulsifier under vigorous 
stirring, thus forming a w/o/w emulsion. In the subsequent procedure, the solvent is 
removed by either evaporation or extraction process. 
One advantage of this method is encapsulation of hydrophilic drugs in an aqueous phase 
with the high encapsulation efficiency. For this reason, the w/o/w emulsion system has 
been used widely for the development of protein delivery systems. The characteristics of 
the particles prepared by the double emulsion method are dependent upon the properties 
of the polymer (such as composition and molecular weight), the ratio of polymer to drug, 
the concentration and nature of the emulsifier, temperature, and the stirring/agitation 
speed during the emulsification process [Park 2005].  
 
1.6.2. Phase Separation 
 
This method involves phase separation of a polymer solution by adding an organic 
nonsolvent. Drugs are first dispersed or dissolved in a polymer solution. An organic 
nonsolvent is added to this solution (e.g. silicon oil) under continuous stirring, by which 
the polymer solvent is gradually extracted and soft coacervate of droplets containing the 
drug are generated. The rate of adding nonsolvent affects the extraction rate of the 
solvent, the size of the particles and encapsulation efficiency of the drug. The commonly 
used nonsolvents include silicone oil, vegetable oil, light liquid paraffin, and low-
molecular-weight polybutadiene. The coacervate phase is then hardened by exposing it 
into an excess amount of another nonsolvent such as hexane, heptane, and diethyl ether. 
The final characteristics of the colloidal product are affected by the molecular weight of 
the polymer, viscosity of the nonsolvent, and polymer concentration. The main 
disadvantage of this method is a high possibility of forming large aggregates. Extremely 
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sticky coacervate droplets frequently adhere to each other before complete phase 
separation.  
This technique is promising for preparation of protein-loaded microcapsules. For 
example, conventional methods of preparing microparticles involve extensive exposure of 
proteins to the interface between aqueous and organic phases, to hydrophobic polymer 
matrix, and to acidic/basic microenviroments resulting from degradation of the polymer. 
These unfavorable interactions are reported to induce conformational changes of proteins. 
On the contrary, the interfacial phase separation technique is shown to minimize these 
sources of protein inactivation [Yeo 2004]. 
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1.6.3. Solvent displacement 
 
1.6.3.1. Nanoprecipitation Method 
 
The nanoprecipitation technique for nanoparticle preparation was first developed and 
patented by Fessi and co-workers in 1989 [Fessi 1989] and it is a straightforward 
technique, rapid and easy to perform. 
The nanoparticle formation is instantaneous and the entire procedure is carried out in only 
one step. The polymer and the drug are dissolved together and precipitated in a 
nonsolvent, miscible with the former one. Nanoprecipitation occurs by a rapid desolvation 
of the polymer when the polymer solution is added to the non-solvent. Indeed, as soon as 
the polymer-containing solvent has diffused into the dispersing medium, the polymer 
precipitates, involving immediate drug entrapment (Figure 1.9).  
 
 
 
Figure 1.9  - Schematic representation of nanoprecipitation procedure 
 
The rapid nanoparticle formation is governed by the so-called Marangoni effect, which is 
due to interfacial turbulences that take place at the interface of the solvent and the non-
solvent and result from complex and cumulated phenomena such as flow, diffusion and 
surface tension variations. Nanoprecipitation often enables the production of small 
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nanoparticles (100–300 nm) with narrow unimodal distribution and a wide range of 
preformed polymers can be used, such as poly(d,l-lactic-co-glycolic acids), cellulose 
derivatives or poly caprolactones. 
This method does not require extended shearing/stirring rates, sonication or very high 
temperatures, and is characterized by the absence of oily-aqueous interfaces, all 
conditions that might damage a protein structure. Moreover, surfactants are not always 
needed and unacceptable toxic organic solvents are generally excluded from this 
procedure. 
However, the original nanoprecipitation method suffers from some drawbacks. This 
technique is mostly suitable for compounds having a hydrophobic nature such as 
indomethacin, which is soluble in ethanol or acetone, but displays very limited solubility 
in water. Recently, formulation and process modifications were investigated to improve 
the versatility of the nanoprecipitation technique, particularly with respect to the 
encapsulation of hydrophilic drugs (e.g. proteins) [Bilati 2005]. 
The nanoprecipitation method has been used extensively to prepare nanoparticles 
containing many different drugs [Fonseca 2002]. 
 
1.6.3.2.  Co-Precipitation Method 
 
The co-precipitation method is an original and straightforward procedure developed by 
the research group where this PhD thesis have been carried out [Cowdall 1999a]. It is 
particularly advantageous for the loading of protein drugs into a polymer matrix. In this 
case, the polymer is dissolved in a water–miscible organic solvent and added dropwise to 
an aqueous solution containing the selected protein and appropriate stabilizers. During the 
co-precipitation process, the polymeric material gives rise to microphase separation 
because of its low water solubility and the concurrent interaction with protein molecules 
leads to nanoparticle formation. Indeed, this methodology does not entail the use of 
chlorinated solvents and it does not require vigorous shear mixing, preventing appreciable 
denaturation of the entrapped protein molecule that typically occurs with other 
techniques. It is well established, in fact, that exposure of proteins to factors such as 
organic solvent and sonication during the encapsulation process can reduce the biological 
activity of proteic active agents [Park 1995]. Albumin, λ-interferon, trypsine, urokinase 
and hemoglobin have been loaded into bioerodible polymeric nanoparticles by following 
the co-precipitation technique [Chiellini 2007]. 
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1.6.3.3. Dialysis Method 
 
Some disadvantages of the conventional methods include the difficulties and necessities 
of removal of solvent and surfactant residues, low particle yield, excessive steps for 
preparation, and the necessity to use a high concentration of surfactant for the preparation 
of small spherical particles and polymeric micelles. The dialysis method is a simple and 
effective preparation method for small and narrow size distributed nanoparticles mostly 
using block graft copolymers and other amphiphilic materials [Jeong 2001]. Polymer, 
drug and surfactants are dissolved in the same organic solvent and placed inside a dialysis 
tube with proper molecular weight cut-off. Dialysis is performed against a nonsolvent, 
miscible with the former one. The displacement of the solvent inside the membrane is 
followed by the progressive aggregation of polymer, drug and surfactants due to a loss of 
solubility and by the formation of homogeneous suspensions of micro- nanoparticles 
(Figure 1.10). Trials of preparations without surfactants were performed. The dialysis 
method was applied to PLGA starting from different solvent solutions and avoiding the 
use of surfactants. The solubility of the particles components in the initial solvents may 
affect the physicochemical properties such as particle size and drug contents, whereas the 
absence of surfactant led to some drawbacks such as instability of the re-dispersed freeze-
dried PLGA nanoparticles and low drug loading efficiency [Jeong 2001]. 
Poly(lactide)/tween 80 copolymers were synthesized, aiming at incorporating a widely 
used emulsifier for biomedical nanoparticles preparation directly in polymer backbone. 
Nanoparticles loaded with anticancer drug were obtained by using the dialysis method 
and without use of additional surfactants/emulsifiers [Zhang 2006].  
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Figure 1.10 -  Schematic representation of dialysis procedure 
 
 
1.6.4. Self assembling 
 
Recently it has been demonstrated that nanoparticles can be obtained by interaction 
between charged polymers and oppositely charged molecules. Such association depends 
on many factors including coulombic interactions, hydrophobicity of the polymer–
molecule pair, and the conformational features of the polymer (Figure 1.11). One special 
class of such systems is the complexes formed by polyions of opposite charges. The 
solution behavior of these complexes strongly depends on their composition. 
Electroneutral complexes that contain equivalent amounts of polyion units and monomers 
are water-insoluble. 
Nonstoichiometric complexes containing an excess of one of the components are 
generally soluble in water. Since these complexes are capable of forming aggregates of 
nanometer size, they have been termed as polyion complex (PIC) micelles or block 
ionomer complexes (BICs) [Gupta 2006]. 
Micellar drug delivery systems display several advantages over other particulate 
configurations. For example, they can significantly enhance the water solubility of 
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hydrophobic drugs for improved bioavailability. They usually exhibit low critical micelle 
concentration (CMC), rendering the drug-loaded micelles stable in the bloodstream to 
achieve fairly long circulation time [Liu 2003]. 
Typical studies were focused on polystyrene-β-poly(ethylene oxide), polystyrene- β -
poly(acrylic acid) and polystyrene- β-poly(methacrylic acid), etc. The traditional micelles 
are unable to sense a signal and respond by changing their structures. Incorporating 
external control over structure and physical properties offers the possibility of 
constructing systems capable of both tunable transformation and controlled transmission 
of energy or information. For this purpose thermosensitive [Liu 2003], pH sensitive 
[Hsiue 2006], and pH and temperature sensitive micelles [De Wolf 2005] had been 
engineered.  
 
 
 
Figure 1.11 - Schematic representation of diblock co-polymers self assembling  
 
 
1.6.5.  Rapid Expansion of Supercritical Fluid Solution 
 
Supercritical fluid technology has played a significant role in the particle formation 
applications. A supercritical fluid is loosely defined as a solvent at a temperature above 
the critical temperature, at which the fluid remains a single phase regardless of pressure. 
However, for practical purposes such as high density for solubility considerations, fluids 
of interest to materials processing are typically at near-critical temperatures. 
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Among the most important properties of a supercritical fluid are the low and tunable 
densities, which can be easily varied from gaslike to liquidlike through a simple change in 
pressure at constant temperature, and the unusual solvation effects at densities near the 
critical density (often discussed in terms of solute–solvent and solute–solute clusterings). 
The production of polymeric nanoparticles through "Rapid Expansion of a Supercritical 
Solution" into either air (RESS) or Liquid Solvent (RESOLV) may conceptually be 
divided into two somewhat related processes. One is the initial formation of nanoparticles 
in the rapid expansion, and the other is the stabilization of the suspended nanoparticles. 
Evidently, the protection of initially formed polymeric nanoparticles represents a different 
set of technical challenges, which are largely independent of the rapid expansion process 
itself, especially if the protection agent is added immediately after the expansion. The 
good news is that many methods for stabilizing nanoparticle suspensions are already 
available in the literature, some of which have shown promise in use with RESOLV. 
Supercritical fluid processing techniques can play a significant role in the particle 
formation and production. In particular, the RESOLV technique offers a unique way to 
prepare clean and narrowly distributed polymeric nanoparticles. Since the nanoparticles 
obtained in RESOLV are suspended, they may be protected from agglomeration by using 
existing stabilization methods and agents. These stable nanoparticle suspensions may find 
many interesting and important applications, as already discussed in the literature 
[Meziani 2006]. Furthermore, a new method called Supercritical Fluid Extraction of 
Emulsions (SFEE) has been investigated. The method combines the advantages of 
traditional emulsion based techniques, namely control of particle size and surface 
properties, with the advantages of continuous supercritical fluid extraction process, such 
as efficient scale-up, higher product purity, and shorter processing times [Chattopadhyay 
2006].  
 
1.6.6. Spray drying 
 
Compared to other conventional methods, spray drying offers several advantages. It 
shows good reproducibility, involves relatively mild conditions, allows for control of the 
particle size, and is less dependent on the solubility of the drug and the polymer. 
Generally, the polymer is dissolved in volatile solvents and the drug is dispersed or 
dissolved in the polymer solution. 
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Solutions or dispersions are sprayed against a stream of cold air (-60°C; top-spraying) 
using a two-fluid pneumatic nozzle with heating facilities. The frozen droplets formed by 
this spray-freezing step are dried during the following atmospheric freezedrying in the 
cold desiccated air stream by sublimation. A filter holds the fine product back in the 
drying chamber, while the water vapor is removed by the circulating air in the cooling 
systems, where the humidity condenses on the refrigerated surfaces [Leuenberg 2002]. 
Recently this method has been used to prepare dry powder aerosol particles [Azarmi 
2006], a powder formulations for controlled delivery of Paciltaxel [Mu 2005], and 
powders for aerosol delivery to the lung [Sham 2004]. 
In an attempt to minimize aggregation of the microparticles, a double-nozzle spray-drying 
technique was developed. While the polymer/drug solution is sprayed from one nozzle, 
aqueous mannitol solution is simultaneously sprayed in order to coat the particulate with 
an anti-adherent agent. The results indicate that the coating of the microspheres with 
mannitol reduces the extent of aggregation and augments the yield of the product [Takada 
1995]. When a protein drug is encapsulated by means of spray drying, a loss of its 
biological activity may occur especially when aqueous phase systems are involved 
[Elversson 2005]. The atomization of a w/o emulsion or cryogenic, non-aqueous 
processes can be used instead [De Rosa 2005]. In the latter technique, the liquid droplets 
of the polymer/drug solution are produced through the spraying nozzle, collected in liquid 
nitrogen containing frozen ethanol, and hardened by placing them at -80 °C where the 
solvent extraction occurs [Johnson 1996]. 
 
1.7. DRUGS & STABILIZING AGENTS 
 
Due to the complexity and multitude of parameters that should be taken into account 
during the preparation of a nanoparticles, the choice of a preparation method is an hard 
task and a general procedure that works for all nanoparticles material seem to do not 
exist. Taking advantage of a deep knowledge of material properties (hydrophilicity or 
hydrophobicity, cristallinity, charge, ionization behaviour), of the mechanisms of 
formation of monodispersed colloids (nucleation, diffusional growth of nuclei, etc.) and 
of all the forces which are involved in their stabilization (Derjaguin-Landau-Verwey-
Overbeek theory [Verwey 1952], hydratation forces, etc.) it is possible to predict which 
will be the method and the protocol more appropriated for obtaining nanoparticles 
possessing small particle size, high loading capacity, extended circulation time, and 
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ability to accumulate in required pathological sites in the body [Torchilin 2006]. Then, 
only the practise and the observation of the behaviours of the molecules in the selected 
mediums (water, organic solvents, etc) and of phenomena that occur during the 
preparation of the colloidal suspension could direct ours efforts towards the aimed target.   
In this respect the characteristics and biological activity of the encapsulated model drugs 
are described by following. 
 
1.7.1. Retinoic Acid (RA) 
 
Only a few nuclear receptor ligands seem to play such an important role throughout life, 
from the earliest days of embryogenesis, to the function of terminally differentiated 
organs as complex as the brain, as retinoids do. Retinoids represent a group of natural or 
synthetic derivatives that activate the retinoic acid receptors pathways. Natural retinoids 
are derived from vitamin A or retinol. The latter one comes either preformed or as it 
provitamin β carotene, in a variety of food such as milk, eggs and many plants [Lei 2003]. 
Chemically, retinoids are composed of three distinct structural domains: a β-ionone ring, 
an isoprenoid tail, and a polar end-group with an oxidation state that may vary: a 
hydroxyl group in retinols, an aldehyde in retinals, and a carboxylic moiety in retinoic 
acids [Noy 2000]. 
Retinoic acid (RA), the main biologically-active derivative of Vitamin A or retinol 
[Armstrong 2005], is a potent regulator of gene transcriptions [Noy 2000], and play an 
important role in regulating cell growth, differentiation [Armstrong 2005], embryonic 
development, apoptosis, homeostasis [Maiti 2006] and can reverse malignant cell growth 
in vitro and in vivo. RA exists in several stereoisomeric forms: predominantly all-trans 
retinoic acid (ATRA) and 13-cis retinoic acid (13cisRA), but also as less-stable isomers 
such as 9-cis retinoic acid (9cisRA). These are all readily oxidised and/or isomerised in 
the presence of light or excessive heat. ATRA is the most thermodynamically stable and 
is the major isomer at equilibrium, but all RA isomers readily isomerise in biological 
systems [Armstrong 2005]. It is present in plasma at a concentration of about 12 nm [Noy 
1992]. All-trans-retinoic acid (ATRA) is being increasingly included in antitumour 
therapeutical schemes for the treatment of various diseases such as acute promyelocytic 
leukaemia, Kaposi’s sarcoma, head and neck squamous cell carcinoma, ovarian 
carcinoma bladder cancer and neuroblastoma [Zuccari 2005] and has shown 
antiangiogenic effects in several systems [Maiti 2006]. As a result of good clinical 
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responses in these malignancies, retinoids are being investigated for their therapeutic 
potential in an increasing range of malignant diseases [Armstrong 2005]. Retinoid 
theraphy has successfully reduced both primary and secondary malignancies. This effect 
may be attribuited to a defect in RA methabolism in patients with epatocarcinoma, many 
of whom have signicantly lower levels of circulating retinol [Redmond 2007].  
However, due to its hydrophobicity [Zuccari 2005], (0.21µM in physiological solution, 
pH 7.3) [Szuts 1991], and short half-lives in blood [Yeong 2004], ATRA parenteral 
administration is very difficult and to date no commercial parenteral formulation is 
available. On the other hand the oral formulations in clinical use are characterized by 
uncertain drug bioavailability due to the variable absorption in the gastrointestinal tract 
and the hepatic first pass effect, implying metabolism of ATRA to less active compounds 
by hepatocytes. Furthermore its intestinal absorption is affected by the pH and fatty acid 
composition of intraluminal bile [Ozpolat 2003]. Therefore, plasma concentration 
following oral administration of ATRA is highly variable [Zuccari 2005]. In addition to 
the poor solubility, the chemical instability of ATRA complicates its administration. 
When ATRA is exposed to many different factors such as light, heat and oxidants, it is 
rapidly being changed into isomerized products such as isotretioin or oxidized products 
such as all-trans-4-oxo. Although some of these products still possess the anticancer 
activity similar to ATRA, it is desirable to get a chemically stable dosage form of ATRA 
for the quality control of drug products [Lim 2004]. 
In spite of its pronounced therapeutical effect, several side effects such as retinoid acute 
resistance, hypertriglyceridemia, mucocutaneous dryness, headache [Jeong 2003], 
hepatotoxicity, nausea, vomiting, and abdominal pain [Armstrong 2005] are reported and 
limit the clinical applications of ATRA [Jeong 2003]. 
Different treatment modalities have been investigated in attempt to overcome the 
accelerated metabolism of ATRA that leads to a progressive decline in plasma ATRA 
concentrations during a chronic daily schedule. These modalities include the use of 
inhibitors of cytochrome p450 enzymes, administration of oral ATRA on an intermittent 
schedule, and encapsulation of ATRA in liposomes [Ozpolat 2003]. Currently, liposomal 
parenteral formulation of ATRA is at the stage of clinical trials (Douer et al., 2001). 
However, in their studies, multilamellar types of liposomes were prepared to provide 
highly efficient loading of lipophilic drugs such as ATRA. Multilamellar types of 
liposomes are relatively large, physically unstable and thus, prone to aggregation. In this 
regard, other types of carriers similar to liposomes but also that can be physically more 
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stable with submicron size to avoid capillary blockade after intravenous injection will be 
advantageous as a parenteral delivery system of ATRA [Hwang 2004]. 
Microparticles [Jeong 2003, Park 2004], nanoparticles [Jeong 2004, Lim 2004], and 
micelles [Zuccari 2005] are being investigated as controlled release devices for retinoic 
acid delivery in cancer treatment.  S-J Lim and co-workers (2004) investigated the 
stability and the biological activity of ATRA encapsulated in solid lipid nanoparticles 
(SLN) powder formulation. ATRA remained intact in SLP powder, indicating that the 
chemical stability of ATRA was substantially improved by incorporation in SLP powder 
but the antiproliferative effects of SLN powder on a wide range of cancer cell lines were 
not significantly different from that of free ATRA [Lim 2004].  Jeong et al (2003) 
investigated the influence of severel parameters, such as drug weight, solvent and 
polymer used, on the characteristics of and drug release of microspheres based on Poly 
(DL-lactide-co-glycolide) (PLGA) [Jeong 2003]. Zuccari and co-workers (2005) prepared 
and amphiphilic  polymer by poly-vynylalchol  (PVA) substitution with oleyl amine and 
evaluated its functional properties with regard to ATRA complexation. They concluded 
that ATRA entrapped into self-assembling polymer micelles may be useful parenteral 
ATRA formulation [Zuccari 2005]. 
 
1.7.2. Human Serum Albumin (HSA) 
 
In humans, albumin is the most abundant plasma protein [Ghuman 2005, Michnik 2005], 
accounting for 55-60% of the measured serum protein. It consists of a single polypeptide 
chain of 585 amino acids with a molecular weight of 66500 Da. The chain is 
characterized by having no carbohydrate moiety, a scarcity of tryptophan and methionine 
residues, and an aboundance of charged residues, such as lysine, arginine, glutamic acid 
and aspartic acid. The mature, circulating molecule is arranged in a series of a-helices, 
folded and held by disulphide bridges. The folding creates subdomains of three 
contiguous α-helices in parallel. A pair of subdomains face each other to form domains. 
These can be seen as cylindrical structures with polar outer walls and a hydrophobic 
central core. The tertiary structure of human albumin crystal has been isolated by x-ray 
crystallography. It is seen as a heart-shaped molecule 80 X 30 A. In solution the shape is 
quite different. The three domains appear to be arranged in an ellipsoid pattern, giving the 
molecule low viscosity. 
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The molecule is very flexible and changes shape readily with variations in environmental 
conditions and with binding of ligands. Despite this, albumin has a resilient structure and 
will regain shape easily, owing to the disulphide bridges, which provide strength, 
especially in physiological conditions. After their rupture, the molecule can re-establish 
these bridges and regain its structure. Denaturation occurs only with dramatic and non-
phisiological changes in temperature, pH and the ionic or chemical environment. 
Albumin has extensively studied and well-established physiological functions in health. 
In healthy subjects, the role of albumin in the maintenance of normal plasma colloidal 
osmotic pressure is well recognized [Karnaukhova 2007]. This is because of its high 
molecular weight and concentration in plasma.  Due to the large extracellular pool of 
albumin, its water solubility and its negative charge, albumin also plays a significant role 
in the regulation of tissue fluid distribution.  
The presence of many charged residue on the albumin molecule and the relative 
abundance of albumin in plasma mean that it can act as an effective plasma buffer 
[Michnik 2005]. At physiological pH, albumin has a net negative charge. It is responsible 
for about half of the normal anion gap. A reduction in plasma protein concentration 
causes metabolic alkalosis [Nicholson 2000].  
The protein binds a wide variety of endogenous ligands including non esterified fatty 
acids, bilirubin, hemin and thyroxine, all of them acidic, liphofilic compounds, in multiple 
sites [Noy 1992]. Many used drugs with acidic or electronegative features also bind HSA. 
Albumin binds RA at the high affinity binding sites that this protein possesses for long-
chain fatty acids. While a degree of albumin-binding may be desirable in helping to 
solubilize compounds that would otherwise aggregate and be poorly distributed, drugs 
with an excessively high affinity for the protein (>95% bound) require correspondingly 
higher doses to achieve the effective concentration in vivo, can be slow distribute to sites 
of action and may not be efficiently eliminated. Fatty acids interact in serum at level of 
between 0.1 and 2 mol per mol of HSA and can both compete and cooperate with drugs 
binding to the protein. In certain disease states, these effect are exacerbated as the fatty 
acid:HSA mole ratio may be as high as six [Ghuman 2005, Michnik 2005].  
It is widely used as a stabilizing component in pharmaceutical and biologic products, such 
as vaccines, recombinant therapies and coatings for medical devices. Drug formulation 
using albumin as a carrier promises to acquire additive beneficial affects physiologically 
due to its known antioxidant properties. Albumin based drug carrier have been developed, 
particularly in the field of chemotherapy to improve the passive tumour targeting 
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properties of anti-cancer drugs. Linking chemiotherapeutics drugs to a macromolecular 
carrier system may enhance tumour targeting, reduce toxicity and overcome drug 
resistence mechanisms. The rationale of this drug design is because plasma proteins 
constitute the major transportable nitrogen reserve in vertebrates. Proliferating tumour 
cells utilize albumin and other plasma proteins for their nutrition and take up albumin by 
fluid phase endocytosis at a greater rate than normal tissues. After lysosomal digestion, 
the derived amino acids serve as source for nitrogen and energy in the tumour cells. These 
favourable properties provide a stimulus for the choice of albumin as a drug carrier where 
the conjugates enjoy the same favourable tumour targeting properties of albumin. E.g. 
high tumour uptake rates, low liver uptake rates and a very long biologic half-life 
[Chuang 2002]. 
 
1.7.3. Chondroitin Sulphate (CS) 
 
Chondroitin sulfate (CS) is an anionic linear polysaccharide, which is synthesized as part 
of proteoglycan (PG) molecules in vertebrates and invertebrates. 
Chondroitin sulfate consists of alternating disaccharide units of glucuronic acid and 
galactosamine and is attached to serine (Ser) residues of the protein cores via a 
tetrasaccharide linkage [Fontini 2006]. Disaccharide units are associated themselves by β  
galactosamine links. The galactosamine residues are sulfated either in position 4 (4-CS) 
or 6 (6-CS): the sulfate groups, together with the carboxyl groups of glucuronic acid, are 
ionized, thus conferring to the chain a strong global negative charge [Bali 2001]. 
Chondroitin sulfate chains are secreted into the extracellular matrix as proteoglycans. 
Proteoglycans provide a framework for collagen and also bind water and cations, forming 
a viscous, elastic layer that lubricates and protects cartilage. The presence of these 
negatively charged aggregates imparts to the matrix of articular cartilage its strong 
affinity for water and is hence the most significant factor that contributes to the 
biomechanical properties of cartilage. [Brief 2001]. The primary function of articular 
cartilage is to provide low friction and wear in synovial joints. Chondroitin sulfate (CS) is 
the major component of aggrecan, the most abundant glycosaminoglycan (GAG) found in 
the proteoglycans of articular cartilage. Oral supplements of CS are widely used for the 
treatment of symptoms of osteoarthritis [Basalo 2007 in press]. Osteoarthritis results in 
the progressive catabolism of cartilage proteoglycans due to an imbalance between 
synthesis and degradation. This relative decrease in the cartilage proteoglycans alters the 
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affinity of the cartilage matrix for water and, in a sense, the ability of water to easily flow 
in or out of the joint surface. Such structural changes in the composition of these 
molecules have been shown to have a negative impact on the biomechanical properties of 
normal adult articular cartilage and synovial fluid, rendering the articular cartilage 
vulnerable to the compressive, tensile, and shear forces that occur during normal joint 
motion. Theoretically, exogenous administration of  glycosaminoglycans (e.g., 
glucosamine sulfate and chondroitin sulfate) to chondrocytes will ameliorate this 
imbalance and restore, or at least prevent further damage to, the articular cartilage of 
osteoarthritic joints [Brief 2001]. In many experimental models CS participate in the 
control of cartilaginous matrix integrity by improving the anabolic activity of 
chondrocytes and by limiting excessive degradation of the cartilaginous matrix. Various 
enzymes are required to degrade cartilage; they are secreted by leukocytes gathering at 
the inflammatory site (elastase) or by chondrocytes (cathepsin B, metalloproteases, etc). 
Leukocyte elastase destroys the proteoglycan barrier of the cartilage and solubilizes 
collagen by disorganizing its molecular network. In vitro studies have shown that CS 
inhibit this enzyme activity by formation of electrostatic bonds between the negatively 
charged sulfate residues and the positive charges at the catalytic site of the enzyme. By its 
anti-chemotactic and scavenger properties, CS also inhibited the development of 
inflammation [Bali 2001]. Studies shown that, even thogh less effective than 
indomethacin and ibuprofen, Chondroitin sulfate effectively inhibits directional 
chemotaxis, phagocytosis, and the release of lysosomal contents characteristic of the 
inflammatory response [Brief 2001]. Oral supplements of CS are widely used for the 
treatment of symptoms of osteoarthritis [Basalo in press]. The actual metabolic uptake of 
orally administered Chondroitin sulfate has been found to be inconsistent possibly 
because of variation in the structure, biochemical properties, and molecular weights of the 
various preparations [Brief 2001]. In was investigated the impact of oral chondroitin 
sulfate on the concentration of glycosaminoglycans in human serum. In that study, 
Chondroitin sulfate was not absorbed either in an intact form or as a sulphated 
oligosaccharide and did not produce any measurable change in the total serum 
concentration of glycosaminoglycans. The authors concluded that the theory that orally 
administered chondroitin sulphate alone offers chondroprotection is biologically and 
pharmacologically unfounded. Studies showed that the absorption rate of chondroitin 4-
sulfate to be between 0% and 8%. [Brief 2001]. 
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CS has also been investigated as a vehicle for the sustained release of drugs, and as an 
absorption enhancer of drugs by mucoadhesion to the gastric cavity and the nasal cavity. 
The preparation of CS microspheres has also been studied [Kofuji 2002]. CS can be 
degraded by anaerobic bacteria, namely Bacteroides thetaiotaomicron and B. ovatus, 
which are resident in the large intestine. In the human colon, CS is present in sloughed 
epithelial cells and dietary meat. This characteristic suggests that CS is a potentially good 
candidate for use as a colon-targeted drug carrier [Peng 2006]. 
CS is also as a potential candidate for long-term protein stabilization. It is capable of 
forming ionic complexes with positively charged proteins. Numerous carboxyl groups on 
CS may mediate a hyperstructural shielding of the labile protein (resulting in protein 
stabilization from degrading conditions) via ionic interactions with positively charged 
proteins. During the preparation of the microspheres, frequent protein denaturation by 
organic solvent was observed. In particular, organic solvents appear to induce physical 
changes, such as insoluble aggregation. CS is believed to enclose labile protein through 
the ionic complex, and then to inhibit certain interactions of the protein with the organic 
solvent. It is also possible that the solidified protein complex may reduce further 
degradation, considering that proteins’ solid phases tend to be more stable than their 
liquid phases. Furthermore, the high molecular weight of CS may prove advantageous for 
better residence in degrading microspheres, thereby supporting the preservation of protein 
bioactivity during protein release. The interaction of Lys and CS in aqueous solution was 
verified via measurements of the zeta potential. The complex is relatively stable in a pH 
range of 8.4–5.8, whereas out of the range it evidenced unstable behavior, due to the pKa 
values of COOH in CS or NH2 in the Lys [lee in press 2007]. 
 
1.7.4. Fibrinogen 
 
Fibrinogen (Fg) has a monomeric molecular weight of 340 kDa and aggregates to form 
fibrin polymer following thrombin cleavage [Ashamakhi 2007]. Published values of 
isoelectric  pH for Fibrinogen lies between pH 5.0 and pH 6.0 [Underwood 1999].  
Fibrinogen molecules are elongated 45 nm structures that consist of two outer D domains, 
each connected by a coiled-coil segment to its central E domain (Figure 1.12). The 
molecule is comprised of two sets of three polypeptide chains termed Aa, Bb, and γ, 
which are joined together in the N-terminal E domain by five symmetrical disulfide 
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bridges. Nonsymmetrical disulfide bridges form a “disulfide ring” in this region 
[Mosesson 2005]. 
 
 
 
 
Figure 1.12 - Schematic diagram of fibrinogen structure, its conversion to fibrin, and the 
thrombin-mediated conversion of native factor XIII to XIIIa. Binding sites for proteins, 
enzymes, receptors, and other molecules that participate in fibrin(ogen) functions are 
illustrated [Mosesson2005]. 
 
Fibrin plays an important role in healing and tissue repair in adults, but less so during 
embryonic development. As a result, relatively few morphogenetic signals involved in 
development (adhesion factors or growth factors) interact specifically with fibrin, though 
they are most active when immobilized in a 3D matrix. 
A great deal of effort has been placed in understanding the molecular and cell biology of 
orphogenetic growth factors, but understanding remains limited, particularly in terms of 
roducing 3D scaffolds as effective therapeutics for repair/ regeneration [Ashammakhi 
2007]. 
Fibrinogen serves a broader physiologic role than merely controlling blood loss but it is 
likely that fibrinogen contributes to repair in a broad spectrum of contexts. However, 
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given that fibrin(ogen) is not essential for embryonic development, including all aspects 
of organogenesis, it would not be anticipated that fibrinogen would not be essential for 
certain types of organ repair (eg, liver regeneration following partial hepatectomy). An 
intriguing extension to the hypothesis that fibrinogen is important in tissue repair in most 
organ systems is that this protein may be an important determinant of the progression of a 
variety of diseases resulting in significant tissue damage.  
Underwood et al (1999) shown that Fibrinogen may serve to increase the rate of cell 
migration along the material without hindering cell adhesion [Underwood 1999]. 
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AIM OF THE WORK 
 
A long–standing research activity on the synthesis and characterization of polymeric 
materials for applications in the biomedical and pharmaceutical field has been carried out 
by chemists, biologists, pharmaceutical technologists, engineers and computer scientists 
constituting the research group active at the Laboratory of Polymeric Materials for 
Biomedical and Environmental Applications of the Department of Chemistry and 
Industrial Chemistry of the University of Pisa [Chiellini 2006, 1995, 1992b; Solaro 2003, 
1997; Signori 2003; Bizzarri 2002a, 1999]. In this framework, the present PhD research 
project is aimed at the development of polymeric colloidal systems for the controlled and 
targeted release of drugs. 
Controlled drug delivery technology represents one of the most rapidly advancing areas 
of science in which several disciplines, such as chemistry, pharmaceutical technology, 
and medicine are contributing to human health care. For many years, fundamental and 
applied investigations have focused on the development of pharmaceutical formulates 
allowing for maximization of the therapeutic efficacy and minimization of the adverse 
effects of the drugs of interest.  
The research project that constitutes the body of the present thesis involves 
multidisciplinary skills and is entirely connected with the aforementioned subject, the 
focal point consisting of the realization of biocompatible polymeric nanoparticle designed 
for the targeted release of drugs. 
The six month stage at the Institute of Polymers, CSIC (Madrid, Spain) was part of the 
activities promoted by the European network of excellence “Expertissues”, “Network of 
Excellence on Novel Therapeutic Strategies for Tissue Engineering of Bone and Cartilage 
Using Second Generation Biomimetic Scaffolds”. In the last years the impact of 
polymeric biomaterials in the field of Regenerative Medicine has brought new impulse to 
the development of multifunctional drug delivery systems and supports for Tissue 
Engineering. 
The primary objective of the present PhD is the advancement of knowledge and 
theoretical understandings of the relations among variables that play important rules in 
the development and optimization of procedures for the preparation of polymeric 
nanoparticles suspensions. The work has been conducted with the practical end in mind of 
preparing nano delivery structures for the delivery of bioactive agents in cancer therapy 
and tissue engineering applications. 
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In the undertaken research activity polymers with different origin (natural and synthetic) 
and characteristics (hydrophobic, hydrophilic, amphiphilic, biodegradable, bioerodible) 
and hydrophobic, hydrophilic and proteic model drugs were encapsulated in order to give 
a better understanding of the suitability and versatility of the methods applied, both 
standard and original procedures, for the preparation of nano drug delivery systems. 
Nanoparticles morphology, size, surface charge and encapsulation efficiency were 
determined, as well as the evaluation of drug release profiles.  
In the perspective of a practical application in the pharmaceutical field, the 
biocompatibility of part of the materials used in the formulation of nanoparticles and the 
whole drug delivery systems were submitted to in vitro cytotoxicity assays and the 
development of a final pharmaceutical form was investigated. Freeze-drying trials in the 
presence of cryoprotector agents were performed. 
The activity of the encapsulated drug was also evaluated to verify the influence of the 
loading and purification processes. 
As natural development of the present research activity, the versatility of the polymeric 
material and preparation method was assessed. RA and CS were selected respectively as 
hydrophobic and hydrophilic model drugs to be encapsulated in the polymeric 
nanocarriers. RA is known to induce differentiation of P19 cells into neurons and controls 
cellular differentiation and proliferation in normal and transformed cells, and finds 
application in both tissue engineering and cancer therapy. CS is an important structural 
component in connective tissues and cartilage and can be used in degenerative articular 
diseases. The possibility to co-encapsulate proteic drug has been evaluated, since the co-
administration of drugs that perform their activity at different level can be more effective.  
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2. GLOSSARY 
 
 
2.1. POLYMERS 
 
 
 
Poly (DL-lactide-co-glycolide) (PLGA) 
 
 
 
Poly (3-hydroxybutyric acid) natural origin (PHB) 
 
 
 
 
Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) / poly(e-caprolactone) 
(PCL-co-PLU) 
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 2–methoxyethanol hemiester of poly(maleic anhydride–alt–butyl vinyl ether (VAM41) 
 
 
 
Chitosan 
 
 
 
Pluronic F-127 (Plu) 
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Polyvinylpyrrolidone (PVP) 
 
 
2.2. DRUGS 
 
 
 
Retinoic Acid (RA) 
 
 
 
Chondroitin Sulphate (CS) 
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2.3. REAGENTS  
 
 
 
1-9 Dimethylmethylene blue (DMMB) 
 
 
 
 
 
 
 
 
 
 
 
 
Tetrazolium salt (WST-1) 
 
 
 
 
 
 
 
 
 
 
Formazan (WST-1) 
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3. EXPERIMENTAL PART 
 
 
3.3.  MATERIALS 
The commercial products were used without any preliminary purification if not otherwise 
stated. 
 
3.1.1. Solvents 
 
3.3.1.1.Chloroform 
The commercial product (J.T. Baker) was used as received. 
 
3.3.1.2.Acetic Acid 
The commercial product (Mallinckrodt Baker) was used as received. 
 
3.3.1.3.Acetone 
The commercial product (Carlo Erba) was used as received. 
 
3.3.1.4.Trifluoroethanol 99% (TFE) 
The commercial product (Aldrich) was used as received 
 
3.3.1.5. Dimethy sulfoxide (DMSO) 
The commercial product (Baker) was used as received. 
 
3.3.1.6. Ethanol 
The commercial product (Aldrich) was used as received. 
 
3.3.1.7. Tetrahydrofuran (THF) 
The commercial product (Carlo Erba) was used as received. 
 
3.3.1.8. N,N- Dimethylformamide 99.9% (DMF) 
The commercial product (Aldrich) was used as received. 
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3.1.2. Reagents 
 
3.1.2.1. Hydrochloric Acid 37-38 % 
The commercial product (J.T. Baker) was used as received. 
 
3.1.2.2. Polyvinylpyrrolidone (PVP) 
The commercial product (MW 25000; Fluka) was used as received. 
 
3.1.2.3. Fibrinogen from human plasma 
The commercial product (Sigma) was used as received. 
 
3.1.2.4. Dialysis Membranes 
Spectra/Por dialysis membranes in cellulose esters (MWCO: 100000, Da) and regenerated 
cellulose (MWCO: 3500, 10000 Da) were purchased from Spectrum Labs. Before use, 
membranes werewashed with deionised water as indicated by the manufacturer and 
conditioned in the desired buffer for 1 hour. 
 
3.1.2.5. Minisart filters 
Minisart Syringe filters (porous size: 0.45µm, 1.2µm, 5 µm) in cellulose acetate 
membranes were purchased form Sartorius. 
 
3.1.2.6. Metallic needles 
2 cm length metal hub needles 7729-02 (22G) and 91018 (18G) were purchased from 
Hamilton. 22G and 18G needles have 0.15 µm and 0.84 mm inner diameter, respectively. 
 
3.1.2.7. Deionised water 
Type III laboratory-grade pure water was obtained from ELIX/RiOs Pretreatment Pack 
(Millipore) equipped with PROGARD 02™ with vent filter (Millipore). 
 
3.1.2.8. 10 N NaOH solution 
10 N NaOH solution was prepared by dissolving 4.0 g of sodium hydroxide in pellets 
(Carlo Erba) in 10 ml of deionised water. 
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3.1.2.9. 1 N NaOH solution 
1 ml of 10 N NaOH solution was diluted with deionized water to make 10 ml of 1 N 
solution. 
3.1.2.10. 10 N HCl solution 
8.27 mL Hydrochloric acid 37-38% solution (J.T. Baker) were diluted with deionized 
water to make 10 mL of solution. 
 
3.1.2.11. 1 N HCl solution 
1 ml of 10 N HCl solution was diluted with deionized water to make 10 ml of 1 N 
solution. 
 
3.1.2.12. Dulbecco’s Phosphate Buffered saline 
The commercial product (Sigma) was used as received 
 
3.1.2.13. 3% mannitol solution 
3 % mannitol solution was prepared by dissolving 3.0 g of Mannitol (Baker) in 100 ml of 
deionised water. 
 
3.1.2.14. Human Serum Albumin (HSA) 
The commercial product (powder 96-99%, Sigma) was used as received. 
 
3.1.2.15. Poly (DL-lactide-co-glycolide) (PLGA) 
The commercial product (MW 40-75 kDa; Sigma) was used as received. 
 
3.1.2.16. VAM41 (2–methoxyethanol hemiester of poly(maleic anhydride–alt–butyl 
vinyl ether) 
The Bioerodible polymer (MW 105 kDa) was pkindly provided by Polymer Laboratories 
Ltd, Church Stretton , United Kindom. Polymers. 
 
3.1.2.17. Poly (3-hydroxybutyric acid) natural origin (PHB) 
The commercial product (Aldrich) was used as received. 
 
3.1.2.18. Retinoic Acid (RA) minimum 98% 
The commercial product (Sigma) was used as received. 
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3.1.2.19. Pluronic F-127 
The commercial product (Sigma) was used as received. 
 
3.1.2.20. Chitosan 
The commercial product (Idebio S.L. Deacetylation degree: 85%) was purified. 
 
3.1.2.21. Chondroitin Sulphate (CS) 
The commercial product (Bioiberica) was used as received. 
 
3.1.2.22. Natriumtripolyphospate (TPP) 
The commercial product (Sigma) was used as received. 
 
3.1.2.23. Buffers pH 3, 8 Titrisol 
The commercial products (Merck) were used as received. 
 
3.1.2.24. 1-9 Dimethylmethylene blue (DMMB) 
The commercial product (Sigma) was used as received. 
 
3.1.2.25. Phosphotungstic acid 
The commercial product (Sigma) was used as received. 
 
3.1.3. Cell Culture Materials 
 
3.1.3.1. Cell line 
The Balb/3T3 Clone A31 (ATCC CCL163) mause embryo fibroblast cell line and SK-N-
SH human neuroblastoma cells were purchased from American Type Culture Collection 
(ATCC) and propagated as indicated by the supplier. 
 
3.1.3.2. Antibiotics 
The commercial product (Gibco), a water solution containing 10000 U/ml of penicillin 
and 10000 µg/ml of streptomycin was stored in sterile 5 ml aliquots at –20 °C. 
 
3.1.3.3. Fetal Bovine Serum (FBS) 
The commercial product (Gibco) was stored in 50 ml sterile aliquots at –20 °C. 
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3.1.3.4. Glutamine 
The commercial product (Gibco, 200 mM water solution) was stored in sterile 5 ml 
aliquots at –20 °C. 
 
3.1.3.5. Dulbecco's Modified Eagles Medium (DMEM) 
The commercial product (Gibco) was stored at 4 °C in the dark. 
 
3.1.3.6. Complete Dulbecco's Modified Eagles Medium (Complete DMEM) 
The complete DMEM solution was prepared by adding penicillin (100 U/ml), 
streptomycin (100 µg/ml), glutamine (4 mM) and 10% fetal bovine serum to DMEM. The 
solution was kept at 4 °C in the dark. 
 
3.1.3.7. Phosphate Buffer Saline without Ca2+ and Mg2+ (PBS4) 
The commercial product (Gibco), 0.01 M pH 7.4 buffer was stored at 4 °C. 
 
3.1.3.8. Cell proliferation reagent (WST–1) 
The commercial product (Roche Molecular Biochemicals) was stored at –20 °C in the 
dark, and used as received. 
 
3.1.3.9. Neutral Red kit 
The commercial product was purchased from Sigma Chemicals. 
 
3.1.3.10. Disposable sterile plastic ware 
Commercial tissue culture flasks, multiwell plates, cryotubes, pipettes, syringes, and 
sterile filters were purchased from Corning Costar and Greiner Labortechnik, and were 
disposed after single use. 
 
3.1.4. Instrumental Characterizations (Instruments) 
 
3.1.4.1. Ultrasonic processor 
Elmusions were prepare by means of Sonics Vibra-cell 
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3.1.4.2. Absorbance measurements on microplates 
Microplate absorbance measurements were performed by means of Benchmark Bio–Rad 
Microplate Reader. All data were processed by using Microplate Manager III (Biorad) 
and Igor Pro (Wavemetrics). 
 
3.1.4.3. CO2 incubator 
Cell cultures were performed in a Hera Cell (Heraeus Instruments S.p.A.) CO2 Incubator 
in 5% CO2 enriched atmosphere. 
 
3.1.4.4. Freeze-drying  
After freezing at –20 °C, lyophilised nanoparticles were dried in 5 Pascal Lio 5P 
lyophilisator, equipped with RV8 (Edwards) vacuum pump. 
 
3.1.4.5. Laminar flow cabinet 
Experiments that required sterile conditions were performed under a Hera Safe HS12 
Bioclass II (Heraeus Instruments S.p.A.) laminar flow cabinet. 
 
3.1.4.6. Optical Microscopy (OM) 
Optical microscopy observations were performed by Nikon Eclipse TE 2000 inverted 
microscope equipped with epifluorescence lamp and Nikon D Eclipse C1 confocal 
system. 
 
3.1.4.7. Particle size analysis 
Dimensional analyses were carried out by Coulter LS230 Laser Diffraction Particle Size 
Analyzer, equipped with small volume module plus. Samples were added into the cell 
until 30–50% obscuration of PIDS detector. 
 
3.1.4.8. pH measurements 
Measurements were performed by Hanna Instruments pH 211 and MP225 (Mettler 
Toledo) pH– meters calibrated with two standard buffer solutions having pH 4.01 and 
7.01, respectively. 
 
3.1.4.9. Refrigerated centrifuge 
Nanoparticle purification processes and cell recovering were performed in ALC®PK121R 
centrifuged, equipped with AM-10 and AM-21 rotors. 
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3.1.4.10. Scanning Electron Microscopy (SEM) 
SEM analyses were performed on lyophilized samples by JEOL LSM5600LV and 
JSMT100 (JEOL) scanning electron microscopes. 
 
3.1.4.11. Environmental Scanning Electron Microscopy (ESEM) 
ESEM analyses were performed on lyophilized samples by Philip XL ESEM TMP 
 
3.1.4.12. Transmission Electron Microscopy (TEM) 
TEM analyses were performed on particles suspensions by Hitachi electron microscope 
600 
 
3.1.4.13. Sputter coater 
Lyophilised samples were sputter-coated with gold, typically 2 cycles of 30 sec at 20 mA, 
in S150 (Edwards) sputter coater. 
 
3.1.4.14. UV–Vis spectroscopy 
Absorption measurements were performed by Jasco V–530 and UNICAM UV 500 
ThermoSpectronic spectrophotometers. 
 
3.1.4.15. AT-IR spectroscopy 
Absorption measurements were performed by Perkin Elmer Spectrum 1 
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3.4.  FORMULATION OF RETINOIC ACID LOADED NANOPARTICLES  
 
All nanoparticles suspensions were prepared applying the standard available techniques 
such as dialysis, nanoprecipitation, co-precipitation and emulsion solvent evaporation 
method, according to general procedures. An innovative method for the preparation of 
nanoparticles based on VAM41 was developed and described below, the colloidal-coating 
method. 
 
3.2.1. PLGA Based Nanoparticles Prepared by Dialysis Method  
 
The nanoparticles suspensions were prepared by dialysis method according to general 
procedure. Data relevant to individuals experiments are summarized in the Table 1, 
whereas typical examples are described in details below. 
 
3.2.1.1.  Preparation of Unloaded Nanoparticles 
 
10 ml of solution 1 mg/ml of PLGA in DMSO were prepared. The solution was 
introduced into a dialysis tube and dialysed against 1.0 l x 3 of distilled water for 3 h and 
the distilled water exchange at intervals of 3~4 h during 24 h. 
 
3.2.1.2.  Preparation of RA Loaded Nanoparticles 
 
15 mg of PLGA were dissolved in 7.5 ml of DMSO and subsequently 700 µl of a solution 
of RA in DMSO (100 mg/ml), 470 µl of a solution of Pluronic F-127 in water (10 mg/ml) 
and 1 ml of water were added drop wise to the above solution. The resulting solution was 
stirred at room temperature for 30’ and then was introduced into a dialysis tube and 
dialysed against 1.0 l x 3 of distilled water for 3 h and the distilled water exchange at 
intervals of 3~4 h during 24 h. 
Concentration of polymer, drug and surfactant in Table 5. are related to the volume of the 
resulting solution. 
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Table 5 - PLGA based nanoparticles formulations prepared by Dialysis method  
 Run Polymer  Volumeb  Pluronic F-127 RA  Solvent  
  (mg/ml)  (l) (mg/ml)  (mg/ml)
 (%
a
DMSO)  
 D-LG-01 2.5 3 -  - 100  
 D-LG-11 2.5 2 -  - 100  
 D-LG-07 2.5 1 -  - 100 
 D-LG-06 1.4 1 -  - 100   
 D-LG-04 1.0 1 -  - 100  
 D-LG-17 1.4 1 -  - 70   
 D-LG-R-24 1.4 1 -  0.7 70   
 D-LG-R-66 1.6 1 0.3  0.8 86.3  
 D-LG-R-67 1.6 1 0.3  0.4 86.3  
 D-LG-R-72 1.5 1 0.5  - 84.5  
 D-LG-R-74 1.5 1 0.5  0.7 84.5  
 D-LG-R-64 1.5  1 0.7  0.7 84.5  
 D-LG-116 1.5  1 0.4  - 85  
 D-LG-R-147 1.5  1 -  0.6 85  
 D-LG-R-83 1.6  1 0.4  0.6 81  
 D-LG-R-87 1.5  1 0.4  0.6 85  
a % v/v DMSO/H20 
b Volume of water in the outer compartment 
 
3.2.2. PHB Based Nanoparticles Prepared by Dialysis Method 
 
The nanoparticles suspensions were prepared by dialysis method according to general 
procedure. Data relevant to individuals experiments are summarized in the Table 6., 
whereas typical examples are described in details below. 
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3.2.2.1.  Preparation of Unloaded Nanoparticles 
 
10 mg of PHB were dissolved in 9 ml of TFE and 1 ml of DMSO was added. The 
resulting was dialyzed against 1.0 l x 3 of distilled water for 3 h and then distilled water 
exchange at intervals of 3-4 h during 24 h. 
 
3.2.2.2. Preparation of RA Loaded Nanoparticles 
 
10 mg of PHB were dissolved in 9.6 ml of TFE. 200 Pl of a solution of PVP in TFE (10 
mg/ml) and 300 Pl of RA in DMSO (10 mg/ml) were added and the resulting solution 
was stirred at room temperature for 20 min, then dialyzed against 1.0 l x 3 of distilled 
water for 3 h and then distilled water exchange at intervals of 3-4 h during 24 h. 
 
Table 6 - PHB based nanoparticles formulations prepared by Dialysis method  
 Run Polymer  PVP  RA  Solvent  
  (mg/ml) (mg/ml) (mg/ml) %
b
TFE  
D-HB-1 1 - - 90  
D-HB-2 1 - 0.3 90  
D-HB-3 1 - 0.5 90  
D-HB-4 1 2 0.3 96  
b % v/v TFE/DMSO 
 
 
3.2.3. PCL-PLU Based Nanoparticles Prepared by Dialysis Method 
 
20 to 50 mg of copolymer were dissolved in 10 to 20 ml of selected organic solvent such 
as DMSO, THF and acetone. 10ml of the solution was dialyzed using regenerated 
cellulose dialysis membranes (molecular weight cut off: 10000, Spectrum Lab, Italy) 
against 1 L of distilled water for 3 hrs. Dialysis was further carried out for 24 h with 
distilled water exchange each 3-4 h and the solution was freeze-dried. 
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3.2.4. PLGA Based Nanoparticles Prepared by Nanoprecipitation Method 
 
The nanoparticles suspensions were prepared by nanoprecipitation method according to 
general procedure. Data relevant to individuals experiments are summarized in the Table 
7, whereas typical examples are described in details below. 
 
3.2.4.1. Preparation of Unloaded Nanoparticles 
 
15 mg of PLGA were dissolved in 7 ml of DMSO and subsequently 200 µl of a solution 
of Pluronic F-127 in DMSO (10 mg/ml) was added drop wise to the above solution. The 
resulting solution was stirred at room temperature for 1 h. This phase dropped in 20 ml of 
water by means of a syringe equipped with a 22G needle under moderate magnetic 
stirring. Once the addition of the polymer solution was completed, the resulting 
dispersion was dialyzed against water for 16 h. 
 
3.2.4.2. Preparation of RA Loaded Nanoparticles 
 
15 mg of PLGA were dissolved in 7 ml of DMSO and subsequently 500 µl of a solution 
of RA in DMSO (100 mg/ml), 200 µl of a solution of Pluronic F-127 in DMSO (10 
mg/ml) and 1 ml of water were added drop wise to the above solution. The resulting 
solution was stirred at room temperature for 1 h. This phase dropped in 20 ml of water by 
means of a syringe equipped with a 22G needle under moderate magnetic stirring. Once 
the addition of the polymer solution was completed, the resulting dispersion was dialyzed 
against water for 16 h. 
 
Table 7 - PLGA based nanoparticles formulations prepared by nanoprecipitation method 
 Run Polymer  Pluronic F-127  RA  DMSO H2O  
  (mg) (mg)  (mg) (ml) (ml)  
 P-LG-102 15 2  - 7.7 -  
 P-LG-103 9 2  5 8.2 - 
 P-LG-99 15 2  5 8.2 -   
 P-LG-101 15 2  5 8.2 1  
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3.2.4.3.Preparation of RA and HSA Loaded Nanoparticles 
 
7.5 mg of PLGA were dissolved in 3.5 ml of DMSO and subsequently 100 µl of a 
solution of Pluronic F-127 in DMSO (10 mg/ml) was added drop wise to the above 
solution. The resulting solution was stirred at room temperature for 1 h. This phase 
dropped in 10 ml of water containing 50 mg of HSA by means of a syringe equipped with 
a 22G needle under moderate magnetic stirring. Once the addition of the polymer solution 
was completed, the resulting dispersion was dialyzed against water for 16 h. 
 
3.2.5. PHB Based Nanoparticles Prepared by Nanoprecipitation Method  
 
The nanoparticles suspensions were prepared by nanoprecipitation method according to 
generalprocedure. Data relevant to individuals experiments are summarized in the Table 
8, whereas 
typical examples are described in details below. 
 
3.2.5.1. Preparation of RA Loaded Nanoparticles 
 
10 mg of PHB were dissolved in 9.8 ml of TFE at about 50°C to form the diffusing phase. 
Then 300µl of a solution of Retinoic Acid in DMSO were added (10 mg/ml). This phase 
dropped in 40 ml of water by means of a syringe equipped with a 22G needle under 
moderate magnetic stirring. Once the addition of the polymer solution was completed, the 
resulting dispersion was dialyzed against water for 16 h. 
 
Table 8 - PHB based nanoparticles formulations prepared by  
 Nanoprecipitation method  
 Run Polymer  RA  Solvent  
   (mg/ml) (mg/ml) (
c
%TFE)  
P-B-150 1 0.3 97   
P-B-153 1.5 0.3 97   
 P-B-154 2.2 0.45 96   
c % v/v TFE/DMSO 
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3.2.6. Pcl-Plu Based Nanoparticles Prepared By Nanoprecipitation 
 
20 to 50 mg of copolymer were dissolved in 10 to 20 ml of selected organic solvent such 
as DMSO, THF, or acetone. Then 4 ml of the solution was added dropwise to 10 ml of 
distilled water under moderate stirring at 25 °C to produce a milky aqueous suspension. 
The solution was dialyzed using regenerated cellulose dialysis membranes (molecular 
weight cut off: 10000, Spectrum Lab, Italy) against 1 L of distilled water for 3 h. Dialysis 
was further carried out for 24 h with distilled water exchange each 3-4 h and then the 
solution was freeze-dried. 
 
3.2.6.1. Preparation of RA Loaded Nanoparticles 
 
PLU-co-PCL nanoparticles containing RA were prepared by nano-precipitation method. 
150 µL of a solution of RA in DMSO (10 mg/ml) were added to 5 ml of the polymeric 
solution and stirred at room temperature. 3 ml of the solution were added drop wise to 10 
ml of distilled water. A yellow milky-like suspension was obtained. The solution was 
dialyzed and then freeze-dried.  
 
3.2.7. VAM41 Based Nanoparticles Prepared by Co-precipitation Method 
 
The nanoparticles suspensions were prepared by nanoprecipitation method according to 
general procedure. Data relevant to individuals experiments are summarized in the Table 
9, whereas typical examples are described in details below. 
 
3.2.7.1.  Preparation of RA Loaded Nanoparticles 
 
40 µl of 25 % HSA solution (corresponding to 10 mg HSA) and 4.55 µl of a solution of 
RA in DMSO (10mg/ml) were added to 5 ml of water under stirring condition. A solution 
of 50 mg of VAM41 in 2.0 ml of 4:1 ethanol/water was prepared and added to the 
HSA/RA solution under magnetic stirring by means of a syringe equipped with a 22G 
needle under moderate magnetic stirring at room temperature. Once the addition of the 
polymer solution was completed, the resulting dispersion was kept under magnetic 
stirring for 30 minutes at room temperature. 
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Table 9 - VAM41 based nanoparticles formulations prepared by  
 Nanoprecipitation method  
 Run Polymer  HSA  RA  HSA / RA a  
  (mg) (mg) (mg)   
 C-V-233 50  10 0.0015 1 / 0.03  
 C-V-235 50  10 0.045 1 / 1  
 C-V-234 50  10 0.15 1 / 3.3   
 C-V-236 50  10 0.45 1 / 10  
 C-V-237 50  50 2.27 1 / 10  
a molar rate 
 
3.2.8. VAM41 Based Nanoparticles Prepared by Colloidal-Coating Method 
 
The nanoparticles suspensions were prepared by colloidal coating method according to 
the procedures below described. 
 
3.2.8.1.  Preparation of Unloaded Nanoparticles 
 
50 mg of VAM41 were solved in 5 ml of water by adding a drop 10 N NaOH and then 
200 µl of 25 % HSA solution (corresponding to 50 mg HSA) were added and the solution 
was left under stirring condition for 1 h and the pH was adjusted to 8. 
Under rapid magnetic stirring 1 N HCl was dropped into the solution until the formation 
of a suspension (~ pH 5). Each drop was added after the disappearing of the flakes formed 
by the previous drop. 
 
3.2.8.2.  Preparation of RA Loaded Nanoparticles 
 
50 mg of VAM41 were solved in 5 ml of water by adding a drop 10 N NaOH and then 
200 µl of 25 
% HSA solution (corresponding to 50 mg HSA) were added and the solution was left 
under stirring condition for 1 h. Subsequently 225 Pl of a solution of Retinoic Acid in 
DMSO (10 mg/ml) were added and the pH was adjusted to 8. 
Under rapid magnetic stirring 1 N HCl was dropped into the solution until the formation 
of a yellowish suspension (~ pH 7.4). Each drop was added after the disappearing of the 
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flakes formed by the previous drop. In the same fashion drops of 1 N and 0.1 N HCl were 
added up to pH 5.3. 
 
3.2.9. Nanoparticles Purification 
 
Nanoparticles suspensions were purified by centrifugation in ALCPK121R centrifuge at 
8000 g for 30 minutes (PLGA NPs, VAM41 NPs) or 9000 g for 30 minutes (PHB NPs), 
at room temperature. The samples were either placed in 50 ml falcon or Eppendorf tubes 
and centrifuged by using AM-10 or AM-21 rotors, respectively. 
 
3.2.10. Cryoprotection 
 
Nanoparticle suspensions purified by centrifugation were frozen at –20°C and lyophilized 
in a 5Pascal Lio 5P lyophilizer. Nanoparticles size distribution of final dispersions were 
assessed. 
Nanoparticle suspensions (6.0 ml) were centrifuged at 8000 g for 30 minutes in an 
ALCPK121R centrifuge, AM-10 rotor. The resulting pellets were dispersed in 3.0 ml of 
aqueous solutions containing 3 % mannitol. The resulting suspensions were frozen at –20 
°C, freeze-dried in a 5Pascal Lio 5P lyophilizator. The recovered lyophilized powders 
were re-dispersed in 3.0 ml of deionised water and granulometry analysis in suspension 
was performed. 
 
3.3. NANOPARTCLES CHARACTERIZATION 
 
3.3.1.  Granulometry in Suspension 
 
Dimensional analyses were carried out by Coulter LS230 Laser Diffraction Particle Size 
Analyzer, equipped with small volume module plus. Nanoparticle suspensions were 
added into the cell until 30–50% obscuration of PIDS detector was reached. Deionised 
water was used as background and diameter distribution was processed using Fraunhofer 
optical model. Three runs were performed on each sample. 
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3.3.2. Morphological Analysis 
 
3.3.2.1.  Scanning Electron Microscopy (SEM) 
 
Nanoparticle morphology was investigated by means of scanning electron microscopy 
(SEM). The samples were prepared from the purified and lyophilised nanoparticles. Gold 
sputtering was performed before SEM analysis. 
 
3.3.2.2.  Transmission Electron Microscopy (TEM) 
 
For the TEM observations, the micelle solutions were stained with phosphotungstic acid. 
The final concentrations of phosphotungstic acid in the micelle solutions were 0.1 wt %. 
A drop of the stained micelle solutions was then placed on a copper grid coated with a 
polymer film, and self-dried in a dry box at 20°C.  
 
3.3.3. Evaluation of Retinoic Acid Incorporation 
 
Samples of purified and lyophilised PLGA and PHB nanoparticles were weighted 
properly and added into 6 ml of ethanol and stirred for 1 h. After the removal of 
supernatant by centrifugation, the remaining nanoparticles were dissolved in 2 ml of 
DCM and this solution was extracted with 6 ml of ethanol. When the extraction was 
completed, DCM was evaporated and the resulting solution was filtered through a 
membrane filter with a pore size of 0.45µm. The alcoholics solutions of RA were joined 
and the final volume was adjusted to 25 ml. RA concentration was determined by UV. 
Total drug content was calculated as the sum of RA amounts both on the surface and 
inside the nanoparticles. 
Drug concentration was determined by using a standard curve (Figure 3.1 ) obtained by 
plotting the average blank-corrected absorbance of each standard vs. its RA concentration 
(1-9 mg/l). 
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Figure 3.1 - Calibration curve used to determine the RA content into PLGA, PHB 
nanoparticles 
 
Samples of purified and lyophilised VAM41 nanoparticles were weighted properly and 
solved into 5 ml of water by adding 1 N NaOH. The final pH was adjusted to 8. Drug 
concentration was determined by using a standard curve (Figure 3.2) obtained by plotting 
the average blank-corrected absorbance of each standard vs. its RA concentration (0.04-
10 mg/l). 
 
 
Figure 3.2 - Calibration curve used to determine the RA content into VAM41 
nanoparticles 
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3.3.4. Evaluation of HSA Incorporation 
 
Fluorescently labeled RA/HSA loaded nanodonuts were prepared as follow: particles 
were prepared with a HSA/HSA-FITC 48:2 mixture. The NP were centrifuged at 8500 g 
for 30 min. The pellet was washed three times and freeze dried over night. The pellet 
sample was dissolved in 1.25ml of PBS at 4°C for 24h. The fluorescence measurements 
were performed by excitation at 540 nm and by emission at 590 nm with a FLUOstar 
Galaxy microplate reader (BMG-Labtechnologies, Offenburg, Germany). The extent of 
HSA incorporation was evaluated. 
 
3.3.5. In Vitro Evaluation of the Activity of the Encapsulated Retinoic Acid 
 
SK-N-SH human neuroblastoma cells were seeded in 6 multi-well plates (1.5x104 
cells/well) and maintained in Minimum Essential Medium (MEM) containing 10% fetal 
calf serum, 4mM glutamine and 100U/ml:100µg/ml penicillin:streptomycin at 37°C in 
5% CO2 for 24h. 
Cells were treated either with 40µM free-RA or 40µM encapsulated RA for 6 days. 
Encapsulated or free RA was added to the cells in fresh growth media at every 48h and 
morphologic differentiation assessed by phase contrast microscopy.   
 
3.4. IN VITRO ASSESSMENT OF CYTOTOXICITY 
 
For cytotoxicity evaluation of PHB and relative nanoparticles a subconfluent monolayer 
of Balb/3T3 clone A31 cell line was incubated with different concentrations of the 
investigated materials for 24 hours. Quantification of cytotoxicity was determined by 
mean of two types of assays such as WST-1 Tetrazolium Salts and Neutral Red Uptake. 
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3.4.1.  Cell Propagation 
 
3.4.1.1. Cryopreservation and Cell Thawing 
 
Cells were suspended in 1.5 ml aliquots of ice–cold fetal bovine serum (FBS) containing 
10% of DMSO. The suspensions were transferred in glass vials that were cooled at –20 
°C for 24 hours, at –80 °C for further 24 hours, and finally stored in liquid nitrogen. 
When needed, cells were thawed by using the following protocol: one ampoule was 
removed from liquid nitrogen and immediately immersed in water bath at 37°C for a few 
minutes. After addition of 5 ml of complete DMEM at 4°C, the ampoule was centrifuged 
at 1000 rpm for 10 min at 10°C in ALC®PK121R centrifuge (AM–10 rotor). The pellet 
was suspended in an appropriate volume of complete DMEM at 37°C. Cells were then 
plated at high density in a 25 ml flask and incubated at 37°C in humidified 5% CO2 
incubator. The culture medium was renewed two hours after seeding. 
 
3.4.1.2.  Cell counting by Dye–Exclusion Hemocytometry 
 
The hemocytometer is a microscope slide with grids on it to give nine large squares 
divided by triple lines. Each large square has 1 mm2 area. The depth of fluid in the 
chamber is 0.1 mm, and therefore the total volume of fluid over each large square is 0.1 
mm3 = 10–4 ml. 
One drop of 0.2 ml cell suspension in 0.15 ml of PBS4 and 0.5 ml of 0.4% trypan blue, 
resulting in a 1:5 dilution (D), was placed in the hemocytometer chamber. The chamber 
was placed on the stage of an inverted optical microscope and all cells excluding trypan 
blue (the dye penetrates non–viable 
cells that appear blue) present in the five large squares were counted, N being the number 
of the counted cells. The number of viable cells (VC) in 1 ml suspension was calculated 
by the following equation: 
 
VC(cells /ml) =
D ⋅ N ⋅104
5  
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3.4.1.3.  Subculturing of Continuous Cell Lines Grown in Monolayers 
 
A 25 ml flask containing exponentially growing cells was observed in an inverted 
microscope to evaluate the level of cell confluence. The complete DMEM medium was 
then emoved and cells were rinsed for a few minutes with PBS4. The buffer solution was 
then removed and cells were incubated with 0.4 ml of trypsin/EDTA solution at 37°C in 
5% CO2 incubator for 5 minutes or until the monolayer started to detach from the flask. 
Cells were suspended in 10 ml of complete DMEM medium and then centrifuged at 1000 
rpm for 5 minutes. The pellet was suspended in an appropriate volume of DMEM and 
plated in a 25 ml flask at a split ratio of 1:6, 1:12, and 1:15. 
 
3.4.2. Sample Preparations 
 
Cytotoxicity of polymers, stabilisers and nanoparticles was assessed by measuring the 
viability of 3T3/A31 fibroblasts grown in DMEM medium containing the test materials. 
Quantitative analyses of cell viability and proliferation were performed by three type of 
assays WST–1 and Neutral Red. 
 
3.4.2.1.  Preparation of Polymer Solutions 
 
Stock polymer solutions were prepared by sospending 100 mg of polymer in 7 ml of 
complete DMEM. The pH of the resulting solutions was adjusted to 7.2–7.3 with 10 N 
NaOH and complete DMEM was added up to a final volume of 10 ml. All stock solutions 
were sterilized by filtration on 0.2 µm Minisart filters and diluted with complete DMEM 
to obtain a range of 0.5-10 mg/ml solutions. 
 
3.4.2.2.  Preparation of Nanoparticle Samples 
 
PHB based nanoparticles were prepared by dialysis method and purified by centrifugation 
at 8000g for 30 minutes, at 4°C. 
Pellets were freeze-dried in 5 Pascal Lio 5P, weighted and re-dispersed in complete cell 
medium to a final concentration of 5 mg/ml. Nanoparticle suspensions were kept under 
magnetic stirring for 12 hour at 4°C and tested for cytotoxicity as described by following. 
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3.4.3. Quantitative Evaluation of Cytotoxicity 
 
A subconfluent monolayer of 3T3/A31 fibroblasts was trypsinized using a 0.25 % trypsin 
1mM EDTA solution. Cells were centrifuged at 1000 rpm for 5 minutes, re–dispersed in 
completeDMEM medium and counted. Appropriate dilutions were made in order to 
obtain 3 x 103 cells per 100 µl of medium, the final volume present in each well of flat–
bottom 96–microwell plates. Plates were incubated at 37°C, 5% CO2 for 24 hours until 
60–70% cell confluence was reached. The medium from each well was then removed and 
replaced with a fresh medium containing different concentration of the material under 
investigation (Figure 3.5, columns 1–10). Control cells (column 11) were incubated with 
fresh growth medium, whereas wells containing only growth medium were used as blank 
(column 12). 
 
 
1 2 3 4 5 6 7 8 9 10 11 12
Decreasing polymer concentration
Control cells
Blank
 
Figure 3.2 - Schematic representation of 96 well cell culture plate used for cytotoxicity 
tests 
 
3.4.3.1.  WST–1 cell proliferation assay 
 
After 24 h incubation in polymer/nanoparticle containing medium, cells were incubated 
with WST– 1 Cell Proliferation Reagent diluted 1:10 (as indicated by the manufacturer) 
for 4 h at 37°C, 5% CO2. Plates were then analyzed with a Bio–Rad Benchmark 
Microplate Reader. The number of viable cells was evaluated from the sample absorbance 
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at 450 nm diminished by the blank absorbance at the same wavelength and by using 620 
nm as reference wavelength.  
 
3.4.3.2.  Neutral Red 
 
Cells were incubated with Neutral Red diluted 1:10 (as indicated by the manufacturer) for 
2 h at 37 °C 5% CO2. Medium containing the vital dye was then removed and cells were 
briefly washed with PBS. The incorporated dye was then liberated from the cells in an 
acidified ethanol solution. An increase or decrease in the number of cells or their 
physiological state results in a concomitant change in the amount of dye incorporated by 
the cells in the culture. Plates were then analyzed with a Biorad Microplate Reader. 
Measurements of Neutral Red absorbance were carried out at 540 nm, with the reference 
wavelength at 620 nm. 
 
3.5. IN -VITRO DRUG RELEASE STUDIES 
 
3.5.1. Releasing Medium: PBS 
 
RA loaded PLGA nanoparticles were suspended in 2 ml of Phosphate Buffer Saline (PBS, 
0.1M, pH 7.4) and then put into a dialysis tube. The dialysis tube was placed into a 50 ml 
cylinder containing 50 ml PBS and the media was stirred at 37°C.  
Whole-media change method on the drug release study was used for prevention of 
saturation of drug. At specific time intervals, whole medium (50 ml) was taken and 
replaced with same volume of fresh PBS. 
RA was extracted with dichloromethane. Then dichloromethane was evaporated under 
reduced pressure and RA solved in ethanol and determined by UV spectrophotometer. 
The peak of RA was obtained by deconvolution. 
 
3.5.2. Releasing Medium: PBS containing HSA 
 
RA-Albumin complex diffusion from dialysis tube (MWCO 100 KDa, 5 ml) was carried 
out in PBS at 37°C. 50 µl of a solution of RA in DMSO (RA 0.287 mg) were added to 2.5 
ml of PBS containing 110 mg of Albumin. At specific time intervals 10 ml was taken and 
replaced with same volume. Samples were analyzed by UV at 347 nm and concentration 
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determined by using a RA/Albumin standard curve in PBS (Figure 3.3). For the 
evaluation of drug release profile RA loaded PLGA and PHB nanoparticles (were 
suspended in 2.5 ml of Phosphate Buffer Saline (PBS, 0.1M, pH 7.4) in which were 
previously dissolved 110 mg of Albumin. The suspensions were put into a dialysis tube 
(MWCO: 100 KDa). The dialysis tube was placed into a 50 ml cylinder containing 50 ml 
PBS and the media was stirred at 37°C. 
At specific time intervals, 10 ml was taken and replaced with same volume of fresh PBS. 
Samples were analyzed by UV at 347 nm. 
 
 
Figure 3.3 - RA/Albumin standard curve in PBS 
 
 
3.6. FORMULATION OF CHONDROITIN SULPHATE LOADED NPS 
 
3.6.1. PLGA Based Nanoparticles Prepared by Nanoprecipitation-Solvent 
Evaporation Method 
 
2 ml of a water solution of CS  were added drop wise to 8 ml of a solution of PLGA in 
acetone (2mg/ml). A milky like suspension formed. Acetone was removed under reduced 
pressure and stirring condition. After the evaporation of acetone, water was added to the 
suspension placed under reduced pressure and stirring condition. 
For the preparation of NS-LG-13 100µl of a solution of Pluronic F-127 in water were 
added to the water solution of CS (Table 10). 
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Table 10 - PLGA loaded nanoparticles prepared by  
  nanoprecipitationSolvent evaporation method 
 
 Run CS Pluronic  
   (mg)  (µl) 
 NS-LG-05  10 -  
 NS-LG-08  10 -  
 NS-LG-11  40 -  
 NS-LG-13  40 1 
 
 
3.6.2. PLGA Based Nanoparticles Prepared by Double Nanoprecipitation 
 
0.5 ml of a solution of CS in water (40mg/ml) were added drop wise to 6 ml of a solution 
of PLGA in acetone (5mg/ml). A milky like suspension formed. The suspension was 
added drop wise to 5 ml of water or a mixture of water and EtOH. Acetone was removed 
under stirring condition. 
For the preparation of DP-LG-28 25mg of Pluronic F-127 were added to 5 ml of ethanol. 
For the preparation of DP-LG-31 9µl of a solution of Tween 20 were added to the water 
solution of CS (Table12). 
 
Table 11 - PLGA loaded nanoparticles prepared 
   by Double Nanoprecipitation  
 Run  H2O/EtOH
a
  
 S17   1:0  
 S18  1:1  
 S19  0:1  
 S21  2:3  
a volume rate 
 
  
3.6.3. VAM41 Based Nanoparticles Prepared by Modified Co-Precipitation Method 
 
VAM41 was solved in 2 ml water by adding a drop of NaOH 10N solution. After the 
complete dissolution of the polymer ph was adjusted to 8 and CS and HSA were added . 
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Pluronic F-127 was also added as stabilizing agent. The resulting solution was added drop 
wise to 10 ml of Buffer solution pH 3. 
 
Table 12 - VAM41 loaded nanoparticles 
  Run  VAM41 CS HSA Pluronic F-127 
  (mg)  (mg)  (mg)  (mg) 
 MP-VH-37 25 10 10 -  
 MP-VH-38 50 10 10 10   
 MP-VH-39 50 - - 10  
 MP-VH-45 50 10 10 10   
 MP-VH-46 50 10 - -   
 MP-VH-71 50 30 10 10  
 
 
3.6.4. Chitosan Based Nanoparticles Prepared by Modified Co-Precipitation 
Method 
 
Chitosan was dissolved in acetic aqueous solution at various concentrations. The 
concentration (5 mg/mL, 2.5 mg/mL) of acetic acid in aqueous solution was, in all case, 
1.5 times that of chitosan. Under magnetic stirring at room temperature, 4ml of a solution 
containing CS and/or sodium tripolyphosphate TPP aqueous solution with a concentration 
of 1.0 mg/mL was added into 10mL chitosan solution (Table 13). 
 
Table 13 - Chitosan loaded nanoparticles 
 Run Chitosan CS Pluronic F-127  
  (mg/mL)  (mg)  (mg) 
 S58 5 10 -  
 S60 5 10 10  
 S63 2.5 10 10  
 S64 2.5 10 -  
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Chitosan was dissolved in acetic aqueous solution at various concentrations (5 mg/mL, 
2.5 mg/mL). The concentration of acetic acid in aqueous solution was, in all case, 1.5 
times that of chitosan. Pluronic was also added. Under magnetic stirring at room 
temperature 10 ml of this solution was added drop wise to 10mL of an aqueous solution 
of CS (Table 14). 
 
Table 14- Chitosan loaded nanoparticles 
 Run Chitosan  CS Pluronic F-127 
  (mg/ml)   (mg)  (mg)  
 S74 2.5 15 -   
 S75 2.5 30  -  
 S76 2.5 15 5  
 
 
3.7. NANOPARTICLES CHARACTERIZATION 
 
3.7.1. Evaluation of CS Encapsulation in PLGA and VAM41 nanoparticles 
 
3.7.1.1.  Determination of CS by UV Spectrophotometry 
 
CS encapsulation was evaluated by means of UV spectrophotometer (UV). 1-9 
Dimethylmethylene blue (DMMB) was used as metachromatic dye for the detection of 
the sulphated glycosaminoglycan (glycosaminoglycans (GAGs) assay). 100 µl of each 
sample was placed in a quartz cuvette, 2.5 ml dimethylmethylene blue colour reagent was 
added and ABS525 was read immediately. The assay was calibrated by use of reagent 
blanks containing 100 µl of Buffer and 2.5 ml of colour reagent 
Calibration curves using chondroitin-6-sulfate as standards showed linear relation 
between absorption at 525 nm of the chondroitin sulfate–DMMB complexes versus 
concentration of chondroitin sulfate in the buffer solution pH 8, with R2 of 0,9919 (Figure 
3.3). 
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Figure 3.3 - CS-DMMB calibration curve 
 
 
Samples of PLGA nanoparticles were weighed, solved in 1ml of CHCL3 and CS extracted 
with 3ml x 3 pH 8 Titrisol buffer. Final volume was adjusted to 10 ml.  CS concentration 
was determined by glycosaminoglycans (GAGs) assay. 
Samples of VAM41 nanoparticles were weighted, solved in pH 8 Titrisol buffer and final 
volume adjusted to 10 ml. CS concentration was determined by glycosaminoglycans 
(GAGs) assay. 
 
3.7.2. Chondroitin Sulphate encapsulation in nanoparticles evaluated by IR 
spectrophotometry  
 
Samples of VAM41 were analyzed by AT-IR. The intensity of the peak at 1031 
(characteristic for CS) and the intensity of the peak at 1721 (characteristic for VAM41) 
were measured. A calibration curve of the % CS in blends of CS/VAM41 versus the rate 
of the peaks (peak 1031 / peak 1721) was obtained as follow: a solution of VAM41 in 
water was prepared by dissolving 75 mg of VAM41 in 3 ml of water by adding 2 drops of 
NaOH 10N. 20 mg, 15mg, 10mg of CS were solved each in 1 ml of the previous solution. 
150 mg of VAM41 were solved in 4 ml of water by adding 2 drops of NaOH 10N and 15 
mg, 7.5 mg of CS were solved in 2 ml each of the previous solution. 
The solutions were freeze-dried and the resulting blend of polymer characterized by AT-
IR.  It was calculated the rate between the intensity of the peak at 1031 (characteristic for 
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CS) and the intensity of the peak at 1721 (characteristic for VAM41) then it was related 
to the percentage of CS in the blends. 
The solutions were freeze-dried and the resulting blend of polymers characterized by AT-
IR.  The rate between the intensity of the peak at 1031 (characteristic for CS) and the 
intensity of the peak at 1721 (characteristic for VAM41) was calculated and related to the 
percentage of CS in the blend (Figure 3.4-3.5).  
 
 
Figure 3.4 - ATR spectrum of VAM41 NPs Figure 3.5 - AT-IR spectrum of VAM41 NPs 
 
Calibration curves based on blends of CS and VAM41 as standards showed linear relation 
between the rate of the intensities of the peaks at 1031 and 1721 versus the percentage of 
CS in the blends, with R2 of 0,9934 (Figure 3.6).      
 
Figure 3.6 - Chondroitin Sulphate calibration curve 
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4. RESULTS & DISCUSSION 
 
 
4.1. NANOPARTICLES: SIGNIFICANCE & FORMULATIONS DEVELOPMENT 
 
Various drug delivery and drug targeting systems are currently applied or under 
development to minimize premature drug degradation upon administration, prevent 
undesiderable side effects exercised onto normal cells, organ and tissues by cytotoxic 
drugs, and increase bioavailability and the fraction of the drug accumulated in the 
pathological area, The availability of these carriers is important for the therapeutic 
application of both hydrophobic, poorly water-soluble therapeutic agents and hydrophilic 
drugs.  
The administration of hydrophobic drug is associated with some serious problems: poor 
absorption and low bioavailability, it is subjected to the formation of aggregate upon 
intravenous administration that might lead to various complications including embolism, 
respiratory system failure, high local drug concentrations at the sites of aggregate 
deposition, which could be associated with local toxic effects of the drug and its 
diminished systemic bioavailability. On the other hand, the hydrophobicity and low 
solubility in water seem to be intrinsic properties of many drugs (including anticancer 
agents, many of which are bulky polycyclic compounds, such as camptothecin, paclitaxel, 
or tamoxifen), since it helps a drug molecule to penetrate a cell membrane and reach 
important intracellular targets [Torchilin 2006]. On the contrary the administration of 
hydrophilic drugs, such as proteins, is limited by the inconvenient and invasive manner in 
which they must be currently be administered. Furthermore proteins are associated with a 
short half-life and repeated injections or continuous infusion throughout the therapy are 
required [Bartus 1998]. 
Nanoparticles based on biodegradable polymers have great potential to provide an ideal 
solution for most of the problem encountered in bioactive agents administration [Solaro 
2003]. But to decide if a particular therapeutic agent is suited to be delivered in a drug 
delivery system many issues such as potency, stability, solubility, size have to be taken 
into account [Allen 2004].  
The setting up of polymeric nanoparticles preparation process requires an accurate 
investigation on polymer and drug physical chemical characteristics. The optimized 
preparation process should guarantee for the chemical stability and biological activity of 
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the incorporated drug. Particularly, when the loaded active agent is a protein, its 
denaturation upon contact with hydrophobic organic solvents should be avoided by using 
appropriate preparation conditions. The encapsulation efficiency and the yield of the 
process should be high enough for mass production and the produced nanoparticles 
should display a homogeneous diameter distribution, in agreement with their end-use 
requirements. Nonetheless, the preparation and purification processes must lead to high 
reproducible results and the release profile of the drug should meet the specific final 
application requisites. Finally, in case of final pharmaceutical dosage forms that involve 
the recovery of a suspension of nanoparticles in appropriate mediums, free-flowing 
nanoparticles should be prepared and appropriate storage conditions should be 
investigated.  
There are a number of techniques available for the preparation of drug loaded 
nanoparticulate systems such as: emulsion solvent evaporation/extraction method, spray 
drying, phase separation-coacervation, interfacial deposition, and in situ polymerization. 
Each method has its own advantages and disadvantages. The choice of a particular 
technique depends on polymer and drug features, site of action and therapy regimes 
[Avgoustakis 2004, General 2001, Sinha 2004]. 
The work performed during the present PhD thesis was designed to optimize and develop 
procedures for the preparation of polymeric nanoparticle suspensions as drug controlled 
delivery systems for hydrophobic and hydrophilic drugs. A variety of polymers including 
PLGA, PHB, VAM41, multi block copolymers of PCL-PLU, and Chitosan, were 
investigated. Retinoic Acid and Chondroitin Sulphate, were loaded into nanoparticles 
respectively as hydrophobic and hydrophilic model drugs. Proteins have been also co-
encapsulated as stabilizing agent or as model proteic drugs. 
Due to the complexity and multitude of parameters which have to be taken in account 
during the preparation of a nanoparticles formulation, the choice of a preparation method 
is an hard task and a general procedure that works for all nanoparticles material seem to 
do not exist. During this work various type of the above mentioned methods for the 
preparation of nanoparticles were investigated, modified and adapted to the features of the 
materials employed. Furthermore original procedures that do not entail the use of organic 
solvents were developed with important implication from the point of view of 
biocompatibility. Nanoparticles were characterized in terms of morphology and size. 
Drug loading was evaluated and drug release studies of the hydrophobic molecule were 
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carried out with an original method that might better reflect bioavailability data. The 
biopharmaceutical properties of the formulation were also investigated. 
 
4.2. RETINOIC ACID LOADED NANOPARTICLES 
 
For the preparation of RA loaded nanoparticles several methods were investigated: 
dialysis, nanoprecipitation, co-precipitation and colloidal-coating. Colloidal-coating is an 
original solvent-free method developed in the framework of the research activity carried 
out in present PhD thesis. The first two methods were employed for the preparation of 
formulations based on PLGA, PHB and the multi block copolymer PCL-co-PLU, while 
the last two for formulations based on VAM41. The resulting nanoparticle suspensions 
were analyzed macroscopically in terms of homogeneity and formation of precipitates, 
and characterized from a dimensional and morphological point of view by means of light 
scattering (LS) and scanning electron microscopy (SEM). 
 
4.2.1. Dialysis Method 
 
Dialysis is a simple and effective preparation method for small and narrow size 
distributed nanoparticles. This method was initially applied for the preparation of core-
shell nanoparticles by using block graft copolymers and other amphiphilic materials and 
then extended to hydrophobic polymers such as PLGA [Jeong 2001, Jeon 2000].  
 
4.2.1.1.  PLGA Based Nanoparticles Prepared By Dialysis Method 
 
 
PLGA nanoparticles were prepared by dialysis technique and some processing conditions 
were changed to observe their effect on particle size, morphology and drug loading. More 
in detail the concentration of polymer and the volume of water against which the polymer 
solution was dialyzed were varied. The possibility to use binary solvent systems to 
dissolve polymer and drug was investigated. A surfactant was added to the the 
formulation in order to improve colloidal suspensions stability and drug encapsulation 
efficiency. 
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I. Influence of the Water Volume in the Receiving Compartment  
 
Dialysis procedure was performed for 24 h in order to remove completely the organic 
solvent and to allow nanoparticles formation. The distilled water was exchanged at 
intervals of 3~4 h. This procedure showed to be effective for the preparation of 
nanoparticles with spherical morphology (Figure 4.1) and monomodal size distribution 
(Figure 4.2).  
 
  
Figure 4.1 -  SEM image Figure 4.2 - Coulter LS Particle size distribution 
 
The water volume, dialyzed against the organic solution, was varied from 3 l to 1 l in 
order to examine whether variation of osmotic pressure had any effect on nanoparticles 
size. The sizes of PLGA nanoparticles obtained by dialyzing the polymeric solution 
against 3, 2 an 1 l of distilled water are shown in Table 15. Variation of the water volume 
did not affect particles diameter size and distribution. Based on these results, subsequent 
formulation were prepared by dialyzing the polymer organic solutions against 1 l of 
water.  
 
Table 15 - Influence water volume on particle size 
 Run PLGA  Volume Diameter Size 
  (mg/ml) (l) (nm± SD) 
 D-LG-01 2.5 3 635±102 
 D-LG-11 2.5 2 634±115 
 D-LG-07 2.5 1 650±105 
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II. Effect of Polymer Concentration and Solvent Composition 
 
The concentration of the polymer significantly affected the diameter size and distribution 
of the resulting nanoparticles. Nanoparticles were prepared from solution of PLGA in 
DMSO with concentrations of 2.5, 1.4 and 1 mg/ml. A significant decrease in 
nanoparticles size was observed when reducing the polymer concentration (Table 4.2).  
 
Table 4.2 - Influence of PLGA concentration and solvent composition on particle size 
 Run PLGA   Solvent Diameter Size Distribution 
  (mg/ml) (%
a
DMSO) (nm± SD) 
 D-LG-01 2.5 100 635±102 monomodal 
 D-LG-06 1.4 100 52±13  trimodal  
 D-LG-04 1.0 100 53±11 bimodal 
 D-LG-17 1.4 70 140±20  monomodal 
a % v/v DMSO/H2O 
 
The homogeneity of the suspension was also affected. Bimodal and trimodal diameter 
size distribution was observed at lower polymer concentrations (Figure 4.3).  
 
 
Figure 4.3 -  Influence of PLGA concentration and  
solvent composition on particle size 
 
 
Fessi et al. reported that the origin of the mechanism of nanocapsule formation by 
nanoprecipitation could be explained in terms of interfacial turbulence or spontaneous 
agitation of the interface between two equilibrated liquid phases involving flow, 
diffusion, and surface processes, the so called Maragoni effect [Bilati 2005]. Although 
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this mechanism is not fully understood at present, it is thought that the principle of PLGA 
nanoparticles formation by the dialysis procedure may be based on a mechanism similar 
to the Fessi et al. method, by subsequent hydrophobic interactions among the polymer 
chains [Jeong 2001]. 
The precipitation of monodispersed colloids from homogeneous solution is a complex 
process. In a supersaturated solution nuclei rapidly generate by diffusive mechanism to 
form the primary particles. These primary particles collide because of Brownian 
movements [Molina-Bolìvar 1999] and aggregate to form secondary particles [Privman 
1999]. The stability of the resulting particles depends on the balance of various attractive 
and repulsive forces acting between particles. It is common to distinguish the two classes 
of colloids whose general behaviour is entirely different. These classes are generally 
called lyophobic and lyophilic colloids, respectively; it is assumed that in the lyophilic 
colloids a strong affinity exists between the particles and the molecules of the dispersion 
medium, whereas in the lyophobic colloids the affinity is either weak or absent. The 
stability of lyophobic colloids is determined only by one factor (the electric charge of the 
particles), while two factors (charge and hydration) contribute to the stability of lyophilic 
colloids [Molina-Bolìvar 1999].  
In the dialysis method, particles begin to form at the level of the inner surface of the 
dialysis membrane.  The layer of supersaturated solution is originated by the flux of non-
solvent that flows into the dialysis tube, mixes and replaces the organic solvent. 
Reasonably at higher concentration of polymer the concentration of primary particles that 
form at the level of this supersaturated layer is higher. Statistically, the number of 
collisions that result in a permanent contact, thus in the formation of secondary particles, 
is higher as well and consequently secondary particles formed are characterized by bigger 
diameters. Our results confirmed this hypothesis. Particles with bigger diameter were 
obtained at higher concentration of polymer but a polymodal distribution of diameters 
was observed when lower polymer concentrations were used. 
The formation of secondary particles is facilitated by changes in the chemical conditions 
of the system. For example, an increase of ionic strength or pH changes may result in a 
reduction of electrostatic barriers that promotes particles aggregation [Privman 1999]. At 
the beginning of the dialysis process particles behave as lyophilic colloids (hydrophobic 
nanoparticles embedded in an organic solvent) which are stabilized by hydratation forces.  
At the end, the percentage of water in solution increase and particles behave as lyophobic 
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colloids (hydrophobic particles in a aqueous environment) stabilized by electrostatic 
repulsions. 
Keeping in mind the behaviour of our particles, PLGA was dissolved in the organic 
solvent and subsequently a percentage of non-solvent (water) was added to the resulting 
solution. The resulting binary solvents system was dialyzed against water. The rationale 
behind this approach was that the presence of an amount of water in the organic solution, 
which has as first consequence a decrease of the polymer concentration, would allow for a 
better stabilization of the forming particles by hydration forces from the beginning of the 
process. Moreover this would avoid the formation of big secondary particles and 
aggregates, thus allowing for the obtainment of nanoparticles with small diameter size 
and a monomodal distribution. Experiments confirmed our assumption (Table 2, Figure 
4.4 , 4.5). 
 
  
Figure 4.4 - SEM image Figure 4.5 - Coulter LS Particle size distribution 
 
 
Nanoparticles with small size, monomodal distribution of the diameter and nice spherical 
shape were obtained. Nanoparticles displayed a diameter size slightly higher than those 
prepared from a monosolvent solution of PLGA in DMSO at the same concentration. 
Such phenomena can be explained as the result of differences of viscosity, solubility of 
the polymer, or miscibility between the binary and monosolvent system (Jeong 2001). 
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III. Effect of Drug and Surfactant 
 
Based on the previous results the preparation of drug loaded nanoparticles was carried out 
by adding RA dissolved in DMSO to a binary solvent solution of PLGA in DMSO and 
water.  
The presence of the drug did not affect particle diameter size (Table 16) but large RA 
yellowish flakes formed during the dialysis process.  
 
Table 16 -  Effect of drug and surfactant on particles size and drug loading 
 Run PLGA Pluronic F-127 RA  Solvent Diameter Size Drug Loading  
  (mg/ml) (mg/ml) (mg/ml) (%
a
DMSO) (number%) (%
 P/P
) 
 D-LG-R-24 1.4 -  0.7 70  107±39  - 
 D-LG-R-66 1.6 0.3  0.8  86.3  152±114  - 
 D-LG-R-67 1.6 0.3  0.4  86.3  551±151  - 
 D-LG-R-72 1.5 0.5  -  84.5  581±210  - 
 D-LG-R-74 1.5 0.5  0.7  84.5  520±137  - 
 D-LG-R-64 1.5 0.7  0.7  84.5   670±17  - 
 D-LG-116 1.5 0.4  -  85   531±73 - 
 D-LG-R-147 1.5 -  0.6  85   564±84 - 
 D-LG-R-87 1.5 0.4  0.6  85   549±170 1 
 D-LG-R-83 1.6 0.4 0.6  81   508±127 1.3 
a % v/v DMSO/H20 
 
 
RA is a hydrophobic compound with one polar, ionisable end group which confer 
amphiphilic character to the molecule. In non-polar hydrocarbon solvent, RA self 
associate by forming tail-to-tail dimers that are stabilized by hydrogen bonding between 
the carboxyl groups of two RA molecules. On the contrary, in water RA self associate in 
micelles like structure by hydrophobic interaction among the rings of several molecules 
[Noy1992]. 
The loading process of hydrophobic drugs into the particles is thought to involve the 
hydrophobic interaction between the drug and the hydrophobic segment of the polymeric 
chains (Jeong 2001). The micelles expose the polar heads of RA on the surface hampering 
the formation of hydrophobic interactions with the polymer and reducing their 
encapsulation.  
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In order to reduce the formation of flakes and to increase the loading efficiency a 
surfactant (Pluronic F-127) was added to the formulation. Pluronic, due to its amphiphilic 
character, could mediate the interaction between the polymer and the drug avoiding the 
formation of flakes and precipitates. The presence of the surfactant influenced the average 
diameter size of the nanoparticles but had only a slight effect on the formation of flakes 
that was just partially reduced. Particles size increased resulting in the range of 500 – 700 
nm (Figure 4.6 – 4.7).  
 
  
Figure 4.6 - D-LG-R-74 SEM image Figure 4.7 - D-LG-R-74 Particle size distribution 
 
 
PLGA, RA and pluronic concentrations were varied in order to optimize the formulation 
and increase the loading efficiency. Particles with an average diameter size of 530 nm and 
a drug loading of 1.3 %  were obtained (Figure 4.8 – 4.9).  
 
  
Figure 4.8 - D-LG-R-83 SEM image Figure 4.9 - D-LG-R-83 Particle size distribution 
 
 
Nanoparticles drug content resulted lower than what expected. Attempts to increase the 
loading were carried out by dialysing the polymer, drug and surfactant solution against 
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ethanol instead of water during the first three hours of dialysis. Ethanol acts as non-
solvent for the polymer, allowing for the formation of nanoparticles and as solvent for 
retinoic acid, avoiding the formation of flakes and precipitates. Nanoparticles with an 
average diameter size of 630 nm, very good spherical shape and drug content of 2.2 % 
were obtained (Figure 4.10 – 4.11).  
 
  
Figure 4.10 - SEM image Figure 4.11 - Particle size distribution 
 
As expected flakes and precipitates of RA did not form during the dialysis and the drug 
loading increased, even though it was still low. In this case the low drug loading could be 
due to the leakage of RA out of the dialysis tube during the dialysis process. Being 
soluble in ethanol and having a molecular weight much lower than that of the cut-off of 
the dialysis membrane (MWRA: 300.4 Da; MWCOmembrane: 10000 Da) it could easily 
passed trough the membrane’s pores during the process. These experiments confirmed 
that the loading efficacy is the major drawback of the dialysis procedure (Jeong 2001) 
 
 
4.2.1.2.  PHB Based Nanoparticles Prepared by Dialysis Method  
 
PHB nanoparticles were prepared by dialysis method. Some processing conditions were 
varied to observe their effect on nanoparticles characteristic such as particle size, 
morphology and drug loading. More in details it was evaluated the influence of the 
concentration of drug and the addition of a surfactant to the formulation.  
In the dialysis process, solvents to make nanoparticles are limited to water-miscible 
solvents, which can dissolve both the polymer and the drug, because water-immiscible 
solvents such as dichloromethane cannot diffuse out or evaporate from the dialysis 
membrane to the outer aqueous environment (Jeong 2001). Chlorinated solvents such as 
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dichloromethane are commonly used to dissolve poly hydroxyalkanoates but water 
miscible-solvents such as DMSO, Acetone, THF and DMF were found to be not effective 
in solubilizing PHB. PHB showed good solubility in TFE at 50°C thus it was chosen as 
solvent. On the contrary, RA has good solubility in polar solvents such as DMSO and 
Acetone but it is poorly soluble in TFE. Based on the results obtained from the 
preparation of PLGA nanoparticles it was decided to use a binary solvent system to make 
nanoparticles, composed of a solvent and a non-solvent of the polymer, a mixture of TFE 
and DMSO was chosen which could respectively dissolve both the polymer and the drug. 
In this case the employment of a binary solvent system was not a choice but a necessary 
condition.  
PHB unloaded nanoparticles with an average diameter size of 53 nm were prepared by 
dialysis method using a binary solvent solution of TFE/DMSO (9:1) (Table 17).  
 
Table 17 - PHB nanoparticles: dialysis  
 Run Pluronic F-127 RA  Solvent Diameter Drug Loading 
  (mg/ml)  mg/ml (%
b
TFE) number % (% P/P) 
 D-HB-1 -  - 90 53±13 - 
 D-HB-2 -  0.5 90 53±16   0.94 
 D-HB-3 -  0.3 90 50±20 - 
 D-HB-4 2  0.3 96 53±17   1.04  
b % v/v TFE/DMSO 
     
Nanoparticles showed a good spherical shape and narrow size distribution of the 
diameters (Figure 4.13 – 4.14).  
 
  
Figure 4.13 - SEM image Figure 4.14 - Particle size distribution 
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The small diameter of the PHB nanoparticles obtained is remarkable in comparison with 
those of PHB microspheres prepared by other techniques such as solvent evaporation 
(Maia 2004).  
 
Effect of Drug and Sufactant 
 
RA loaded PHB nanoparticles were prepared by adding to the solution of TFE containing 
PHB the solution of retinoic acid in DMSO at various concentrations. The average 
diameter size of retinoic acid loaded nanoparticles was 53 nm with a drug content of 0.94 
% (Figure 4.15 – 4.16).   
 
  
Figure 4.15 - SEM image Figure 4.16 - Particle size distribution 
 
The addition of retinoic acid did not affect the diameter of the resulting nanoparticles. 
Flakes of retinoic acid formed during the dialysis process as it occurred during the 
preparation of PLGA nanoparticles.  
In order to reduce the formation of flakes and precipitates and to increase the drug content 
a surfactant, PVP, was added to the formulation. Particles with an average size diameter 
of 53 nm were obtained with a drug content of 1.05 % (D-HB-4). In this case the 
surfactant did not effect the diameter size of the nanoparticles but also did not improve 
the RA encapsulation (Table 17., Figure 4.17 – 4.18). 
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Figure 4.17 - SEM image  Figure 4.18 - Particle size distribution 
 
 
4.2.1.3.PCL-co-PLU Based Nanoparticles Prepared by Dialysis Method 
 
Even if the dialysis method was initially applied for the preparation of core-shell 
nanoparticles by using block graft copolymers and other amphiphilic materials, poor 
results were obtained by using the multi block copolymers developed by the research 
group involved in the present study.  
In order to prepare multi block copolymers based nanoparticles or core shell nanoparticles 
PCL-co-PLU was dissolved at various concentration in DMSO. The resulting solution 
was then dialyzed against water. At the beginning of the process the clear polymer 
solution turned milky thus indicating the formation of a colloidal suspension. Anyhow at 
the end of the process the solution turned clear. Probably the hydrophilicity of the 
polymer was too high and the formed particles were unstable in water and re-dissolved. 
 
4.2.2. Nanoprecipitation Method 
 
By using dialysis method good results in term of size and diameters distribution of 
nanoparticles were obtained though they were characterized by low drug content and 
loading efficiency. Low drug content indicates high drug loss during particles preparation 
and that a large quantity of carrier would be required to achieve sufficient amount of drug 
at the target site (Govender 1999). In this respect, nanoprecipitation was investigated as 
method for the preparation of nanoparticles with higher drug content. The 
nanoprecipitation technique (or solvent displacement method) was first developed and 
patented by Fessy and co-workers (1989). This technique presents numerous advantages, 
in that it is a straightforward technique, rapid and easy to perform.  Nanoprecipitation 
often enables the production of small nanoparticles (100-300 nm) with narrow 
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monomodal distribution. This technique is mostly suitable for drugs having a 
hydrophobic nature because their limited solubility in water reduce even up to zero drug 
leakage to the outer medium (Bilati 2005). 
 
4.2.2.1.  PLGA Based Nanoparticles Prepared by Nanoprecipitation Method 
 
PLGA nanoparticles were prepared by nanoprecipitation method. Some processing 
conditions were changed to observe their effect on nanoparticles particle size, 
morphology and drug loading. More in details, the influence of the polymer concentration 
and the possibility to use a binary solvent system to solve polymer and drug were 
investigated.  
Preliminary tests were performed by preparing unloaded nanoparticles based on PLGA 
and pluronic (P-LG-102). A slight milky like suspension formed but subsequently some 
agglomerated appeared in solution. The suspension was filtered through 5 µm filters and 
then analyzed by light scattering. Nanoparticles with an average diameter size of 125 nm 
were obtained (Table 18, Figure 4.19).  
 
  
Figure 4.19 -  Particle size distribution 
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Table 18 - PLGA based nanoparticles formulations prepared  
by nanoprecipitation method 
 Run Diameter Drug Loading 
  (number %) (% 
P/P
) 
 P-LG-102 125±17 - 
 P-LG-99 132±18 14 
 P-LG-103 147±20 27  
 P-LG-101 52±89 21 
  
 
I. Effect of Drug 
 
Drug loading was carried out by adding to the polymers solution a solution of retinoic 
acid in DMSO. In this case a yellowish milky like suspension was obtained and flakes did 
not form.  
The formation of uniform colloids by direct precipitation of the organic solution is 
assumed to involve a short nucleation burst, followed by diffusional growth of the nuclei 
to form identical, finely dispersed particles [Privman 1999]. Retinoic acid, due to its 
hydrophobic nature, can act as nucleating agent favouring particles formation and 
avoiding the formation of flakes. Indeed, by dropping a DMSO solution containing only 
retinoic acid in water, a stable yellowish colloidal suspension is formed. Hence, both the 
polymer and drug give rise to microphase separation that leads to the formation of a 
colloidal nanoparticulate suspension. RA molecules probably absorb on the surface of 
PLGA nanoparticles and the presence of their hydrophilic heads might stabilize the 
formulation and avoid the formation of aggregates observed during the preparation of the 
unloaded nanoparticles. By nanoprecipitation methods particles with an average diameter 
size of 132 nm and a drug content of 14 % were obtained. 
 
II. Effect of Polymer Concentration and Solvent Composition 
 
The influence of polymer concentration on the resulting nanoparticles was evaluated. It 
was observed that at lower polymer concentration the diameter of nanoparticles increased 
as well as drug encapsulation.  
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Based on the good results obtained by using a binary solvent system during the 
preparation of nanoparticles by dialysis, the same approach was also investigated for their 
preparation by nanoprecipitation. A DMSO/water solution of PLGA, pluronic and 
retinoic acid was dropped in distilled water under stirring condition. As it happened in the 
case of dialysis, the presence of water in the polymer solution reduced the particles size. 
Particles with an average diameter size of 52 nm and a drug content of 21 % were 
obtained (Figure 4.20 – 4.21). Drug encapsulation was slightly lower than for samples 
prepared without water. 
 
  
Figure 4.20 - P-LG-101 SEM image Figure 4.21 - P-LG-101 Particle size distribution 
 
 
For the preparation of retinoic acid loaded nanoparticles, nanoprecipitation method in 
comparison with dialysis method has shown to be quicker, and more effective for 
preparing nanoparticles with monomodal size distribution and higher drug loading 
content, up to 27 times higher. 
 
4.2.2.2. PLGA Based Nanoparticles Loaded with RA and HSA Prepared by 
Nanoprecipitation  
 
In order to improve the stability and half life of retinoic acid loaded nanoparticles, a novel 
formulation based on PLGA and HSA for the delivery of retinoic acid was developed.  
Albumin is the most well studied plasma protein and an attractive macromolecular carrier 
due to its availability in pure form and its biodegradability, non toxicity and 
nonimmunogenicity. Albumin-based drug carrier systems have been developed 
particularly in the field of chemotherapy to improve the passive tumor targeting 
properties of anti-cancer drugs. It is widely used as a stabilizing component in 
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pharmaceutical and biological products. Drug formulation using albumin as a carrier 
promises to acquire additive beneficial affects physiologically due to its known 
antioxidant properties [Chuang 2002].  
Albumin was loaded into nanoparticles to enhance the stability of NPs, increase the 
affinity of nanoparticles for RA, to protect the drug against degradation, which is highly 
sensitive to light, air and oxidizing agents, and to prevent the rapid clearance of 
nanoparticles by mononuclear phagocyte system endowing the particles with an 
hydrophilic surface that avoid opsonisation.  It has been reported that pre-coating of 
nanoparticles or liposomes with some given serum protein which lacks opsonic activity 
such as serum albumin, resulted in less affinity to macrophages but the mechanisms 
behind this observation were not fully addressed and remain to be elucidated [Ogawara 
2004]. ABI-007 is a formulation of paclitaxel that is bound to human serum albumin by 
high-pressure homogeneization of paclitaxel in the presence of albumin using the so 
called nanoparticles albumin-bound (nab) technology. The resulting product is an 
extremely small particle with a mean size of approximately 130 nm. Several factors such 
as the presence of albumin receptors in cell surface, the increased need of nutrients by 
tumor cells and the lack of sequestering Cremophor micelles lead to increased 
intratumoral concentration of this new taxane [Moreno 2005]. ABI-007 demonstrated 
greater efficacy and a favorable safety profile compared with standard paclitaxel and is in 
phase III clinical trial [Gradishar 2005]. 
Although a lot of work has been done on stabilization of colloidal systems by non-ionic 
macromolecules, cationic and anionic polyelectrolyte, only a little attention has been paid 
to stabilization by amphoteric macromolecules such as protein [Molina 1999].   
Furthermore, HSA can be considered as a model proteic drug co-encapsulated with RA. 
The co-administration of drugs that perform their activity at different level of cancer 
development may be more effective for its eradication. For instance, the simultaneous 
targeting of the tumor and vascular compartments proved very effective, because it 
combines a decrease in tumor cell nourishment with the active destruction of tumor cells, 
leading to a regression of primary tumors and the eradication of distant metastases [Lode 
1999].  
Basically the same recipe for the preparation of P-LG-164 was used but albumin was 
added to the non-solvent water solution and co-encapsulated into the nanoparticles. Ring-
shape nanoparticles with an average diameter size of 570 nm, albumin content of 78 % 
and retinoic acid content of 15.4 % were prepared (Figure 4.22 – 4.23).  
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Figure 4.22 - P-LG-164 SEM image Figure 4.2 - P-LG-101 Particle size distribution 
 
 
Due to their shape nanoparticles were called nano-Donuts since they closely resemble the 
American cakes but 100000 times smaller (Figure 4.24 – 4.25). 
 
   
Figure 4.24 - P-LG-164 SEM image Figure 4.25 - Donuts image 
  magnification 
 
 
The shape of the nanostructures might be the results of opposite repulsive and attractive 
forces. The polymer and the drug tend to aggregate and form particles in order to reduce 
the free surface exposed to water reducing the system energy. Instead, HSA conferring 
lyophilic character to the particles, hampers their complete aggregation by repulsive 
hydration forces.    
  
4.2.2.3.  PHB Based Nanoparticles Prepared by Nanoprecipitation  
 
PHB nanoparticles were prepared by nanoprecipitation method. Based on the previous 
results TFE was used as solvent for PHB.  Since retinoic acid is not soluble in TFE the 
1 µm 
1 µm 10 cm 
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utilization of a binary solvent system turned out to be a necessary condition for the 
preparation on nanoparticles. 
The first step was the study of the suitability of this method for the preparation of PHB 
nanoparticles.  
PHB was dissolved in TFE and then a percentage of DMSO was added. The resulting 
solution was dropped in water under stirring condition. Nanoprecipitation failed and large 
flakes and filaments formed. This effect was overcome neither by adding a surfactant nor 
by varying the volume of non-solvent.  
 
I. Effect of Drug 
 
Taking into account the stabilizing and nucleating effect of RA, observed during the 
preparation of PLGA nanoparticles by nanoprecipitation, RA was added to the 
formulation in order to understand weather or not its behaviour was exploitable for the 
preparation of NPs using other polymers. Once again the presence of retinoic acid 
triggered the formation of nanoparticles. A stable yellowish like suspension formed and 
flakes were not present in solution. Nanoparticles with an average diameter size of 130 
nm and drug content of 23 % were obtained (Figure 4.24 – 4.25).  
  
Figure 4.24 - P-B-150 SEM image Figure 4.25 - P-LG-150 Particle size distribution 
 
 
II. Effect of Polymer Concentration and Solvent Composition 
 
The influence of the concentration of the polymer and the effect of the solvents ratio in 
solution were evaluated. Only a slight influence on diameter size was observed in both 
cases (Table 19). 
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Table 19 - PHB based nanoparticles formulations  
 prepared by Nanoprecipitation method  
 Run Diameter  Drug Loading 
   (number %) (%
P/P
) 
P-B-150 133±17  28.2 
P-B-153 150±21   -  
 P-B-154 130±17  23.7 
 
 
As previously observed during the preparation of PLGA nanoparticles, nanoprecipitation 
method gave better result in term of drug encapsulation in comparison with dialysis 
method. Drug content was 23 times higher. However it was not been possible to prepare 
drug-free nanoparticles.  This phenomenon can be explained as follow. Studies carry out 
in TFE evidenced that PHB retain its solid-state helical conformation in solution [Pouton 
1996] which confer rigidity and low degree of flexibility to the polymer. Both 
nanoparticles preparation methods are based on the principle of solvent displacement. 
During the dialysis process the displacement of the organic solvent occur gradually and 
the polymer is not subjected to direct stirring forces. PHB molecules have the time to 
properly bend, interact by hydrophobic interaction and organize to form structures with 
low interfacial energy and higher stability, such as nanoparticles. During the 
nanoprecipitation process the displacement of the solvent is rapid and the polymer might 
tend to aggregate to reduce the interfacial energy by rapidly agglomerating in non regular 
structures. Moreover in nanoprecipitation molecules are subjected to stirring forces which 
might give rise to the formation of fibers.    
 
4.2.2.4.  PCL-co-PLU Based Nanoparticles Prepared by Nanoprecipitation 
 
Various solvent have been investigated for the preparation of nanoparticles based on the 
amphiphilic copolymer PCL-co-PLU including DMSO, THF, Acetone, and DMF. The 
particle size of PLGA nanoparticles prepared from Acetone were relatively larger than 
those prepared from the others. 
Nanoprecipitation results from various phenomena that govern the diffusion of the solvent 
trough the polymer into the non-solvent. It is therefore expected that many parameter 
affect the final mean particles size, including the dielectric constant, the affinity of the 
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solvent for the non-solvent and the solvent-polymer interactions just to mention some 
[Bilati 2005].  Depending on the solvent used to dissolve the polymer, the average 
diameter of nanoparticle ranged from 60 to 600 nm (Table 20, Figure 4.26 – 4.27).  
 
Table 20 - PCL-co-PLU based nanoparticles formulations  
prepared by Nanoprecipitation method 
 Run Diameter  Solvent 
   (number %)  
P-PP-T 56±13  THF 
P-PP-D 132±27   DMSO  
 P-PP-A 630±124  Acetone 
 
 
  
Figure 4.26 - P-PP-D Particle size Figure 4.27 - P-PP-A Particle size  
 
Among the solvents used, DMSO, since it is considered as non-toxic (it is in Class 3 of 
ICH classification) and gave good results in term of particles diameter size, was chosen 
for the preparation of drug loaded nanoparticles.   
Drug loaded nanoparticles were prepared by adding to the DMSO polymer solution an 
amount of RA solved in DMSO. The average size of the resulting nanoparticles (P-PR-D) 
was 60 nm (Figure 4.28). 
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 Figure 4.28 - P-PR-D Particle size distribution 
 
The size of the loaded particles was smaller than the unloaded ones. This might be 
attribute to the presence of RA that acted as nucleating agent. The obtained suspension 
was dialyzed and centrifuged in order to remove the organic solvent and to harvest the 
material for a morphological evaluation of the particles (Figure 4.29).  
 
  
 Figure 4.29.-  SEM image 
 
Clearly the material was too soft and could not withstand the centrifugation process. The 
particles coalesced in an unshaped mass of polymer and drug. Hence, morphology of 
nano-particles prepared from PLU-co-PCL was observed in solution by TEM as shown in 
Figure 4.30.  
 
 
RESULTS & DISCUSSION 
 125 
  
 Figure 4.30 – PCL-co-PLU NPs TEM image 
 
The analysis showed that PCL-co-PLU exhibit a core-shell structure and spherical shape. 
 
4.2.3. Co-Precipitation Method 
 
The co-precipitation technique is an original procedure set up for the encapsulation of 
proteins. The process of co-precipitation is based on the dropwise addition of a solution of 
the synthetic polymer in water-miscible organic solvents to an aqueous protein solution, 
under gentle magnetic stirring. During the co-precipitation process, the polymeric 
material gives rise to microphase separation because of its low water solubility; 
concurrent interaction with protein molecules leads to nanoparticles formation. This 
original straightforward procedure, developed by the research group involved in the 
present study [Cowdall 1999a, 1999b], appears advantageous for the loading of protein 
drugs into a polymer matrix. 
Indeed, this methodology does not entail the use of chlorinated solvents and it does not 
require vigorous shear mixing, thus preventing the appreciable denaturation of the 
entrapped protein molecule that often occurs of other techniques. It is well established, in 
fact, that exposure of proteins to factors such as organic solvent and sonication during the 
encapsulation process can reduce the biological activity [Park 1995, Zambaux 1999, 
Pawar 2004]. 
Human Serum Albumin (HSA) is the most abundant protein in plasma (600 µM) and is 
one of the most important factors affecting the distribution and the free, active 
concentration of many administered drugs [Ghuman 2005]. Retinoids are effectively 
transported in the blood-stream bound to proteins and the acidic derivatives (RA) mainly 
by albumin [Tsukada 2002]. Regarding the mode of binding of RA to albumin, it has been 
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suggested that this ligand associates with the high-affinity sites that albumin is know to 
have for long-chain fatty acids [Noy 2002]. 
Based either on the expertise acquired in loading proteins by co-precipitation method and 
on the above mentioned ability of albumin to bind retinoic acid it was decided to 
investigate the possibility to encapsulate RA through the encapsulation of its natural 
carrier. The idea was to complex RA with HSA, the complexation occur naturally by 
adding RA to a water solution of HSA, and then to load HSA into nanoparticles. 
Albumin is the most well studied plasma protein and an attractive macromolecular carrier 
due to its availability in pure form and its biodegradability, non toxicity and 
nonimmunogenicity. Drug formulation using albumin as a carrier promises to acquire 
additive beneficial affects physiologically due to its known antioxidant properties 
[Chuang 2002]. Albumin was loaded into nanoparticles aiming at enhancing the stability 
of NPs, increase the affinity of nanoparticles for retinoic acid and protect the drug against 
degradation, which is highly sensitive to light, air and oxidizing agents. 
Nanoparticles were prepared following different HSA/RA rates (Table 21).  
 
Table 21 - VAM41 based nanoparticles formulations prepared by Co-precipitation 
 Run HSA  RA  HSA / RAc Diameter Drug Loading 
  (mg) (mg)    Number % (%
P/P
)  
 C-V-233 10 0.0015 1 / 0.03 112±20  - 
 C-V-235 10 0.045 1 / 1 107±20  - 
 C-V-234 10 0.15 1 / 3.3 -   - 
 C-V-236 10 0.45 1 / 10 79±17  - 
 C-V-237 50 2.27 1 / 10 90±47  4.4 
c
 molar rate 
 
 
The obtained nanoparticles suspensions were analyzed in term of size and size 
distribution. The influence of the mole ratios between retinoic acid and albumin and of 
their concentration on nanoparticles size were investigated. It can be seen that a decrease 
in nanoparticles size could be achieved by decreasing the molar rate HSA/RA. This can 
be explained as following: it was observed that RA is soluble in water at a concentration 
of 1,5 mM, as evidenced by the clarity of the solution and the lack of any observed 
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scattering at pH > 7.4. When the pH is lowered to 7-6 retinoic acid self associate in 
micellar like structure with diameter of 120 nm, this phenomenon is macroscopically 
evidenced by the formation of torbidity and by granulometry measurements. A further 
decrease of the solution pH leads to the formation of flakes and precipitation of retinoic 
acid. In presence of 0.15 mM of albumin (nHSA / nRA 1:10) no precipitation of retinoic 
acid could be observed and a yellowish milky like suspension with a diameter size of 90 
nm formed. At pHs below 5 this colloidal suspension looses its stability and agglomerate. 
This anomalous behaviour could be explained by the so-called hydration forces  [Molina-
Bolìvar 1999]. Proteins adsorb on colloids surface and it is well established that water 
molecules strongly bind to protein surface. Polar surfaces induce an ordering of the 
solvent which exponentially decays away from the surface. An overlap of the ordered 
solvent layers near to the two mutually approaching surfaces creates repulsive forces 
[Molina-Bolìvar 1997].  
At a pH below the critical micelle concentration (CMC) the negative surface charge 
which stabilize the retinoic acid micelles is gradually lost. Particles frequently encounter 
and interact forming aggregates that precipitate. In presence of albumin, once its binding 
sites for retinoic acid are saturated, the surface of the colloidal suspension is covered by 
the protein and particles retain their stability in the absence of electrostatic repulsive 
forces. At pH values lower than pI protein molecules have a compact structure and an 
additional electrostatic attraction force exist that favours the protein (with positive charge) 
surface union [Molina-Bolìvar 1999] which leads to the loss of colloidal stability of our 
system at pHs below 5. 
The data reported above, taken together with the recognized presence of two or three 
binding sites for retinoic on serum albumin [Noy 1992, Karnaukhova 2007] might explain 
the obtained value of particles diameter size. In samples C-V-233 and C-V-235 the 
amount of HSA present in the solution and used to prepared the nanoparticles, was 
enough to complex and keep in solution all retinoic acid. The formation of the 
nanoparticles was trigged by the desolvatation of the polymer and the ethanol 
precipitation of albumin. In samples C-V-236 and C-V-237 retinoic acid was in excess in 
respect to HSA and a colloidal suspension was already present in solution when the 
polymer solution was dropped. The precipitation of the polymer allows for the RA / HSA 
complex encapsulation with subsequent formation of nanoparticles (Figure 4.31 – 4.32).  
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Figure 4.31 - C-V-237 SEM image Figure 4.32 - C-V-237 Particle size distribution 
 
Once again retinoic acid acted as nucleating agent and drove the formation of the particles 
together with the desolvatation of the polymer. 
 
4.2.4. Colloidal–Coating Method 
 
Although a number of different method exist for the preparation of nanoparticles it was 
highly desirable to provide with an alternative method, aimed at producing polymeric 
particles, that do not entail the utilization of organic solvents which are mostly toxic. 
Such a method is expected to receive a particular attention in biotechnological field 
[Chenite 1999].  
An organic solvent-free method has been developed for the preparation of VAM 41 
nanoparticles loaded with RA. This method is easy to perform, effective for the 
preparation of small nanoparticles with narrow size distribution and operator friendly 
since do not require to handle toxic organic solvents. 
This method was conceived by taking into account the characteristics of the material used 
which are following described.  
As already mentioned RA is soluble in water, at the concentrations used, at pHs above 7.4 
and forms micelle like structures at pH 6-7 which are stabilized by the presence of 
albumin. VAM41, due to the presence of the carboxylic ionisable group is soluble in 
water at pHs above 8 and it is insoluble at pHs below 7 (Figure 4.33). Albumin is soluble 
at all the mentioned pHs, able to complex RA and to stabilize colloidal particles, and due 
the presence of many charged residues on the molecule can act as a buffer accepting and 
releasing protons. At physiological pH (7.4) has a net negative charge [Nicholson 2000]. 
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Figure 4.33 - Carboxylic moieties confer amphiphilic behaviour to RA 
    and water solubility to VAM41 
 
It was observed that the addition of a drop of chloride acid 1N to a basic water solution of 
VAM41 and albumin, under energetic stirring, leaded as expected to the formation of 
flakes of polymer in solution. Unexpectedly, after few second, these flakes completely 
redissolve.  Albumin, thanks to its buffering properties, was able to deprotonate the 
carboxylic moieties of VAM41 and to dissolve the formed polymer flakes. The further 
addition of drops of acid leaded to a slow decrease of the pH of the solution,  to a 
reduction of the ability of albumin to accept protons and a milky like colloidal suspension 
of VAM41 started forming at about pH 6. At pH 5.5 a rough colloidal suspension of 
VAM41 with average diameter size of the particles of 2.74 µm (Figure 4.34) was 
observed that became 4.64 µm at pH 2.5. 
 
  
 Figure 4.34 - Particle size distribution obtained from a water  
  solution containing VAM41 and HSA 
 
On the bases of this observation and keeping in mind the characteristic of the material 
employed a water solution of VAM41, RA and albumin was prepared by adding a base to 
the water solution. Subsequently HCl 1N and 0.1N were added under energetic stirring in 
order to prepare nanoparticles. As already experienced after the addition of the first drops 
of acid to the solution flakes formed and that subsequently redissolved. As hypothesize at 
roughly pH 7.4 micelles of RA formed while the polymer kept redissolving in the same 
O
O O H
O O
n
O
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fashion. The subsequent additions of acid provoked the polymer to absorb and coat 
uniformly the surface of the formed colloidal suspension. The energetic stirring was 
essential for a uniform distribution of the polymers on RA micelles.  Somehow this 
process  resemble the practice of tablet coating in which tablets are loaded in large 
rotating pans and coated with polymers or polysaccharide. In the case of tablet coating is 
the evaporation of the solvent that trigger the coating process, in this case the decrease of 
pH. The colloidal suspension was stable up to pH 5.3. Below this pH particle joined 
together forming a dense aggregate which could be uniformly redispersed just by adding 
drops of diluted NaOH. The formation of aggregates could be ascribed to the above 
mentioned loss of colloids stabilizing effect of proteins at pHs close to its pI.  
Once again RA acted as nucleating agent for preparing its nanoparticular suspension. 
The preparation of nanoparticles was followed by pH meter and light scattering (Table 
22)  
 
Table 22.- Colloidal-Coating progress 
 pH Diameter (nm) Macroscopic observations 
  number % 
      8 - yellowish solution 
 ↓  7.5 59±11 slight yellowish milky like suspension 
 ↓  6.2 - dense yellowish milky like suspension  
 ↓  5 .2 87±44 presence of agglomerates in solution 
 ↑  5.7 78±17 yellowish milky like suspension 
 ↓  5.3 69±14 dense yellowish milky like suspension 
  
Nanoparticles with an average diameter size of about 65 nm and a drug loading content of 
6.7 % were prepared by using this technique. Drug loading efficiency was 97 % (Figure 
4.35-4.36). 
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Figure 4.35 -  SEM image  Figure 4.36 -  Particle size distribution 
 
Drug loading efficiency is very high, drug loading depend on the extent of acidification of 
the solution, the lower is the pH reached the higher is the amount of polymer that form 
nanoparticles. 
This method present numerous advantages if compared to the other nanoparticles 
preparation methods: do not entail the utilization of toxic organic solvents with obvious 
implications from a toxicity point of view, it is easy to perform, allows for the preparation 
of small nanoparticles with  narrow size distribution. It is based on a reversible process 
and wastes of material in case of accidental errors during the preparation are avoid, it is 
possible to prepare multi-layer nanocapsules by adding at different stages of the 
preparation different polymers and might be extendible for the preparation of ferrofluids 
or in general to encapsulate any substance that can act as nucleating agent. 
Basically it is suitable for any materials with water solubility influenced by the pH. 
 
4.3. NANOPARTICLES PURIFICATION 
 
Following preparation NPs needs to be purified in order to remove the excess of drug, 
polymer, surfactant and organic solvent if present. Thus, formulations are dialyzed 
against water, to remove the organic solvent, centrifuged to remove the excess of polymer 
and drug, freeze dried for one day and store at 4°C. Lyophilisation is commonly applied 
to pharmaceutics to obtain dry powder that are easy to handle, allow for better long term 
storage and improve physical and chemical stability of the material, e.g. avoiding 
component degradation and microbial contamination. This method is particularly 
indicated for thermally labile biological compounds, such as proteins, but requires the use 
of stabilising agents and additives [Allison 1999]. Furthermore, a freeze-dried 
pharmaceutical product to be used in humans should maintain a good appearance, very 
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low residual moisture, easy dissolution or re-dispersion and acceptable biochemical 
stability during prolonged storage [Wang 1999]. 
In general, the lyophilisation of polymeric micro– and nano- particles leads to the 
formation of sticky soft powders that are very difficult to re-disperse in injectable media 
and homogeneous diameter distributions of particles in suspension are hardly restored 
[Bozdag 2005]. The drug delivery system developed in the present work displayed similar 
behaviour and the direct lyophilisation of the purified nanoparticles led to the formation 
of spongy powders that were only partially re-dispersible either in water or in 
physiological solution. The freezing process itself represented a stressing condition for 
the nanoparticles, as evidenced by the formation of large white aggregates after defrosting 
frozen suspensions, still present even after prolonged stirring. On the other hand, issues 
associated with re-dispersion process were not avoided when the removal of water from 
nanoparticles was performed under vacuum at room temperature. Figure 4.37 shows the 
particles size of PLGA nanoparticles after redistribution. The harvested NPs could not be 
easily re-suspended since the preparation results highly agglomerated. 
 
 
 1)  2)  
 Figure 4.37 - Particles size before (1) and after (2) purification 
 
In the nanoparticles system one of the major advantage is the ease of long-term storage of 
drug-loaded nanoparticles in a freeze-dried form until used. Therefore, it is necessary to 
confirm the reconstitution of freeze-dried surfactant-free nanoparticles; this is important 
for administering it through intravenous injection [Jeong 2001]. 
For overcoming this problem, after centrifugation the NPs were re-suspended in a 
solution 3% of Mannitol and then freeze dried again [Bozdag 2005]. 
Mannitol is a cryoprotecting agent, protects the particles against aggregation by providing 
spatial separation and immobilizing the particles in a glassy matrix during the 
dehydration. 
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A yellowish cake easily redispersable was obtained and light scattering measurements 
confirm that a good resuspension was achieved by using a 3% solution of mannitol 
(Figure 4.38 – 4.39). 
 
1)  2)  
Figure 4.38 - Particles size before (1) and after (2) purification 
 
 
 
 
 
 
 
  
Figure 4.39 - Harvested NPs re-dispersed in water 
 
 
4.4.  NANOPARTICLE FORMULATIONS CHARACTERIZATION 
 
4.4.1. Release Studies   
 
A key goal in pharmaceutical development of dosage forms is a good understanding of 
the in vitro and in vivo correlation performance of the dosage form. It would be 
desiderable, therefore, to develop in vitro tests that reflect bioavailability data. 
Dissolution media and methods related to the in vivo controlling process are particularly 
important in case good in vitro-in vivo correlation are to be obtained. For biodegradable 
parenteral delivery systems in most cases, diffusion, dissolution and erosion govern drug 
release and a simple kinetic model is unlikely to explain the overall in vivo release 
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behaviour. Only few examples can be found in the literature where an in vitro drug 
release method accurately predicts the in vivo release profile for parenteral biodegradable 
depot systems. In general an aqueous test medium or buffered solution are recommended 
by FDA as the initial medium for development of an in vitro-in vivo correlation. For 
poorly soluble drugs non-aqueous and hydro-alcoholic system are discouraged and more 
extreme testing condition should be justified [Emami 2006]. 
For the in vitro evaluation of the release profile of RA from micro and nanoparticles, 
liposome, micelles, etc. several methods were adopted in former studies. Çirpanli et al 
(2005) studied the release profile of RA loaded PLGA microspheres in a binary solvent 
system of ethanol:phosphate buffer solution (7:4) [Çirpanli 2005], Choi et al (2006) 
immersed in 40 l of PBS,  atRA-loaded microspheres based on Poly(l-lactide)-
poly(ethylene glycol) diblock copolymer, other authors did not show any data relative to 
release kinetics of the proposed formulations [Jeong 2004, Lim 2004].  
The poor solubility of RA in water hampers or make difficult the evaluation of the drug 
release kinetics in phosphate buffer solution (PBS) at 37°C, which is commonly used in 
in vitro environment that should match the in vivo condition. 
Our preliminary drug release experiments were performed in PBS (pH 7.4) at 37° C. A 
suspension of RA-loaded PLGA nanoparticles in PBS was placed in a dialysis tube. The 
dialysis tube was placed in a bottle containing PBS and the whole exchange of the release 
medium at specific time intervals was used in order to prevent the saturation of the drug. 
Figure 4.40 shows the drug release from the PLGA nanoparticles.  
 
 
Figure 4.40 - Drug release profile of PLGA NPs in PBS 37°C 
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It is evident that the amount of drug, diffused out from the dialysis tube in the outer 
releasing medium, is constant despite the medium was analyzed at different time 
intervals. Evidently the amount of released drug was dependent only on the solubility of 
RA in PBS and it was not correlated to the drug release rate from the nanoparticles. 
Indeed, more than the 90% of RA precipitated as large flakes in the bottom of the dialysis 
tube at the end of the experiment. This can be due to  the formation of dimers and higher 
aggregates in solution by the hydrogen bonds between –COO- and –COOH groups of the 
free RA [Szuts 1991], that precipitate in the membrane during the process.  
The utilization of a binary solvent system, such as phosphate buffer with ethanol, 
is of great help to increase the threshold of drug saturation in the releasing medium, and 
allows for the determination of poor water soluble drug release kinetics. However, this 
method is suitable for a comparative evaluation of different nanoparticles formulations 
but it is far from representing the real physiological conditions and our wish is to develop 
a system that best reflects the in vivo behaviour. The utilization of phosphate buffer 
solution is an approximation of the physiological conditions as well, but it can be 
effective for evaluating the release profile of hydrophilic drugs, such as protein, that can 
diffuse out from the particles to the aqueous environment of the cells or plasma without 
binding macromolecular carriers. The presence of such carries have a great influence on 
the release rate of hydrophobic drugs and on the stability of drug delivery systems [Allen 
2004], as confirmed by our studies carried out in the present research.  
The dissolution of a hydrophobic drug in water or phosphate buffer is a 
thermodynamically unfavoured process. The threshold of drug saturation is rapidly 
reached and once in these conditions, the dissolved solute is in equilibrium with its solid 
state. At this point a drug delivery system behaves, unless it degrades rapidly, as a 
reservoir system that can releases free drug only when the concentration of the drug in 
solution decreases. In case the degradation of the particles occurs before the complete 
release of the drug, the former one would form aggregates and then precipitate. Assuring 
sink conditions in vitro for a poor soluble drug such as RA is very difficult and it is highly 
probable to measure a release profile which is dependent only on the release medium 
exchanges time intervals.    
This is why we decided to approach the physiological conditions by adding HSA 
to the suspension of nanoparticles in phosphate buffer. As already mentioned, albumin is 
the most abundant protein in human plasma (600µM) and is one of the most important 
factors affecting the distribution and the free, active concentration of many administered 
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drugs [Ghuman 2005]. Retinoids are effectively transported in the blood-stream bound to 
proteins and the acidic derivatives mainly by albumin [Tsukada 2002]. There are many 
Retinoic binding proteins that serve a myriad of important functions in vertebrate 
organism. Cytosolic retinoic binding protein solubilize and stabilize retinoids within the 
cell. Extracellular retinoic-binding proteins such as serum retinol-binding protein, 
albumin stabilize and target the transfer of retinoids between cells. Nuclear retinoic acid 
receptors RAR and RXR are essential mediators for the transcriptional activation of a 
number of genes involved in growth and differentiation [Bernstein 1995]. 
RA concentration in solution was determined by spectrophotometry measurements 
of the UV absorbance of the complex HSA-RA. For the measurement of the intensity of 
the peak of RA deconvolution of the UV spectrum was not necessary since the pick of 
albumin do not overlap, or just partially, that of RA (Figure 4.41 – 4.42).  
 
  
Figure 4.41 - UV spectrums of RA in ethanol (blue line) and HSA in PBS (red line) 
 
 
Figure 4.42 - UV spectrum of RA-HSA in PBS 
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Furthermore albumin allowed avoiding the utilization of antioxidants that are 
necessary to add to the releasing medium because retinoids rapidly decompose in aqueous 
solution thus making the spectrophotometric determination less accurate [Szuts 1991].  
The cumulative release profiles of RA obtained from PLGA and PHB nanoparticles are 
illustrated in Figure 4.43. 
 
 
Figure 4.43 - RA release profile from PHB (green) and PLGA (blu) NPs  
 in PBS containing HSA. Red line, complex RA-HSA 
 diffusion profile. 
 
 
The initial burst of release from both formulations was ascribed to the rapid dissolution of 
the nanoparticles in the presence of HSA. The addition of mannitol which was added to 
the formulation in order to obtain a good resuspension of nanoparticles (see 3.2.10), did 
not influenced the rate of diffusion of the complex HSA-RA (Figure 4.44).   
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Figure 4.44 -  Diffusion profile of the complex RA-HSA in  
 absence (blue dots) or in presence (red dots) of mannitol 
 
Macroscopically it was observed that an opalescent suspension of nanoparticles turned 
clear when HSA was added. It was assumed that the high affinity of albumin to RA 
causes the rapid release of the drug from the particles. The drug that diffuses through the 
aqueous space from the nanoparticles, rapidly binds the acceptor albumin that avoids the 
saturation of the solution and triggers the rapid release of further drug, leading to the 
rapid dissolution of the nanoparticles. It has already been reported that neutral 
hydrophobic drugs or those with intermediate solubility tend to be rapidly released in the 
presence of proteins or cell membranes [Allen 2004]. This disaggregating effect of HSA 
on RA loaded nanoparticles was not observed on the unloaded ones. It is well known that 
in most cases, the property of the carrier changes when the drug is attached to it and this 
can severely limit the carrier’s utility [Petrak 2005]. Since albumin is the most abundant 
protein in human plasma it is likely that these nanoparticles formulation would display a 
similar behaviour in vivo. Anyway, only in vivo tests might confirm this hypothesis since 
the blood environment is surely more complex and molecules such as fatty acid might 
hamper the interaction among HSA and the nanoparticles. The sustained release that 
follow the initial burst could be due to remaining RA bound to the polymer present in 
solution.  
Nanoparticles loaded with RA and HSA macroscopically showed to be stable for 
longer period of time in presence of HSA. The turbidity of the suspension disappeared 
after almost 15 min instead of the few seconds like for those not loaded with HSA.  
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4.4.2. Determination of RA / HSA interactions 
 
Interactions between HSA with retinoic acid were investigated by UV spectroscopy.  
Figure .  shows the absorption spectra of retinoic acid in ethanol, a single intense 
absorption band at  3 nm and of HSA in PBS, a single intense and narrow absorption band 
at nm. As it can be seen the peak of HSA do not overlap, or just partially, that of retinoic 
acid. Figure shows the absorption spectra of a HSA-RA complex. 
HSA-RA complex solutions were prepared by mixing a concentrated DMSO stock 
solution of retinoic acid and a PBS of HSA maintaining final ligand protein molar ratios 
of 1:0.5, 1:1, 2:1, 3:1, 4:1, and 5:1. The interaction of RA with HSA was investigated by 
UV analysis.  
The rate between the intensity of the peak of RA at 347 nm and HSA at 280 nm was 
plotted against their molar rate (Table 23, Figure 4.46). 
 
Table 23 - relation between RA-HSA molar rate and their maximum of absorbance 
 n RA / n HSA Peak 347 nm / Peak 280 nm 
 0.5 0.4581 
 1 0.8052 
 2 1.259 
 3 1.777 
 4 2.078 
 5 1.830 
 
 
Figure 4.45 - RA/HSA intensity peak rate against their molar rate 
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The graph shows a linear correlation between the peaks rate and the molar rate that range 
from 0.5 to 4. A significant drop in the absorption rate occur when the moles of retinoic 
acid are 5 times those of HSA. The initial linear correlation and the apparent visual clarity 
of the samples are a manifestation of a complexation of the ligand within the protein 
while the drop in absorbance rate and the increased opalescence of the samples most 
likely reflects the saturation of the protein binding sites which leads to RA micelles 
formation. 
The plotting of the molar ratio against RA acid absorbance at 347 nm might give some 
more information about the stoichiometry of the binding (Figure 4.46). The step graph 
obtained suggests that albumin has binding sites with different affinity for RA. When the 
rate between retinoic acid and HSA is 1 or less the ligand is practically completely 
complexed and solubilized. When the moles of retinoic acid are 2 or 3 times those of 
HSA there is an equilibrium between free and complexed RA. The peak of absorbance is 
lower because free RA forms aggregate in solution reducing its absorbance.     
The datas suggest that HSA is able to complex and solubilize at least two molecules of 
retinoic acid with different affinity.   
 
  
Figure 4.46 - RA/HSA intensity peak rate against RA absorbance at 347 nm 
 
 
4.4.3. Evaluation of the Activity of the Encapsulated Retinoic Acid 
 
During the preparation of nanoparticles by Colloidal Coating, RA is subjected to the 
variations of pH, freezing and drying process. In order to examine whether the activity of 
RA was affected by incorporation in VAM41 nanoparticles, it was tested on SK-N-SH 
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human neuroblastoma cell line that are known to undergo inhibition of proliferation and 
neuronal differentiation upon treatment with RA. Numerous studies have shown that RA 
induces differentiation, growth arrest, and apoptosis in neuroblastoma cell lines by 
inhibition of telomerase activity, and in increased endogenous ceramide levels [Kraveka 
2003]. The growth inhibitory effects of RA incorporated in nanoparticles formulation was 
not significantly different from the one observed for the free ATRA treatment of SK-N-
SK cells. These data suggest that the anticancer activity of RA was not impaired by the 
nanoparticles incorporation and freeze-drying process (Table 24). 
CESARE ERRICO – PHD THESIS 
 142
 Control ATRA VAM41 NPs 
 
    
 Day 1 Day 1 Day 1 
 
    
 Day 2 Day 2 Day 2 
 
    
 Day 3 Day 3 Day 3 
 
    
 Day 6 Day 6 Day 6 
 
Table 24 - Induction of differentiation of RA on SK-N-SH by encapsulated and free RA 
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4.4.4. In-Vitro Citotoxicity Studies 
 
In order to evaluate the biocompatibility of polymers and their resulting nanoparticles, in 
vitro experiments were carried out using the balb 3T3 mouse embryo fibroblasts clone 
A31 cell line, following the procedures of ISO 10993 – Part 5: “Test for cytotoxicity – in 
vitro methods”. 
Cytotoxicity, defined as the “in vitro evaluation of toxicological risks using cell culture”, 
is a rapid, standardized, sensitive and inexpensive way to assess the in vitro 
biocompatibility of materials to be used in biomedical applications. Assays deal with the 
assessment of various aspects of cellular function such as cell viability and proliferation, 
loss of membrane integrity, reduced cell adhesion, biosynthetic activity and altered cell 
morphology. Moreover, the information gained from these types of investigations may be 
used in the design of further in vivo experiments [Chiellini 2007].  
PHB and relative nanoparticles were suspended in Dulbecco’s Modified Eagles Medium 
since they are not water soluble at different concentrations ranging between 1 and 10 
mg/ml. Cells were incubated for 24 h with polymer and nanoparticles suspension and then 
tested for cell viability and proliferation using WST-1 tetrazolium salt and Neutral Red 
Uptake. The obtained results predominantly indicate a high level of cytocompatibility of 
the investigated materials. In vitro cytotoxicity of PHB resulted fairly low as highlighted 
by the high IC50 values obtained both with tetrazolium salts and neutral red assays (Figure 
4.45). PHB based nanoparticles prepared by dialysis method exhibited as well a very 
good cytocompatibility and can be considered fully biocompatible (Figure 4.46). 
 
 
Figure 4.45 - In vitro PHB citotoxicity Figure 4.46 - In vitro PHB nanoparticles 
citotoxicity 
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4.5. METHODS FOR ENCAPSULATING CHONDROITIN SULPHATE  
 
Chondroitin sulfate (CS) is a copolymer of d-glucuronic acid and sulfated N-acetyl-d-
galactosamine in C4 or C6 [Penga 2006]. It is an important structural component in 
connective tissues and cartilage [Penga 2006] and could be used as therapeutic agents in 
degenerative articular diseases [Bali 2001].  
CS is a highly water soluble macromolecules, negatively charged. These characteristics 
make the achievement of a sustained intra-articular drug level difficult because of the 
solubility of the drug [Kofuji 2002]. It is therefore necessary to use a vehicle that controls 
the drug release. We investigated the preparation of suitable vehicles for intra-articular 
injection in regenerated cartilages tissue to allow its sustained release, as an example.  
Bioerodible (VAM41), synthetic (PLGA), natural (Chitosan) polymers and 
nanoprecipitation or co-precipitation methods were used to develop the formulations. The 
limit of nanoprecipitation method mainly concerns the possibility to achieve an efficiently 
loading of hydrophilic drug substances inside the nanoparticles [Peltonen 2004]. The drug 
is easily lost in water during the preparation and incompatibilities between the polymer 
and the drug could worse the situation. Due to the wide differences among the utilized 
polymers the nanoprecipitation and co-precipitation methods had to be adjusted and 
modified in relation to the physical-chemical characteristics of the utilized material. 
These preliminary results confirm that methods based on nanoprecipitation are most 
suitable for compounds having a hydrophobic nature. However, the present research 
dealing with water-soluble drug incorporation provide encouraging results and further 
evidences that the presence of a nucleating agent is of relevance for the preparation of 
nanoparticles by nanoprecipitation.    
 
4.5.1. Nanoprecipitation-Solvent Evaporation Method 
 
4.5.1.1.  PLGA Based Nanoparticles Prepared by Nanoprecipitation-Solvent 
Evaporation Method 
 
In this method a water solution containing CS was added to a solution of PLGA in 
acetone, a solvent in which CS is not soluble. A suspension of CS in acetone was formed 
and placed under stirring and vacuum condition in order to remove the organic solvent. 
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The rationale behind was that during the evaporation of acetone the suspension of CS 
should have been covered by the polymer.  
Nanoparticles with an average diameter size from 430 to 820 nm with a good spherical 
morphology were prepared (Table 25, Figure 4.47 – 4.48).  
 
Table 25.- PLGA based NPs formulation prepared by  
 Nanoprecipitation Solvent-Evaporation method 
 Run  Diameter (nm) 
   number % 
 NS-LG-5  429±31 
 NS-LG-8  909±532 
 NS-LG-11  822±440 
 NS-LG-13  619±331 
 
 
  
Figure 4.47 - NS-LG-5 SEM image Figure 4.48 - NS-LG-5 Particle size distribution 
 
 
The final size of nanoparticles depended on the extent of acetone evaporation, which in 
turn was strictly correlated to the applied pressure, temperature and stirring rate. Even if 
all parameters were kept as much as possible constant the diameter size of the obtained 
nanoparticles could not be strongly ascribed to variations of CS concentrations or to the 
presence of surfactants. UV and IR spectrophotometry studies showed that detectable 
amounts of CS were not present into the nanoparticles formulations (See 4.6.1.). 
Incompatibilities between the hydrophobic PLGA and the hydrophilic, negatively charged 
CS could have hampered the encapsulation. The addition of a surfactant mediating the 
interactions was not effective for overcoming this problem. 
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4.5.2. Double Nanoprecipitation Method 
 
4.5.2.1.  PLGA Based Nanoparticles Prepared by Double Nanoprecipitation 
 
In this method a water solution containing CS was added to a solution of PLGA in 
acetone, a solvent in which CS is not soluble. The resulting suspension of CS was 
dropped in water or in a mixture of water and ethanol. Theoretically PLGA should 
precipitate thus encapsulating the particles of CS. The addition of a percentage of ethanol 
water may enhance the process of encapsulation since both polymers are not soluble in 
this solvent. 
Nanoparticles with a good spherical shape and average diameter size from 57 nm to 565 
nm were obtained (Table 26). 
 
Table 26 - PLGA based NPs formulation prepared by  
 Double Nanoprecipitation method 
 Run H2O/EtOH Diameter (nm) 
    number % 
 S17  1:0   147±20 
 S18 1:1   57±24 
 S19 0:1   88±100 
 S21 2:3   565±181 
 
 
 Also in this case UV and IR spectrophotometry studies showed that detectable amounts 
of CS were not present into the nanoparticles formulations confirming the incompatibility 
of the two polymers or a not suitability of these methods for the encapsulation of CS. 
Two different surfactants were added in order to mediate the interaction between CS and 
PLGA and reduce their incompatibility (Table 27). 
 
 
 
 
 
RESULTS & DISCUSSION 
 147 
Table 27 - Influence of surfactants on particles size 
 Run  Surfactant Diameter (nm) 
    Number % 
 DP-LG-28  Pluronic F-127 271±61 
 DP-LG-31  Tween 20   88±12 
 DP-LG-49  - 435±161 
 
 
The presence of a surfactant influenced the diameter size of the resulting nanoparticles 
but did not improve the encapsulation of CS. 
The formulation method employed appears effective for preparing NPs with good 
diameter sizes and good spherical shape but not suitable to encapsulate CS (Figure 4.49 – 
4.50, 4.51 – 4.52). 
 
  
Figure 4.49 - DP-LG-31 SEM image Figure 4.50 - DP-LG-31 Particle size distribution 
 
 
  
Figure 4.51 - DP-LG-49 SEM image Figure 4.52 - DP-LG-49 Particle size distribution 
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4.5.3. Modified Co-Precipitation Method 
 
4.5.3.1.  VAM41 Based Nanoparticles Prepared by Modified Co-Precipitation Method 
 
VAM41 is an hemiesters of maleic anhydride and alkyl vinyl ethers. It is water insoluble 
at low pHs but becomes water soluble at pH 7 as consequence of the deprotonation of its 
carboxylic acid moieties. At these pHs the affinity between the polymer and the drug is 
supposed to be very low, since they are both negatively charged and generate electrostatic 
repulsive forces. Consequently the encapsulation values that could be expected should be 
low as well.  
For the preparation of VAM41 nanoparticles the attitude of CS to form ionic complexes 
with positively charged proteins was exploited.  When the pH of a solution of CS and 
HSA was lowered below the pI of the protein, nanosized colloidal suspensions formed 
(Figure 4.53). Attractive electrostatic forces between the positively charged protein and 
the negatively charged CS generate self- assembled nanoparticular structures. Hence, 
positive charged proteins could intermediate the interaction between VAM41 and CS 
since both polymers were negatively charged.  
Thus it was conceived to prepare a water solution at pH 8 containing VAM41, a protein 
and CS and to drop the resulting solution in a pH 3 buffer solution. Theoretically the 
polymer should precipitate encapsulating the self assembled colloidal structure of CS and 
the protein. In addition the polymer itself could interact with the positively charged 
protein. 
 
 
Figure 4.53 - Particle size distribution 
 
Two model proteins, HSA and Fibrinogen, were added to the formulations as nucleating 
agent or as proteic model drugs. CS may mediate a hyperstructural shielding of the labile 
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protein resulting in protein stabilization from degrading conditions [Lee 2007], thus it 
appears to be a useful excipient to add to protein drug delivery systems. 
Nanoparticles based on VAM41 and loaded with either HSA or Fibrinogen and CS were 
prepared. The average diameter size of nanoparticles ranged from 64 to 138 nm (Table 
28, Figure 4.54 – 4.55).  
 
Table 28 - VAM41 based NPs formulation prepare by  
 a modified co-precipitation method 
 Run   Diameter (nm) 
   Number % 
 MP-VH-37  84±51 
 MP-VH-38  138±35  
 MP-VH-39  70±17  
 MP-VH-45  110±20  
 MP-VH-46  64±16 
 MP-VH-71  66±48 
 
  
  
Figure 4.54.- MP-LG-71 SEM image Figure 4.55.- MP-LG-71 Particle size distribution 
 
Nanoparticles based on VAM41 and loaded with Fibrinogen and CS were also prepared. 
The average diameter size was 163 nm (Figure 4.56 - 4.57). 
 
CESARE ERRICO – PHD THESIS 
 150
  
Figure 4.56 - MP-VF-59 SEM image Figure 4.57 - MP-VF-59 Particle size distribution 
 
 
IR analysis confirmed the presence of CS and proteins into the nanoparticles (See 4.6.2). 
 
4.5.3.2.  Chitosan Based Nanoparticles Prepared by Modified Co-Precipitation 
Method 
 
Since problems of incompatibility between the polymers seemed to have a strong effect 
on the resulting suspension and its drug loading values, our attention was devoted to the 
choice of a polymer that was endowed with all the necessary characteristic of 
biocompatibility, biodegradability and affinity for the molecule to be encapsulated. 
Chitosan, which is soluble at acid pHs and positively charged once dissolved, seemed to 
be the best candidate for preparing nanoparticles loaded with CS. The opposite charges of 
the two polymers were thought to have the potentiality to originate very strong ionic 
interactions which would be resulted in high drug loadings. 
Nanoparticles were first prepared using a standard procedure for the preparation of 
nanoparticles by ionic gelation of chitosan with tripolyphosphate anions (TPP) as cross-
linker agent. Nanoparticles with an average diameter size of 90 nm were prepared (Table 
29, Figure 4.58 – 4.59).  
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Table 29 - Chitosan  based nanoparticles formulations 
 prepared by Naprecipitation method  
 Run Diameter nm 
   (Number %) 
 NT-Ch-58  98±78 
 NT-Ch-60  90±10 
 NT-Ch-63  95±69 
 NT-Ch-64  96±50 
 
 
  
Figure 4.58 - NT-Ch-60 SEM image Figure 4.59 - NT-Ch-60 Particle size distribution 
 
 
Nanoparticles were hardly redispersible after the centrifugation and had the tendency to 
form aggregates in solution. The purification process was a critical step during the 
preparation of this kind of nanoparticles.      
In a second trial, Chitosan was dissolved in acetic aqueous solution at various 
concentrations (5 mg/mL, 2.5 mg/mL) and Pluronic was added as surfactant. This 
solution was added drop wise to an aqueous solution of CS under magnetic stirring at 
room temperature. 
Nanoparticles with an average diameter size ranging from 80 to 210 nm were obtained 
(Table 30, Figure 4.60 – 4.61).  
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Table 30 - Chitosan loaded nanoparticles 
 Sample  Diameter (nm) 
 S74  190±78  
 S75 210±110 
 S76 79±73 
 
  
Figure 4.60 - SEM image (S76)  Figure 4.61 - Particle size distribution 
 
 
Also in this case nanoparticles were hardly redispersible after the centrifugation and 
tended to form aggregates in solution. The SEM image showed particles with an average 
diameter size lower than that obtained by LS analysis. Particles propbably collapse and 
aggregate during the centrifugation.  
 
4.6.   NANOPARTICLES CHARACTERIZATION  
 
4.6.1. Evaluation of CS Encapsulation in PLGA NPs 
 
4.6.1.1.  Determination by UV Spectrophotometry 
 
Several spectrophotometric assays are available in literature to measure levels of sulfated 
GAGs in biological samples. Many of these assays are based on changes in the absorption 
spectrum of the dye 1,9-dimethylmethylene blue (DMMB) when bound to Glyco Amino 
Glycans (GAGs). Calibration curves using chondroitin-6-sulfate as standards showed 
linear correlation between absorption at 525 nm of the chondroitin sulfate–DMMB 
complexes versus concentration of chondroitin sulfate in the buffer solution pH 8, with R2 
of 0,9919 (Figure 4.62). 
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Figure 4.62 - CS-DMMB calibration curve 
 
PLGA nanoparticles were solved in CH2Cl2 and CS extracted with water. The analysis of 
the samples evidenced that chondroitin sulphate was not encapsulated into the 
nanoparticles. The characteristic band of absorbance of CS was not present in the 
spectrum of the extracted (Figure 4.63). 
 
 
Figure 4.63 - UV spectrum of PLGA NPs (red line) and CS (blue line) 
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4.6.1.2.  Determination by IR Spectrophotometry 
 
Samples of nanoparticles were analyzed by AT-IR. The characteristic bands of 
absorbance of CS were not present in the spectrum of the nanoparticles confirming the 
absence of encapsulated CS in the formulations (Figure 4.64). 
 
 
Figure 4.64 - ATIR spectrums of PLGA NPS (red line) 
 and CS (blue line) 
 
 
4.6.2.  Evaluation of CS Encapsulation in VAM41 NPs 
 
4.6.2.1.  Determination of CS Encapsulation in VAM41 NPs by UV 
Spectrophotometry 
 
By the same method adopted for the evaluation of the encapsulation of CS into PLGA 
nanocapsules it was possible to evaluate the encapsulation of CS of the VAM41 
nanoparticles containing Fibrinogen but not of those containing HSA. The colorant dye 
interacts with both the proteins but only the peak of the complex HSA-DMMB overlaps 
that of the complex CS-DMMB (Figure 4.65).   
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Figure 4.65 - UV spectrums of CS, HSA and Fibrinogen 
 bound to DMMB 
 
 
VAM41 nanoparticles were dissolved in pH 8 Tritisol buffer (Merck) and analyzed. The 
analysis of the samples evidenced that CS interacts, some how, with the polymer VAM41 
during the preparation of the nanoparticles. Indeed the peak of absorbance results 
displaced towards higher values of wave-length (Figure 4.66).  
 
 
Figure 4.66 - UV spectrums of CS and CS after the 
 encapsulation 
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It was demonstrated that this displacement was not due to the interference of the others 
molecules in solution. Different solutions of both CS and Fibrinogen, Pluronic or VAM41 
were analyzed (Figure 4.67). Only the CS extracted from the NPs showed the 
characteristic displacement.     
 
 
Figure 4.67 - UV spectrums 
 
 
HPLC or GPC analysis of the sample could be effective to verify the interaction and for 
calculating the drug loading. 
 
4.6.2.2.  Determination of CS Encapsulation in VAM41 NPs by IR  Spectrophotometry  
 
Chondroitin Sulphate encapsulation in nanoparticles was evaluated by IR 
spectrophotometry. A sample of NPs was analyzed by AT-IR tanking into account the 
rate between intensity of the peak at 1031 (characteristic for CS) and the intensity of the 
peak at 1721 (characteristic for VAM41). The rates between these two peaks were related 
to the percentage of the polymers in a sample of nanoparticles.  
A calibration curve of the % of CS in blends of CS/VAM41 versus the rate of the peaks 
(peak 1031 / peak 1721) was obtained preparing solution of VAM41 containing different 
percentages of CS. 
The solutions were freeze-dried and the resulting blend of polymers characterized by 
ATIR.  The rate between the intensity of the peak at 1031 (characteristic for CS) and the 
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intensity of the peak at 1721 (characteristic for VAM41) was calculated and related to the 
percentage of CS in the blend (Figure 4.68 -4.69).  
 
 
Figure 4.68 - VAM41 NPs ATR spectrum Figure 4.69 - VAM41 NPs ATR spectrum  
 
 
Calibration curves based on blends of CS and VAM41 as standards showed linear relation 
between the rate of the intensities of the peaks at 1031 and 1721 versus the percentage of 
CS in the blends, with R2 of 0,9934 (Figure 4.70).      
 
 
Figure 4.70 - CS / VAM41 IR standard curve 
 
 
The ratios in the sample S53 and S59 (Figure 4.71), (formulations prepared following the 
same recipe) are 0,57 and 0,54 indicating that the method is effective for the evaluation of 
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drug loading and that the formulations are reproducible. Anyway it is not possible to 
understand if the interaction between the polymers affects the IR spectrum as well. 
 
 
Figure 4.71 - S59 IR spectrum 
 
 
4.6.3. Evaluation of CS encapsulation in Chitosan NPs 
 
4.6.3.1.  Determination of CS encapsulation in Chitosan NPs by microanalysis 
 
Chitosan nanoparticles were not soluble in water and neither in acid or basic water 
solution or in organic solvents (acetone, CHCl3). Thus, samples of nanoparticles were 
analyzed by microanalysis to detect the presence of sulphur which is correlated to the 
presence of CS within the particles (Table 31 - 32, Figure 4.71 – 4.72).  
 
 
 
Figure 4.71 - Survey of S78 NPs sample Table 31 - Weigt percentage of S in S78 sample 
 
Element  Wt %  At % 
 C K 56.72 64.92 
 N K 04.43 04.35 
 O K 32.70 28.10 
 S K 06.15 02.64 
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Figure 4.7 - Survey of S60 NPs sample Table 32 - Weigt percentage of S in S60 sample 
 
 
The presence of sulphur indicate that CS is encapsulated in the nanoparticles but an 
evaluation of the percentage of loading by using the date above reported would be 
approximate since the rate between the percentage of C and O don not correspond to a 
reliable value. 
 
Element  Wt %  At % 
 C K 51.54 62.18 
 N K 05.25 05.44 
 O K 28.07 25.43 
 P K 10.27 04.80 
 S K 03.71 01.67 
 ClK 01.16 00.48 
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5. CONCLUDING REMARKS 
 
The development and set up of procedures for the preparation of polymeric nanoparticle 
suspensions for targeted and release of bioactive agents for cancer and tissue engineering 
applications was the main objectives of the present PhD research. The results so far 
achieved allow for drawing the following concluding remarks: 
 
• Retinoic Acid Loaded Nanoparticles for Cancer Treatment. 
 Dialysis and Nanoprecipitation methods were investigated for the preparation of 
nanoparticles based on PLGA, PHB and the copolymer PCL-co-PLU. Best results in 
term of diameter size and drug loading were obtained by using nanoprecipitation 
method. Some processing conditions were varied in order to assess their effect on 
nanoparticle ultimate characteristics. The utilization of binary solvent solution 
composed by a mix of polymer and drug solvent and non-solvent resulted to be 
effective for preparing nanoparticles with a narrow size distribution of diameters and 
good encapsulation values.  The small diameter of PHB nanoparticles prepared was 
very exceptional when compared with those of PHB microsphere prepared by other 
techniques commonly used such as solvent evaporation. HSA was co-encapsulated 
with RA in PLGA nanoparticles to improve the stability and half life of nanoparticles.  
 The Co-precipitation technique, previously developed and deeply investigated by the 
research group involved in the present study, was adopted and the formulation 
parameters were optimised for the preparation of VAM41 based NPs loaded with 
retinoic acid. This technique was conceived for the encapsulation of proteic drug and 
developed for the encapsulation of HSA as proteic model drug. Since HSA is one of 
the RA carrier in blood it was investigated the possibility to encapsulate RA through 
the encapsulation of its natural carrier. The novel concept of “carrying the carrier” 
resulted to be effective for encapsulating RA and preparing spherical nanoparticles 
with 100 – 150 nm diameter and narrow size distribution.  
 An organic solvent-free method, called “Colloidal-Coating”, has been developed for 
the preparation of VAM 41 nanoparticles loaded with RA. This method presents 
numerous advantages when compared with other nanoparticles preparation methods. 
It does not entail the utilization of toxic organic solvents with obvious implications 
from a toxicity stand point, it is easy to perform and allows for the preparation of 
small nanoparticles with  narrow size distribution. It is based on a reversible process 
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and wastes of material in case of accidental errors during the preparation are avoided, 
allowing for the preparation of multi-layer nanocapsules by adding at different 
preparation stages the different polymers and might be extendible to incorporate 
ferrofluids or in general to encapsulate any substance that can act as nucleating agent. 
The activity of RA encapsulated by colloidal-coating method was evaluated. The data 
obtained suggested that the anticancer activity of RA was not impaired by 
incorporation and purification processes. 
 Drug release studies were carried out by an original method that might better reflect 
bioavalability data. Since HSA is one of the most abundant plasma protein it was 
added to the releasing medium and problems related to the poor solubility of RA in 
water were overcame. Solubility problems often hamper the evaluation of 
hydrophobic drugs release kinetics in phosphate buffer solution (PBS) at 37°C, which 
is commonly used in in vitro test controls that should match the in vivo 
bioenviroment. The obtained results shown that HSA affected the stability and 
lifetime of nanoparticle formulations.  
 
• CS loaded Nanoparticles for tissue engineering applications. 
Nanoprecipitation method was adopted for the encapsulation of CS in PLGA, 
VAM41 and Chitosan based NPs since this method gave the best results in term of 
particle size and drug loading for encapsulating RA. Nanoprecipitation method 
presents its limits on loading efficacy of hydrophilic drugs inside NPs. The expertise 
acquired for encapsulating RA showed that the presence of a nucleating agent was 
fundamental for encapsulating drug with this method. The formation of primary 
nucleoi in the case of CS was achieved through a primary precipitation of CS in 
acetone (Nanoprecipitation-Solvent evaporation, Double Nanoprecipitation methods), 
or through the formation of insoluble aggregates with proteins or polymers in water 
(Modified Co-precipitation methods). PLGA, VAM 41 and Chitosan nanoparticles 
were prepared. No detectable amounts of CS were loaded onto the PLGA 
nanoparticles indicating the unsuitability of the method for the encapsulation of this 
drug or a strong incompatibility between the hydrophobic polymer and hydrophilic 
drug. Hence it is advisable to choose the polymeric carrier in relation to the 
characteristic of the drug that has to be encapsulated. CS was instead loaded into the 
VAM41 and Chitosan NPs. A quantitative determination of the drug content was not 
possible due to several occurrences. CS interacted somehow with VAM41 and its 
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characteristic band of absorbance at UV was shifted at higher wavelength. Chitosan 
nanoparticles were insoluble in all the tested solvents and a quantitative evaluation of 
CS content was carried out by XPS analysis. 
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